Pyridazinone compounds and uses thereof

ABSTRACT

Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-α.

CROSS-REFERENCE

This application is a continuation of U.S. Non-Provisional applicationSer. No. 17/088,469, filed Nov. 3, 2020, which is a continuation ofInternational Patent Application No. PCT/US2019/060157, filed Nov. 6,2019, which claims the benefit of U.S. Provisional Application Ser. No.62/756,553 filed Nov. 6, 2018, each of which is hereby incorporatedherein by reference in its entirety.

BACKGROUND OF THE INVENTION

Skeletal muscle is the largest organ system in the human body, servingtwo primary purposes. The first is force production to enable musclecontraction, locomotion, and postural maintenance; the second isglucose, fatty acid and amino acid metabolism. The contraction ofskeletal muscle during every-day activity and exercise is naturallyconnected to muscle stress, breakdown and remodeling which is importantfor muscle adaptation. In individuals with neuromuscular conditions,such as Duchenne Muscular Dystrophy (DMD), muscle contractions lead tocontinued rounds of amplified muscle breakdown that the body strugglesto repair. Eventually, as patients age, a pathophysiological processemerges that leads to excess inflammation, fibrosis, and fatty depositaccumulation in the muscle, portending a steep decline in physicalfunction and contribution to mortality.

DMD is a genetic disorder affecting skeletal muscle and is characterizedby progressive muscle degeneration and weakness. There remains a needfor treatments that reduce muscle breakdown in patients withneuromuscular conditions such as DMD.

SUMMARY OF THE INVENTION

The present disclosure generally relates to substituted pyridazinonecompounds or salts of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II),or (IIa) and pharmaceutical compositions thereof. The substitutedpyridazinone compounds or salts of Formula (I), (Ia), (Ib), (Ic), (Id),(Ie), (II), or (IIa) disclosed herein may be used to treat or preventneuromuscular diseases. In some embodiments, a compound or salt ofFormula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II), or (IIa) is aninhibitor of skeletal muscle contraction. In some embodiments, acompound or salt of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II), or(IIa) is an inhibitor of myosin. In some embodiments, a compound or saltof Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II), or (IIa) is aninhibitor of skeletal muscle myosin II.

In some aspects, methods of treating a movement disorder may compriseadministering a compound or salt of any one of Formula (I), (Ia), (Ib),(Ic), (Id), (Ie), (II), (IIa), (III), or (III′) to inhibit skeletalmuscle myosin II. In some embodiments, said movement disorder comprisesmuscle spasticity. In some embodiments, said muscle spasticity may beselected from spasticity associated with multiple sclerosis, Parkinson'sdisease, Alzheimer's disease, or cerebral palsy, or injury, or atraumatic event such as stroke, traumatic brain injury, spinal cordinjury, hypoxia, meningitis, encephalitis, phenylketonuria, oramyotrophic lateral sclerosis.

The disclosure provides compound and salts thereof for use in treatingdisease. In certain aspects, the disclosure provides a compound or saltof Formula (I), (Ia), (Ib), (Ic), (Id), (II) or (IIa), pharmaceuticalcompositions thereof as well as methods of use in the treatment ofdisease.

In certain aspects, the disclosure provides a compound represented byFormula (I):

or a salt thereof, wherein:

-   each X is independently selected from C(R³), N, and N⁺(—O⁻) wherein    at least one X is N or N⁺(—O⁻);-   A is selected from —O—, —NR⁴—, —CR⁵R⁶—, —S—, —S(O)—, and —S(O)₂—;-   R¹ is selected from:    -   C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰,        —N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —S(O)R¹⁰,        —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), —CN, C₃₋₁₀ carbocycle and 3-        to 10-membered heterocycle, wherein the C₃₋₁₀ carbocycle and 3-        to 10-membered heterocycle are each optionally substituted with        one or more R⁹; and    -   C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle, each of        which is optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂,        —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰,        —S(O)₂R¹⁰, —NO₂, ═O—═S, ═N(R¹⁰), —CN, C₁₋₆ alkyl, C₂₋₆ alkenyl,        and C₂₋₆ alkynyl, wherein C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆        alkynyl are each optionally substituted with one or more R⁹; or    -   R¹ together with R³ form a 5- to 10-membered heterocycle or        C₅₋₁₀ carbocycle, wherein the 5- to 10-membered heterocycle or        C₅₋₁₀ carbocycle is optionally substituted with one or more R⁹;        or R¹ together with R⁵ form a 3- to 10-membered heterocycle or        C₃₋₁₀ carbocycle, wherein the 3- to 10-membered heterocycle or        C₃₋₁₀ carbocycle is optionally substituted with one or more R⁹;        or R¹ together with R⁴ form a 3- to 10-membered heterocycle,        wherein the 3- to 10-membered heterocycle is optionally        substituted with one or more R⁹;-   R² is a heteroaryl optionally substituted with one or more    substituents independently selected from:    -   halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂,        —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂,        —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰,        —NO₂, ═O, ═S, ═N(R¹⁰), and —CN; and when R² is pyridyl or        pyrimidyl, a substituent on a nitrogen atom of the pyridyl or        pyrimidyl is optionally further selected from —O;    -   C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂,        —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰,        —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), —CN, C₃₋₁₀ carbocycle and 3-        to 10-membered heterocycle, wherein the C₃₋₁₀ carbocycle and 3-        to 10-membered heterocycle are each optionally substituted with        one or more R⁹; and    -   C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle, each of        which is optionally substituted with one or more R⁹;-   R³, R⁵, and R⁶ are each independently selected from:    -   hydrogen, halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, and —CN; and    -   C₁₋₆ alkyl optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —NO₂, and —CN; or    -   R³ together with R¹ form a 5- to 10-membered heterocycle or        C₅₋₁₀ carbocycle, wherein the 5- to 10-membered heterocycle or        C₅₋₁₀ carbocycle is optionally substituted with one or more R⁹;        or R⁵ together with R¹ form a 3- to 10-membered heterocycle or        C₃₋₁₀ carbocycle, wherein the 3- to 10-membered heterocycle or        C₃₋₁₀ carbocycle is optionally substituted with one or more R⁹;-   R⁴ is independently selected from:    -   hydrogen; and    -   C₁₋₆ alkyl optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —NO₂, and —CN; or R⁴ together with R¹ form a 3- to 10-membered        heterocycle, which is optionally substituted with one or more        R⁹;-   R⁷ and R⁸ are independently selected from:    -   halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, —CN, and C₁₋₆ alkyl        optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —NO₂, and —CN;-   each R⁹ is independently selected from:    -   halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂,        —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂,        —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰,        —NO₂, ═O, ═S, ═N(R¹⁰), and —CN; and    -   C₁₋₃ alkyl, C₂₋₃ alkenyl, and C₂₋₃ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂,        —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰,        —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), and —CN;-   each R¹⁰ is independently selected from:    -   hydrogen; and    -   C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —CN, —OH, —SH, —NO₂, —NH₂,        ═O, ═S, —O—C₁₋₆ alkyl, —S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —NH(C₁₋₆        alkyl), C₃₋₁₀ carbocycle, 3- to 10-membered heterocycle; and    -   C₃₋₁₀ carbocycle, and 3- to 10-membered heterocycle, each of        which is optionally substituted with one or more substituents        independently selected from halogen, —CN, —OH, —SH, —NO₂, —NH₂,        ═O, ═S, —O—C₁₋₆ alkyl, —S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —NH(C₁₋₆        alkyl), C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀        carbocycle, 3- to 10-membered heterocycle, and C₁₋₆ haloalkyl;-   n is 0, 1, or 2; and-   p is 0, 1, or 2.

In certain aspects, the disclosure provides a compound represented byFormula (II):

or a salt thereof, wherein:

-   T is selected from —O—, —NR¹⁴—, —CR¹⁵R¹⁶—, —C(O)—, —S—, —S(O)—, and    —S(O)₂;-   R¹¹ is selected from:    -   C₁₋₅ haloalkyl optionally further substituted with one or more        substituents independently selected from —OR²⁰, —SR²⁰, —N(R²⁰)₂,        —NO₂, ═O, ═S, —CN, C₃₋₁₀ carbocycle and 3- to 10-membered        heterocycle, wherein the C₃₋₁₀ carbocycle and 3- to 10-membered        heterocycle are each optionally substituted with one or more        R¹⁹;-   R¹² is a heteroaryl optionally substituted with one or more    substituents independently selected from:    -   halogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂, —C(O)R²⁰, —C(O)N(R²⁰)₂,        —N(R²⁰)C(O)R²⁰, —N(R²⁰)C(O)N(R²⁰)₂, —OC(O)N(R²⁰)₂,        —N(R²⁰)C(O)OR²⁰, —C(O)OR²⁰, —OC(O)R²⁰, —S(O)R²⁰, —S(O)₂R²⁰,        —NO₂, ═O, ═S, ═N(R²⁰), —CN; and when R¹² is pyridyl or        pyrimidyl, a substituent on a nitrogen atom of the pyridyl or        pyrimidyl is optionally further selected from —O;    -   C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂,        —C(O)R²⁰, —C(O)N(R²⁰)₂, —N(R²⁰)C(O)R²⁰, —N(R²⁰)C(O)N(R²⁰)₂,        —OC(O)N(R²⁰)₂, —N(R²⁰)C(O)OR²⁰, —C(O)OR²⁰, —OC(O)R²⁰, —S(O)R²⁰,        —S(O)₂, —NO₂, ═O, ═S, ═N(R²⁰), —CN, C₃₋₁₀ carbocycle and 3- to        10-membered heterocycle, wherein the C₃₋₁₀ carbocycle and 3- to        10-membered heterocycle are each optionally substituted with one        or more R¹⁹; and    -   C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle, each of        which is optionally substituted with one or more —R¹⁹;-   R¹⁴ is selected from:    -   hydrogen, and C₁₋₆ alkyl optionally substituted with one or more        substituents independently selected from halogen, —OR²⁰, —SR²⁰,        —N(R²⁰)₂, —NO₂, and —CN;-   each R¹⁵ and R¹⁶ is independently selected from:    -   hydrogen, halogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂—, —NO₂, —CN, and C₁₋₆        alkyl optionally substituted with one or more substituents        independently selected from halogen, —OR²⁰, —SR²⁰)₂, —N(R²⁰)₂,        —NO₂, and —CN;-   each R¹⁷ and R¹⁸ is independently selected from:    -   halogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂, —NO₂, —CN, and C₁₋₆ alkyl        optionally substituted with one or more substituents        independently selected from halogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂,        —NO₂, and —CN;-   each R¹⁹ is independently selected from:    -   halogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂, —C(O)R²⁰, —C(O)N(R²⁰)₂,        —N(R²⁰)C(O)R²⁰, —N(R²⁰)C(O)N(R²⁰)₂, —OC(O)N(R²⁰)₂,        —N(R²⁰)C(O)OR²⁰, —C(O)OR²⁰, —OC(O)R²⁰, —S(O)R²⁰, —S(O)₂R²⁰,        —NO₂, ═O, ═S, ═N(R²⁰), —CN; and

C₁₋₃ alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl, each of which is optionallysubstituted with one or more substituents independently selected fromhalogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂, —C(O)R²⁰, —C(O)N(R²⁰)₂, —N(R²⁰)C(O)R²⁰,—N(R²⁰)C(O)N(R²⁰)₂, —OC(O)N(R²⁰)₂, —N(R²⁰)C(O)OR²⁰, —C(O)OR²⁰,—OC(O)R²⁰, —S(O)R²⁰, —S(O)₂R²⁰, —NO₂, ═O, ═S, ═N(R²⁰), and —CN;

-   each R²⁰ is independently selected from:    -   hydrogen; and    -   C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —CN, —OH, —SH, —NO₂, —NH₂,        ═O, ═O, —O—C₁₋₆ alkyl, —S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —NH(C₁₋₆        alkyl), C₃₋₁₀ carbocycle, 3- to 10-membered heterocycle; and    -   C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle, each of        which is optionally substituted with one or more substituents        independently selected from halogen, —CN, —OH, —SH, —NO₂, —NH₂,        ═O, ═S, —O—C₁₋₆ alkyl, —S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —NH(C₁₋₆        alkyl), C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀        carbocycle, 3- to 10-membered heterocycle, and haloalkyl;-   w is 0, 1, or 2; and-   z is 0, 1, or 2.

In certain aspects, the disclosure provides a method of treatingactivity-induced muscle damage, comprising administering to a subject inneed thereof a compound or salt of Formula (III′):

or a salt thereof, wherein:

each Y is independently selected from C(R³), N, and N⁺(—O⁻);

A is absent or selected from —O—, —CR⁵R⁶—, —C(O)—, —S—, —S(O)—, and—S(O)₂—;

R¹ is selected from:

-   -   C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰,        —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰), —N(R¹⁰)C(O)N(R¹⁰)₂,        —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰,        —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), —CN, C₃₋₁₀ carbocycle, and 3-        to 10-membered heterocycle, wherein the C₃₋₁₀ carbocycle and 3-        to 10-membered heterocycle are each optionally substituted with        one or more R⁹; and    -   C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle, each of        which is optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹)₂,        —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰,        —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), and —CN; or    -   R¹ together with R³ form a 5- to 10-membered heterocycle or        C₅₋₁₀ carbocycle, wherein the 5- to 10-membered heterocycle or        C₅₋₁₀ carbocycle is optionally substituted with one or more R⁹;        or R¹ together with R⁵ form a 3- to 10-membered heterocycle or        saturated C₃₋₁₀ carbocycle, wherein the 3- to 10-membered        heterocycle or saturated C₃₋₁₀ carbocycle is optionally        substituted with one or more R⁹; or R¹ together with R⁴ form a        3- to 10-membered heterocycle, wherein the 3- to 10-membered        heterocycle is optionally substituted with one or more R⁹; and    -   when A is —NR⁴—, R¹ is additionally selected from hydrogen, and        when A is —C(O)—, R¹ is additionally selected from —N(R¹⁰)₂ and        —OR¹⁰;    -   when A is absent R¹ is further selected from halogen, —OR¹⁰,        —SR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰,        —N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰,        —OC(O)R¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰, —NO₂, and —CN;

-   R² is a heteroaryl optionally substituted with one or more    substituents independently selected from:    -   halogen, —OR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂,        —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂,        —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰,        —NO₂, ═O, ═S, ═N(R¹⁰), and —CN; and when R² is pyridyl or        pyrimidyl, a substituent on a nitrogen atom of the pyridyl or        pyrimidyl is optionally further selected from —O⁻;    -   C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰,        —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂,        —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰,        —NO₂, ═O, ═S, ═N(R¹⁰, —CN, C₃₋₁₀ carbocycle and 3- to        10-membered heterocycle, wherein the C₃₋₁₀ carbocycle and 3- to        10-membered heterocycle are each optionally substituted with one        or more R⁹; and    -   C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle, each of        which is optionally substituted with one or more R⁹;

-   each R³, R⁵, and R⁶ is independently selected from:    -   hydrogen, halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, —CN, and C₁₋₆        alkyl optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —NO₂, and —CN; or    -   R³ together with R¹ form a 5- to 10-membered heterocycle or        C₅₋₁₀ carbocycle, wherein the 5- to 10-membered heterocycle or        C₅₋₁₀ carbocycle is optionally substituted with one or more R⁹;        R⁵ together with R¹ form a 3- to 10-membered heterocycle or        C₃₋₁₀ carbocycle, wherein the 3- to 10-membered heterocycle or        C₃₋₁₀ carbocycle is optionally substituted with one or more R⁹;

-   R⁴ is independently selected from:    -   hydrogen; and    -   C₁₋₆ alkyl optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —NO₂, and —CN; or R⁴ together with R¹ form a 3- to 10-membered        heterocycle, which is optionally substituted with one or more        R⁹;

-   each R⁷ and R⁸ is independently selected from    -   halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, —CN, and C₁₋₆ alkyl        optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —NO₂, and —CN;

-   each R⁹ is independently selected from    -   halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂,        —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂,        —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰,        —NO₂, ═O, ═S, ═N(R¹⁰), —CN; and    -   C₁₋₃ alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂,        —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰,        —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), and —CN;

-   each R¹⁰ is independently selected from    -   hydrogen; and    -   C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —CN, —OH, —SH, —NO₂, —NH₂,        ═O, ═S, —O—C₁₋₆ alkyl, —S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —NH(C₁₋₆        alkyl), C₃₋₁₀ carbocycle, 3- to 10-membered heterocycle; and    -   C₃₋₁₀ carbocycle, and 3- to 10-membered heterocycle, each of        which is optionally substituted with one or more substituents        independently selected from halogen, —CN, —OH, —SH, —NO₂, —NH₂,        ═O, ═S, —O—C₁₋₆ alkyl, —S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —NH(C₁₋₆        alkyl), C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀        carbocycle, 3- to 10-membered heterocycle, and haloalkyl;    -   R³⁰ and R³¹ are independently selected from R¹⁰ or R³⁰ and R³¹        come together to form a C₃₋₇ carbocycle, wherein the 3- to        7-membered heterocycle, wherein C₃₋₇ carbocycle and 3- to        7-membered heterocycle are optionally substituted with R⁹;

-   n is 0, 1, or 2; and

-   p is 0, 1, or 2.

In certain aspects, the disclosure provides a method of treating aneuromuscular condition or treating activity-induced muscle damage or ofinhibiting muscle myosin II, comprising administering to a subject inneed thereof a compound or salt of any one of Formulas (I), (Ia), (Ib),(Ic), (Id), (Ie), (II), and (IIa).

In certain aspects, the disclosure provides a method of treating amovement disorder, comprising administering to a subject in need thereofa compound or salt of any one of Formulas (I), (Ia), (Ib), (Ic), (Id),(Ie), (II), and (IIa).

In certain aspects, the disclosure provides a pharmaceutical compositioncomprising a compound or salt of any one Formulas (I), (Ia), (Ib), (Ic),(Id), (Ie), (II), and (IIa) or a pharmaceutically acceptable excipient.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in thisspecification are herein incorporated by reference to the same extent asif each individual publication, patent, or patent application wasspecifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity inthe appended claims. A better understanding of the features andadvantages of the present invention will be obtained by reference to thefollowing detailed description that sets forth illustrative embodiments,in which the principles of the invention are utilized, and theaccompanying drawings (also “Figure” and “FIG.” herein), of which:

FIG. 1 depicts excessive contraction-induced injuries, which precede theinflammation and irreversible fibrosis that characterizes late-stage DMDpathology;

FIG. 2 depicts N-benzyl-p-tolyl-sulfonamide (BTS), an inhibitor offast-fiber skeletal muscle myosin, has been shown to protect musclesfrom pathological muscle derangement in embryos from zebrafish model ofDMD;

FIG. 3 depicts the force decrease pre injury at 100 Hz for variouscompounds of the disclosure;

FIG. 4 depicts the post injury force decrease at 175 Hz for variouscompounds of the disclosure;

FIG. 5 depicts mid lengthening force drop for various compounds of thedisclosure; and

FIG. 6 depicts the TA mass increase after injury for various compoundsof the disclosure.

FIG. 7 depicts Buffer A and Buffer B, stored on ice until use.

FIG. 8 depicts buffer preparation.

DETAILED DESCRIPTION OF THE INVENTION

While preferred embodiments of the present invention have been shown anddescribed herein, it will be obvious to those skilled in the art thatsuch embodiments are provided by way of example only. Numerousvariations, changes, and substitutions will now occur to those skilledin the art without departing from the invention. It should be understoodthat various alternatives to the embodiments of the invention describedherein may be employed in practicing the invention. It is intended thatthe following claims define the scope of the invention and that methodsand structures within the scope of these claims and their equivalents becovered thereby.

In certain aspects, the disclosure provides methods for treatingneuromuscular conditions through selective inhibition of fast-fiberskeletal muscle myosin. In particular, methods of the disclosure may beused in the treatment of DMD and other neuromuscular conditions.

Skeletal muscle is mainly composed of two types of fibers, slow-twitchmuscle fiber (i.e., type I) and fast-twitch muscle fiber (i.e., typeII). In each muscle, the two types of fibers are configured in amosaic-like arrangement, with differences in fiber type composition indifferent muscles and at different points in growth and development.Slow-twitch muscle fibers have excellent aerobic energy productionability. Contraction rate of the slow-twitch muscle fiber is low buttolerance to fatigue is high. Slow-twitch muscle fibers typically have ahigher concentration of mitochondria and myoglobin than do fast-twitchfibers and are surrounded by more capillaries than are fast-twitchfibers. Slow-twitch fibers contract at a slower rate due to lower myosinATPase activity and produce less power compared to fast-twitch fibers,but they are able to maintain contractile function over longer-terms,such as in stabilization, postural control, and endurance exercises.

Fast twitch muscle fibers in humans are further divided into two mainfiber types depending on the specific fast skeletal myosin they express(Type IIa, IIx/d). A third type of fast fiber (Type IIb) exists in othermammals but is rarely identified in human muscle. Fast-twitch musclefibers have excellent anaerobic energy production ability and are ableto generate high amounts of tension over a short period of time.Typically, fast-twitch muscle fibers have lower concentrations ofmitochondria, myoglobin, and capillaries compared to slow-twitch fibers,and thus can fatigue more quickly. Fast-twitch muscles produce quickerforce required for power and resistance activities.

The proportion of the type I and type II can vary in differentindividuals. For example, non-athletic individuals can have close to 50%of each muscle fiber types. Power athletes can have a higher ratio offast-twitch fibers, e.g., 70-75% type II in sprinters. Enduranceathletes can have a higher ratio of slow-twitch fibers, e.g., 70-80% indistance runners. The proportion of the type I and type II fibers canalso vary depending on the age of an individual. The proportion of typeII fibers, especially the type IN, can decline as an individual ages,resulting in a loss in lean muscle mass.

The contractile action of skeletal muscle leads to muscle damage insubjects with neuromuscular disease, e.g., DMD, and this damage appearsto be more prevalent in fast fibers. It has been observed that acuteforce drop after lengthening injury is greater in predominantly fasttype II fiber muscles compared to predominantly slow type I fibermuscles in dystrophy mouse models. It has also been demonstrated thatthe degree of acute force drop and histological damage in dystrophymouse models is proportional to peak force development duringlengthening injury. Excessive contraction-induced injuries, whichprecede the inflammation and irreversible fibrosis that characterizeslate-stage DMD pathology are shown in FIG. 1 [Figure adapted: Claflinand Brooks, Am J Brooks, Physiol Cell, 2008,]. Contraction-inducedmuscle damage in these patients may be reduced by limiting peak forcegeneration in type II fibers and possibly increasing reliance onhealthier type I fibers. N-benzyl-p-tolyl-sulfonamide (BTS), aninhibitor of fast-fiber skeletal muscle myosin, has been shown toprotect muscles from pathological muscle derangement in embryos fromzebrafish model of DMD as shown in FIG. 2 . [Source: Li and Amer,PLoSONE, 2015].

Inhibitors of skeletal muscle myosin that are not selective for the typeII fibers may lead to excessive inhibition of skeletal musclecontraction including respiratory function and unwanted inhibition ofcardiac activity as the heart shares several structural components (suchas type I myosin) with type I skeletal muscle fibers. While not wishingto be bound by a particular mechanistic theory, this disclosure providesselective inhibitors of fast-fiber skeletal muscle myosin as a treatmentoption for DMD and other neuromuscular conditions. The targetedinhibition of type II skeletal muscle myosin may reduce skeletal musclecontractions while minimizing the impact on a subject's dailyactivities.

Definitions

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as is commonly understood by one of skill in theart to which this invention belongs.

As used in the specification and claims, the singular form “a”, “an” and“the” includes plural references unless the context clearly dictatesotherwise.

The term “C_(x-y)” or “C_(x)-C_(y)” when used in conjunction with achemical moiety, such as alkyl, alkenyl, or alkynyl is meant to includegroups that contain from x to y carbons in the chain. For example, theterm “C₁₋₆ alkyl” refers to substituted or unsubstituted saturatedhydrocarbon groups, including straight-chain alkyl and branched-chainalkyl groups that contain from 1 to 6 carbons.

The terms “C_(x-y) alkenyl” and “C_(x-y) alkynyl” refer to substitutedor unsubstituted unsaturated aliphatic groups analogous in length andpossible substitution to the alkyls described above, but that contain atleast one double or triple bond, respectively.

The term “carbocycle” as used herein refers to a saturated, unsaturatedor aromatic ring in which each atom of the ring is carbon. Carbocycleincludes 3- to 10-membered monocyclic rings, 5- to 12-membered bicyclicrings, 5- to 12-membered spiro bicycles, and 5- to 12-membered bridgedrings. Each ring of a bicyclic carbocycle may be selected fromsaturated, unsaturated, and aromatic rings. In an exemplary embodiment,an aromatic ring, e.g., phenyl, may be fused to a saturated orunsaturated ring, e.g., cyclohexane, cyclopentane, or cyclohexene. Abicyclic carbocycle includes any combination of saturated, unsaturatedand aromatic bicyclic rings, as valence permits. A bicyclic carbocyclefurther includes spiro bicyclic rings such as spiropentane. A bicycliccarbocycle includes any combination of ring sizes such as 3-3 spiro ringsystems, 4-4 spiro ring systems, 4-5 fused ring systems, 5-5 fused ringsystems, 5-6 fused ring systems, 6-6 fused ring systems, 5-7 fused ringsystems, 6-7 fused ring systems, 5-8 fused ring systems, and 6-8 fusedring systems. Exemplary carbocycles include cyclopentyl, cyclohexyl,cyclohexenyl, adamantyl, phenyl, indanyl, naphthyl, andbicyclo[1.1.1]pentanyl.

The term “aryl” refers to an aromatic monocyclic or aromatic multicyclichydrocarbon ring system. The aromatic monocyclic or aromatic multicyclichydrocarbon ring system contains only hydrogen and carbon and from fiveto eighteen carbon atoms, where at least one of the rings in the ringsystem is aromatic, i.e., it contains a cyclic, delocalized (4n+2)π-electron system in accordance with the Htickel theory. The ring systemfrom which aryl groups are derived include, but are not limited to,groups such as benzene, fluorene, indane, indene, tetralin andnaphthalene.

The term “cycloalkyl” refers to a saturated ring in which each atom ofthe ring is carbon. Cycloalkyl may include monocyclic and polycyclicrings such as 3- to 10-membered monocyclic rings, 5- to 12-memberedbicyclic rings, 5- to 12-membered spiro bicycles, and 5- to 12-memberedbridged rings. In certain embodiments, a cycloalkyl comprises three toten carbon atoms. In other embodiments, a cycloalkyl comprises five toseven carbon atoms. The cycloalkyl may be attached to the rest of themolecule by a single bond. Examples of monocyclic cycloalkyls include,e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, andcyclooctyl. Polycyclic cycloalkyl radicals include, for example,adamantyl, spiropentane, norbornyl (i.e., bicyclo[2.2.1]heptanyl),decalinyl, 7,7 dimethyl bicyclo[2.2.1]heptanyl, bicyclo[1.1.1]pentanyl,and the like.

The term “cycloalkenyl” refers to a saturated ring in which each atom ofthe ring is carbon and there is at least one double bond between tworing carbons. Cycloalkenyl may include monocyclic and polycyclic ringssuch as 3- to 10-membered monocyclic rings, 6- to 12-membered bicyclicrings, and 5- to 12-membered bridged rings. In other embodiments, acycloalkenyl comprises five to seven carbon atoms. The cycloalkenyl maybe attached to the rest of the molecule by a single bond. Examples ofmonocyclic cycloalkenyls include, e.g., cyclopentenyl, cyclohexenyl,cycloheptenyl, and cyclooctenyl.

The term “halo” or, alternatively, “halogen” or “halide,” means fluoro,chloro, bromo or iodo. In some embodiments, halo is fluoro, chloro, orbromo.

The term “haloalkyl” refers to an alkyl radical, as defined above, thatis substituted by one or more halo radicals, for example,trifluoromethyl, dichloromethyl, bromomethyl, 2,2,2-trifluoroethyl,1-chloromethyl-2-fluoroethyl, and the like. In some embodiments, thealkyl part of the haloalkyl radical is optionally further substituted asdescribed herein.

The term “heterocycle” as used herein refers to a saturated, unsaturatedor aromatic ring comprising one or more heteroatoms. Exemplaryheteroatoms include N, O, Si, P, B, and S atoms. Heterocycles include 3-to 10-membered monocyclic rings, 6- to 12-membered bicyclic rings, 5- to12-membered spiro bicycles, and 5- to 12-membered bridged rings. Abicyclic heterocycle includes any combination of saturated, unsaturatedand aromatic bicyclic rings, as valence permits. In an exemplaryembodiment, an aromatic ring, e.g., pyridyl, may be fused to a saturatedor unsaturated ring, e.g., cyclohexane, cyclopentane, morpholine,piperidine or cyclohexene. A bicyclic heterocycle includes anycombination of ring sizes such as 4-5 fused ring systems, 5-5 fused ringsystems, 5-6 fused ring systems, 6-6 fused ring systems, 5-7 fused ringsystems, 6-7 fused ring systems, 5-8 fused ring systems, and 6-8 fusedring systems. A bicyclic heterocycle further includes spiro bicyclicrings, e.g., 5 to 12-membered spiro bicycles, such as2-oxa-6-azaspiro[3.3]heptane.

The term “heteroaryl” refers to a radical derived from a 5 to 18membered aromatic ring radical that comprises two to seventeen carbonatoms and from one to six heteroatoms selected from nitrogen, oxygen andsulfur. As used herein, the heteroaryl radical is a monocyclic,bicyclic, tricyclic or tetracyclic ring system, wherein at least one ofthe rings in the ring system is aromatic, i.e., it contains a cyclic,delocalized (4n+2) π-electron system in accordance with the Mickeltheory. Heteroaryl includes fused or bridged ring systems. Theheteroatom(s) in the heteroaryl radical is optionally oxidized. One ormore nitrogen atoms, if present, are optionally quaternized. Theheteroaryl is attached to the rest of the molecule through any atom ofthe ring(s). Examples of heteroaryls include, but are not limited to,azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl,benzofuranyl, benzoxazolyl, benzo[d]thiazolyl, benzothiadiazolyl,benzo[b][1,4]dioxepinyl, benzo[b][1,4]oxazinyl, 1,4-benzodioxanyl,benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl,benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl(benzothiophenyl), benzothieno[3,2-d]pyrimidinyl, benzotriazolyl,benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl,cyclopenta[d]pyrimidinyl,6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl,5,6-dihydrobenzo[h]quinazolinyl, 5,6-dihydrobenzo[h]cinnolinyl,6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazinyl, dibenzofuranyl,dibenzothiophenyl, furanyl, furanonyl, furo[3,2-c]pyridinyl,5,6,7,8,9,10-hexahydrocycloocta[d]pyrimidinyl,5,6,7,8,9,10-hexahydrocycloocta[d]pyridazinyl,5,6,7,8,9,10-hexahydrocycloocta[d]pyridinyl, isothiazolyl, imidazolyl,indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl,isoquinolyl, indolizinyl, isoxazolyl,5,8-methano-5,6,7,8-tetrahydroquinazolinyl, naphthyridinyl,1,6-naphthyridinonyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl,5,6,6a,7,8,9,10,10a-octahydrobenzo[h]quinazolinyl, 1-phenyl-1H-pyrrolyl,phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl,purinyl, pyrrolyl, pyrazolyl, pyrazolo[3,4-d]pyrimidinyl, pyridinyl,pyrido[3,2-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrazinyl,pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl,quinolinyl, isoquinolinyl, tetrahydroquinolinyl,5,6,7,8-tetrahydroquinazolinyl,5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl,6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidinyl,5,6,7,8-tetrahydropyrido[4,5-c]pyridazinyl, thiazolyl, thiadiazolyl,triazolyl, tetrazolyl, triazinyl, thieno[2,3-d]pyrimidinyl,thieno[3,2-d]pyrimidinyl, thieno[2,3-c]pyridinyl, and thiophenyl (i.e.thienyl).

The term “heterocycloalkyl” refers to a saturated ring with carbon atomsand at least one heteroatom. Exemplary heteroatoms include N, O, Si, P,B, and S atoms. Heterocycloalkyl may include monocyclic and polycyclicrings such as 3- to 10-membered monocyclic rings, 6- to 12-memberedbicyclic rings, 5- to 12-membered spiro bicycles, and 5- to 12-memberedbridged rings. The heteroatoms in the heterocycloalkyl radical areoptionally oxidized. One or more nitrogen atoms, if present, areoptionally quaternized. The heterocycloalkyl is attached to the rest ofthe molecule through any atom of the heterocycloalkyl, valencepermitting, such as any carbon or nitrogen atoms of theheterocycloalkyl. Examples of heterocycloalkyl radicals include, but arenot limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl,imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl,morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl,2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl,piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl,thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl,thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl,2-oxa-6-azaspiro[3.3]heptane, and 1,1-dioxo-thiomorpholinyl.

The term “heterocycloalkenyl” refers to an unsaturated ring with carbonatoms and at least one heteroatom and there is at least one double bondbetween two ring carbons. Heterocycloalkenyl does not include heteroarylrings. Exemplary heteroatoms include N, O, Si, P, B, and S atoms.Heterocycloalkenyl may include monocyclic and polycyclic rings such as3- to 10-membered monocyclic rings, 6- to 12-membered bicyclic rings,and 5- to 12-membered bridged rings. In other embodiments, aheterocycloalkenyl comprises five to seven ring atoms. Theheterocycloalkenyl may be attached to the rest of the molecule by asingle bond. Examples of monocyclic cycloalkenyls include, e.g.,pyrroline (dihydropyrrole), pyrazoline (dihydropyrazole), imidazoline(dihydroimidazole), triazoline (dihydrotriazole), dihydrofuran,dihydrothiophene, oxazoline (dihydrooxazole), isoxazoline(dihydroisoxazole), thiazoline (dihydrothiazole), isothiazoline(dihydroisothiazole), oxadiazoline (dihydrooxadiazole), thiadiazoline(dihydrothiadiazole), dihydropyridine, tetrahydropyridine,dihydropyridazine, tetrahydropyridazine, dihydropyrimidine,tetrahydropyrimidine, dihydropyrazine, tetrahydropyrazine, pyran,dihydropyran, thiopyran, dihydrothiopyran, dioxine, dihydrodioxine,oxazine, dihydrooxazine, thiazine, and dihydrothiazine.

The term “substituted” refers to moieties having substituents replacinga hydrogen on one or more carbons or substitutable heteroatoms, e.g., anNH or NH₂ of a compound. It will be understood that “substitution” or“substituted with” includes the implicit proviso that such substitutionis in accordance with permitted valence of the substituted atom and thesubstituent, and that the substitution results in a stable compound,i.e., a compound which does not spontaneously undergo transformationsuch as by rearrangement, cyclization, elimination, etc. In certainembodiments, substituted refers to moieties having substituentsreplacing two hydrogen atoms on the same carbon atom, such assubstituting the two hydrogen atoms on a single carbon with an oxo,imino or thioxo group. As used herein, the term “substituted” iscontemplated to include all permissible substituents of organiccompounds. In a broad aspect, the permissible substituents includeacyclic and cyclic, branched and unbranched, carbocyclic andheterocyclic, aromatic and non-aromatic substituents of organiccompounds. The permissible substituents can be one or more and the sameor different for appropriate organic compounds.

In some embodiments, substituents may include any substituents describedherein, for example: halogen, hydroxy, oxo (═O), thioxo (═S), cyano(—CN), nitro (—NO₂), imino (═N—H), oximo (═N—OH), hydrazino (═N—NH₂),—R^(b)—OR^(a), —R^(b)—OC(O)—R^(a), —R^(b)—OC(O)—OR^(a),—R^(b)—OC(O)—N(R^(a))₂, —R^(b)—N(R^(a))₂, —R^(b)—C(O)R^(a),—R^(b)—C(O)OR^(a), —R^(b)—C(O)N(R^(a))₂, —R^(b)—O—R^(c)—C(O)N(R^(a))₂,—R^(b)—N(R^(a))C(O)OR^(a), —R^(b)—N(R^(a))C(O)R^(a),—R^(b)—N(R^(a))S(O)_(t)R^(a) (where t is 1 or 2), —R^(b)—S(O)_(t)R^(a)(where t is 1 or 2), —R^(b)—S(O)_(t)OR^(a) (where t is 1 or 2), and—R^(b)—S(O)_(t)N(R^(a))₂ (where t is 1 or 2); and alkyl, alkenyl,alkynyl, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl,cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl,and heteroarylalkyl, any of which may be optionally substituted byalkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl,oxo (═O), thioxo (═S), cyano (—CN), nitro (—NO₂), imino (═N—H), oximo(═N—OH), hydrazine (═N—NH₂), —R^(b)—OR^(a), —R^(b)—OC(O)—R^(a),—R^(b)—OC(O)—OR^(a), —R^(b)—OC(O)—N(R^(a))₂, —R^(b)—N(R^(a))₂,—R^(b)—C(O)R^(a), —R^(b)—C(O)OR^(a), —R^(b)—C(O)N(R^(a))₂,—R^(b)—O—R^(c)—C(O)N(R^(a))₂, —R^(b)—N(R^(a))C(O)OR^(a),—R^(b)—N(R^(a))C(O)R^(a), —R^(b)—N(R^(a))S(O)_(t)R^(a) (where t is 1 or2), —R^(b)—S(O)_(t)R^(a) (where t is 1 or 2), —R^(b)—S(O)_(t)OR^(a)(where t is 1 or 2) and —R^(b)—S(O)_(t)N(R^(a))₂ (where t is 1 or 2);wherein each R^(a) is independently selected from hydrogen, alkyl,cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocycloalkyl,heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl, wherein eachR^(a), valence permitting, may be optionally substituted with alkyl,alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo(═O), thioxo (═S), cyano (—CN), nitro (—NO₂), imino (═N—H), oximo(═N—OH), hydrazine (═N—NH₂), —R^(b)—OR^(a), —R^(b)—OC(O)—R^(a),—R^(b)—OC(O)—OR^(a), —R^(b)—OC(O)—N(R^(a))₂, —R^(b)—N(R^(a))₂,—R^(b)—C(O)R^(a), —R^(b)—C(O)OR^(a), —R^(b)—C(O)N(R^(a))₂,—R^(b)—O—R^(c)—C(O)N(R^(a))₂, —R^(b)—N(R^(a))C(O)OR^(a),—R^(b)—N(R^(a))C(O)R^(a), —R^(b)—N(R^(a))S(O)_(t)R^(a) (where t is 1 or2), —R^(b)—S(O)_(t)R^(a) (where t is 1 or 2), —R^(b)—S(O)_(t)OR^(a)(where t is 1 or 2) and —R^(b)—S(O)_(t)N(R^(a))₂ (where t is 1 or 2);and wherein each R^(b) is independently selected from a direct bond or astraight or branched alkylene, alkenylene, or alkynylene chain, and eachRe is a straight or branched alkylene, alkenylene or alkynylene chain.

Double bonds to oxygen atoms, such as oxo groups, are represented hereinas both “═O” and “(O)”. Double bonds to nitrogen atoms are representedas both “═NR” and “(NR)”. Double bonds to sulfur atoms are representedas both “═S” and “(S)”.

The phrases “parenteral administration” and “administered parenterally”as used herein means modes of administration other than enteral andtopical administration, usually by injection, and includes, withoutlimitation, intravenous, intramuscular, intra-arterial, intrathecal,intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal,transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular,subarachnoid, intraspinal and intrasternal injection and infusion.

The phrase “pharmaceutically acceptable” is employed herein to refer tothose compounds, materials, compositions, and/or dosage forms which are,within the scope of sound medical judgment, suitable for use in contactwith the tissues of human beings and animals without excessive toxicity,irritation, allergic response, or other problem or complication,commensurate with a reasonable benefit/risk ratio.

The phrase “pharmaceutically acceptable excipient” or “pharmaceuticallyacceptable carrier” as used herein means a pharmaceutically acceptablematerial, composition or vehicle, such as a liquid or solid filler,diluent, excipient, solvent or encapsulating material. Each carrier mustbe “acceptable” in the sense of being compatible with the otheringredients of the formulation and not injurious to the patient. Someexamples of materials which can serve as pharmaceutically acceptablecarriers include: (1) sugars, such as lactose, glucose and sucrose; (2)starches, such as corn starch and potato starch; (3) cellulose, and itsderivatives, such as sodium carboxymethyl cellulose, ethyl cellulose andcellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7)talc; (8) excipients, such as cocoa butter and suppository waxes; (9)oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil,olive oil, corn oil and soybean oil; (10) glycols, such as propyleneglycol; (11) polyols, such as glycerin, sorbitol, mannitol andpolyethylene glycol; (12) esters, such as ethyl oleate and ethyllaurate; (13) agar; (14) buffering agents, such as magnesium hydroxideand aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17)isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20)phosphate buffer solutions; and (21) other non-toxic compatiblesubstances employed in pharmaceutical formulations.

The term “salt” or “pharmaceutically acceptable salt” refers to saltsderived from a variety of organic and inorganic counter ions well knownin the art. Pharmaceutically acceptable acid addition salts can beformed with inorganic acids and organic acids. Inorganic acids fromwhich salts can be derived include, for example, hydrochloric acid,hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and thelike. Organic acids from which salts can be derived include, forexample, acetic acid, propionic acid, glycolic acid, pyruvic acid,oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid,tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid,methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid,salicylic acid, and the like. Pharmaceutically acceptable base additionsalts can be formed with inorganic and organic bases. Inorganic basesfrom which salts can be derived include, for example, sodium, potassium,lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese,aluminum, and the like. Organic bases from which salts can be derivedinclude, for example, primary, secondary, and tertiary amines,substituted amines including naturally occurring substituted amines,cyclic amines, basic ion exchange resins, and the like, specificallysuch as isopropylamine, trimethylamine, diethylamine, triethylamine,tripropylamine, and ethanolamine. In some embodiments, thepharmaceutically acceptable base addition salt is chosen from ammonium,potassium, sodium, calcium, and magnesium salts.

As used herein, “treatment” or “treating” refers to an approach forobtaining beneficial or desired results with respect to a disease,disorder, or medical condition including but not limited to atherapeutic benefit and/or a prophylactic benefit. A therapeutic benefitcan include, for example, the eradication or amelioration of theunderlying disorder being treated. Also, a therapeutic benefit caninclude, for example, the eradication or amelioration of one or more ofthe physiological symptoms associated with the underlying disorder suchthat an improvement is observed in the subject, notwithstanding that thesubject may still be afflicted with the underlying disorder. In certainembodiments, for prophylactic benefit, the compositions are administeredto a subject at risk of developing a particular disease, or to a subjectreporting one or more of the physiological symptoms of a disease, eventhough a diagnosis of this disease may not have been made. Treatment viaadministration of a compound described herein does not require theinvolvement of a medical professional.

Compounds

The following is a discussion of compounds and salts thereof that may beused in the methods of the disclosure. In certain embodiments, thecompounds and salts are described in Formulas (I), (Ia), (Ib), (Ic),(Id), (Ie), (II), and (IIa).

In one aspect, disclosed herein is a compound represented by Formula(I):

or a salt thereof, wherein:

-   each X is independently selected from C(R³), N, and N⁺(—O⁻) wherein    at least one X is N or N⁺(—O⁻);-   A is selected from —O—, —NR⁴—, —CR⁵R⁶—, —C(O)—, —S—, —S(O)—, and    —S(O)₂—;-   R¹ is selected from:    -   C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰—, —SR¹⁰, —N(R¹⁰)₂,        —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —OC(O)R¹⁰,        —N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —S(O)R¹⁰,        —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), —CN, C₃₋₁₀ carbocycle and 3-        to 10-membered heterocycle, wherein the C₃₋₁₀ carbocycle and 3-        to 10-membered heterocycle are each optionally substituted with        one or more R⁹; and    -   C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle, each of        which is optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂,        —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰,        —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), —CN, C₁₋₆ alkyl, C₂₋₆ alkenyl,        and C₂₋₆ alkynyl, wherein C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆        alkynyl are each optionally substituted with one or more R⁹; or    -   R¹ together with R³ form a 5- to 10-membered heterocycle or        C₅₋₁₀ carbocycle, wherein the 5- to 10-membered heterocycle or        C₅₋₁₀ carbocycle is optionally substituted with one or more R⁹;        R¹ together with R⁵ form a 3- to 10-membered heterocycle or        C₃₋₁₀ carbocycle, wherein the 3- to 10-membered heterocycle or        C₃₋₁₀ carbocycle is optionally substituted with one or more R⁹;        or R¹ together with R⁴ form a 3- to 10-membered heterocycle,        wherein the 3- to 10-membered heterocycle is optionally        substituted with one or more R⁹;-   R² is a heteroaryl optionally substituted with one or more    substituents independently selected from:    -   halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂,        —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂,        —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰,        —NO₂, ═O, ═S, ═N(R¹⁰), and —CN; and when R² is pyridyl or        pyrimidyl, a substituent on a nitrogen atom of the pyridyl or        pyrimidyl is optionally further selected from —O⁻;    -   C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂,        —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰,        —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), —CN, C₃₋₁₀ carbocycle and 3-        to 10-membered heterocycle, wherein the C₃₋₁₀ carbocycle and 3-        to 10-membered heterocycle are each optionally substituted with        one or more R⁹; and    -   C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle, each of        which is optionally substituted with one or more R⁹;-   each R³, R⁵, and R⁶ is independently selected from:    -   hydrogen, halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, —CN, and C₁₋₆        alkyl optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —NO₂, and —CN; or    -   R³ together with R¹ form a 5- to 10-membered heterocycle or        C₅₋₁₀ carbocycle, wherein the 5- to 10-membered heterocycle or        C₅₋₁₀ carbocycle is optionally substituted with one or more R⁹;        R⁵ together with R¹ form a 3- to 10-membered heterocycle or        C₃₋₁₀ carbocycle, wherein the 3- to 10-membered heterocycle or        C₃₋₁₀ carbocycle is optionally substituted with one or more R⁹;-   R⁴ is independently selected from:    -   hydrogen; and    -   C₁₋₆ alkyl optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —NO₂, and —CN; or R⁴ together with R¹ form a 3- to 10-membered        heterocycle, which is optionally substituted with one or more        R⁹;-   R⁷ and R⁸ are independently selected from:    -   halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, —CN, and C₁₋₆ alkyl        optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —NO₂, and —CN;-   each R⁹ is independently selected from:    -   halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂,        —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂, —OC(C)N(R¹⁰)₂,        —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰,        —NO₂, ═O, ═S, ═N(R¹⁰), —CN; and    -   C₁₋₃ alkyl, C₂₋₃ alkenyl, and C₂₋₃ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂,        —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰,        —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), and —CN;-   each R¹⁰ is independently selected from:    -   hydrogen; and    -   C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —CN, —OH, —SH, —NO₂, —NH₂,        ═O, ═S, —O—C₁₋₆ alkyl, —S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —NH(C₁₋₆        alkyl), C₃₋₁₀ carbocycle, 3- to 10-membered heterocycle; and    -   C₃₋₁₀ carbocycle, and 3- to 10-membered heterocycle, each of        which is optionally substituted with one or more substituents        independently selected from halogen, —CN, —OH, —SH, —NO₂, —NH₂,        ═O, ═S, —O—C₁₋₆ alkyl, —S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —NH(C₁₋₆        alkyl), C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀        carbocycle, 3- to 10-membered heterocycle, and C₁₋₆ haloalkyl;-   n is 0, 1, or 2; and-   p is 0, 1, or 2.

In certain embodiments, for a compound or salt of Formula (I), each X isindependently selected from C(R³) and N wherein at least one X is N. Insome embodiments, one X is N and one X is C(R³). In some embodiments,one X is N⁺(—O⁻) and one X is C(R³). In some embodiments, each X is N.In some embodiments, one X is N, and one X is N⁺(—O⁻).

In certain embodiments, for a compound or salt of Formula (I), each X isfurther selected from C(R³).

In some embodiments, a compound or salt thereof of Formula (I) isrepresented by Formula (Ia):

In some embodiments, a compound or salt thereof of Formula (I) isrepresented by Formula (Ib):

In some embodiments, a compound or salt thereof of Formula (I) isrepresented by Formula (Ic):

In some embodiments, a compound or salt thereof of Formula (I) isrepresented by Formula (Id):

In certain embodiments, a compound of Formula (I) is represented byFormula (Ia) or Formula (Ib):

In certain embodiments, a compound of Formula (I) is represented byFormula (Ic) or Formula (Id):

In certain embodiments, the compound of Formula (I) is represented byFormula (Ia) or Formula (Ic):

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), (Id), A is selected from —O—, —NR⁴—, —CR⁵R⁶—, and—C(O)—. In some embodiments, A is selected from —O— and —NR⁴. In someembodiments, A is —O—.

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), or (Id), R¹ is selected from:

-   -   C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰,        —N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —S(O)R¹⁰,        —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), —CN, C₃₋₁₀ carbocycle and 3-        to 10-membered heterocycle, wherein the C₃₋₁₀ carbocycle and 3-        to 10-membered heterocycle are each optionally substituted with        one or more R⁹; and    -   C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle, each of        which is optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂,        —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰,        —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), and —CN; or    -   R¹ together with R³ form a 5- to 10-membered heterocycle or        C₅₋₁₀ carbocycle, wherein the 5- to 10-membered heterocycle or        C₅₋₁₀ carbocycle is optionally substituted with one or more R⁹;        or R¹ together with R⁵ form a 3- to 10-membered heterocycle or        C₃₋₁₀ carbocycle, wherein the 3- to 10-membered heterocycle or        C₃₋₁₀ carbocycle is optionally substituted with one or more R⁹;        or R¹ together with R⁴ form a 3- to 10-membered heterocycle,        wherein the 3- to 10-membered heterocycle is optionally        substituted with one or more R⁹.

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), or (Id), R¹ is selected from:

-   -   C₁₋₅ alkyl optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —CN, C₃₋₇ carbocycle and        3- to 7-membered heterocycle, wherein the C₃₋₇ carbocycle and 3-        to 7-membered heterocycle are each optionally substituted with        one or more R⁹; and    -   C₃₋₇ carbocycle optionally substituted with one or more        substituents independently selected from halogen, —OR¹⁰, —SR¹⁰,        —N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —CN, C₁₋₆        alkyl, and C₁₋₆ haloalkyl; or    -   or R¹ together with R⁴ form a 3- to 6-membered heterocycle,        wherein the 3- to 6-membered heterocycle is optionally        substituted with one or more R⁹.

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), or (Id), R¹ is selected from:

-   -   C₁₋₅ alkyl optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, C₃₋₅        carbocycle and 3- to 5-membered heterocycle, wherein the C₃₋₅        carbocycle and 3- to 5-membered heterocycle are each optionally        substituted with one or more R⁹;    -   C₄-C₆ saturated carbocycle; or    -   R¹ together with R⁴ form a 5-membered saturated heterocycle        optionally substituted with one or more R⁹;    -   wherein R⁹ is independently selected from halogen, —OR¹⁰,        —N(R¹⁰)₂, —NO₂, ═O, —CN; and C₁₋₃ alkyl optionally substituted        with one or more substituents independently selected from        halogen, —OR¹⁰, —N(R¹⁰)₂, —NO₂, ═O, and —CN.

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), (Id), R¹ is selected from —CHF₂, —CH(CH₃)₂,—CH₂CH(CH₃)₂, —CH₂CF(CH₃)₂, —CH₂CF₃, —CH₂CH₂CF₃, —CH₂CH₂OCH₃,—CH₂CH₂OCF₃, —CH₂C(CH₃)₂OCH₃, —CH₂SCH₃, —CH₂CH₂SCH₃, —CH₂CH(CH₃)SCH₃,—CH₃, —CH₂CH₃, —CH₂CH₂CH₃, —CH(CH₃)CH₂CH₃, —CH₂CF₂CH₃, —CH₂C(CH₃)₃,—CH₂CH(CH₃)₂

or R¹ together with R⁴ form a 5-membered saturated heterocyclesubstituted with —CH₃, or —CF₃.

In some embodiments, R¹ is selected from C₁₋₅ alkyl optionallysubstituted with one or more substituents independently selected fromhalogen, —OR¹⁰, —SR¹⁰, C₃₋₅ carbocycle and 3- to 5-membered heterocycle,wherein the C₃₋₅ carbocycle and 3- to 5-membered heterocycle are eachoptionally substituted with one or more R⁹.

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), (Id), R¹ is C₁₋₆ alkyl optionally substitutedwith one or more substituents independently selected from halogen,—OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰,—C(O)OR¹⁰, —OC(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂,—N(R¹⁰)C(O)OR¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), —CN, C₃₋₁₀carbocycle and 3- to 10-membered heterocycle, wherein the C₃₋₁₀carbocycle and 3- to 10-membered heterocycle are each optionallysubstituted with one or more R⁹. In some embodiments, R¹ is C₁₋₆ alkylsubstituted with one or more substituents independently selected fromhalogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰,—C(O)OR¹⁰, —OC(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂,—N(R¹⁰)C(O)OR¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), —CN, C₃₋₁₀carbocycle and 3- to 10-membered heterocycle, wherein the C₃₋₁₀carbocycle and 3- to 10-membered heterocycle are each optionallysubstituted with one or more R⁹. In some embodiments, R¹ is C₁₋₆ alkylsubstituted with one or more substituents independently selected fromhalogen, —OR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰,—C(O)OR¹⁰, —OC(O)R¹⁰, —NO₂, ═O, ═N(R¹⁰), —CN, C₃₋₁₀ carbocycle and 3- to10-membered heterocycle, wherein the C₃₋₁₀ carbocycle and 3- to10-membered heterocycle are each optionally substituted with one or moreR⁹. In some embodiments, R¹ is selected from C₁₋₃ alkyl optionallysubstituted with one or more substituents independently selected fromhalogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, ═O, ═S, ═N(R¹⁰), —CN, C₃₋₁₀carbocycle and 3- to 10-membered heterocycle, wherein the C₃₋₁₀carbocycle and 3- to 10-membered heterocycle are each optionallysubstituted with one or more R⁹.

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), (Id), R¹ is C₁₋₃ alkyl substituted with one ormore substituents independently selected from halogen, —OR¹⁰, —N(R¹⁰)₂,—NO₂, ═O, —CN, C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle,wherein the C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle are eachoptionally substituted with one or more R⁹. In some embodiments, R¹ isC₁₋₃ alkyl substituted with one or more halogen substituents. In someembodiments, R¹ is a C₁₋₃ fluoroalkyl. In some embodiments, R¹ isselected from —CHF₂ and —CH₂CF₃. In some embodiments, R¹ is C₃₋₁₀carbocycle optionally substituted with one or more substituentsindependently selected from halogen, —CN, —OH, —SH, —NO₂, —NH₂, ═O, ═S,—O—C₁₋₆ alkyl, —S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —NH(C₁₋₆ alkyl), C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ carbocycle, 3- to 10-memberedheterocycle, and C₁₋₆ haloalkyl. In some embodiments, R¹ is selectedfrom C₁₋₃ alkyl optionally substituted with one or more substituentsindependently selected from halogen, —OR¹⁰, C₃₋₁₀ carbocycle and 3- to10-membered heterocycle, wherein the C₃₋₁₀ carbocycle and 3- to10-membered heterocycle are each optionally substituted with one or moreR⁹. In some embodiments, R¹ is selected from —CHF₂, —CH₂CF₃,—CH₂CH₂OCF₃, —CH₃, —CH₂CH₃, —CH₂CH₂CH₃, and —CH₂CH₂OCH₃,

In some embodiments, R¹ is selected from —CHF₂, —CH(CH₃)₂, —CH₂CH(CH₃)₂,—CH₂CF(CH₃)₂, —CH₂CF₃, —CH₂CH₂CF₃, —CH₂CH₂OCH₃, —CH₂CH₂OCF₃,—CH₂C(CH₃)₂OCH₃, —CH₂SCH₃, —CH₂CH₂SCH₃, —CH₂CH(CH₃)SCH₃, —CH₃, —CH₂CH₃,—CH₂CH₂CH₃, —CH(CH₃)CH₂CH₃, —CH₂CF₂CH₃, —CH₂C(CH₃)₃, —CH₂CH(CH₃)₂,

In some embodiments, R¹ is —CH₂CF₃.

In some embodiments, for a compound or salt of any one of Formula (I),(Ia), (Ib), (Ic), (Id), R¹ together with R⁴ form a 3- to 6-memberedheterocycle, wherein the 3- to 6-membered heterocycle is optionallysubstituted with one or more R⁹. In some embodiments, R¹ together withR⁴ form a 5-membered saturated heterocycle optionally substituted withone or more R⁹. In some embodiments, R¹ together with R⁴ form a5-membered saturated heterocycle optionally substituted with one or moresubstituents selected from C₁₋₃ alkyl, and C₁₋₃ haloalkyl.

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), or (Id), R¹ is selected from optionallysubstituted C₃-C₆ cycloalkyl, such as cyclopropyl, cyclobutyl,cyclopentyl, bicyclopentyl, and spiropentyl, any of which is optionallysubstituted. In certain embodiments, R¹ is selected from alkyl, e.g.,methyl, ethyl, propyl, iso-propyl, t-butyl, iso-butyl, sec-butyl, any ofwhich may be optionally substituted. In some embodiments, R¹ is selectedfrom optionally substituted saturated C₄-C₆ cycloalkyl. In certainembodiments, R¹ is selected from:

In certain embodiments, R¹ is selected from:

In certain embodiments, R¹ is selected from optionally substituted

In some embodiments, R¹ is

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), (Id), R¹ together with R³ form a 5- to10-membered heterocycle or C₅₋₁₀ carbocycle, wherein the 5- to10-membered heterocycle or C₅₋₁₀ carbocycle is optionally substitutedwith one or more R⁹. In some embodiments, R¹ together with R³ form aC₅₋₁₀ carbocycle or 5- to 10-membered heterocycle, such as a C₅₋₆carbocycle or 5- to 6-membered heterocycle, for example:

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), (Id), R¹ together with R⁵ form a 3- to10-membered heterocycle or C₃₋₁₀ carbocycle, wherein the 3- to10-membered heterocycle or C₃₋₁₀ carbocycle is optionally substitutedwith one or more R⁹. In some embodiments, R¹ together with R⁵ form a 3-to 10-membered heterocycle or C₃₋₁₀ carbocycle, for example:

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), (Id), R¹ together with R⁴ form a 3- to10-membered heterocycle, wherein the 3- to 10-membered heterocycle isoptionally substituted with one or more R⁹. In some embodiments, R¹together with R⁴ form a 3- to 10-membered heterocycle, for example:

In some embodiments, for a compound or salt of any one of Formula (I),(Ia), (Ib), (Ic), (Id), each R⁹ of R¹ is independently selected fromhalogen, —OR¹⁰, —N(R¹⁰)₂, —NO₂, ═O, —CN; and C₁₋₃ alkyl optionallysubstituted with one or more substituents independently selected fromhalogen, —OR¹⁰, —N(R¹⁰)₂, —NO₂, ═O, and —CN. In some embodiments, eachR⁹ of R¹ is independently selected from halogen and —OR¹⁰; and C₁₋₃alkyl optionally substituted with one or more substituents independentlyselected from halogen and —OR¹⁰. In some embodiments, each R⁹ of R¹ isindependently selected from —CH₃, —CF₃, and ═O

In some embodiments, for a compound or salt of any one of Formula (I),(Ia), (Ib), (Ic), (Id), R² is an optionally substituted 5-memberedheteroaryl, 6-membered heteroaryl, or a 9-membered bicyclic heterocycle.In some embodiments, R² is an optionally substituted 5-memberedheteroaryl. In certain embodiments, R² is an optionally substituted5-membered heteroaryl with at least one endocyclic nitrogen or oxygenatom in the 5-membered heteroaryl, e.g., oxazole, isoxazole, thiazole,pyrrole, pyrazole, furan, diazole, triazole, imidazole, oxadiazole,thiadiazole, isoxazole, isothiazole, and tetrazole. In certainembodiments, for a compound or salt of any one of Formula (I), (Ia),(Ib), (Ic), (Id), R² is selected from:

any one of which is optionally substituted. In some embodiments, R² isselected from:

any one of which is optionally substituted. In some embodiments, R² isselected from:

any one of which is optionally substituted. In some embodiments, R² isselected from:

any one of which is optionally substituted.

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), (Id), R² is selected from optionally substituted5- or 6-membered monocyclic heteroaryl and optionally substituted9-membered bicyclic heteroaryl. In some embodiments, R² is selected fromisoxazole, oxazole, thiadiazole, triazole, isothiazole, tetrazole,pyrazole, pyrrole, furan, imidazole, oxadiazole, thiazole, pyridine,pyridazine, pyrimidine, pyrazine, tetrazine, benzoxazole, benzothiazole,benzimidazole, indole, indazole, and imidazopyridine, any of which isoptionally substituted. In some embodiments, R² is selected fromisoxazole, oxazole, thiadiazole, triazole, tetrazole, pyrazole,oxadiazole, thiazole, pyridine, pyridazine, pyrazine, benzoxazole,indazole, and imidazopyridine, any of which is optionally substituted.In some embodiments, R² is not substituted at either ortho position onR² relative to the point of connectivity to the rest of the molecule. Insome embodiments, R² is not substituted at either ortho position on R²with a carbocycle or heterocycle. In some embodiments, R² is selectedfrom isoxazole, oxazole, thiadiazole, triazole, tetrazole, pyrazole,oxadiazole, thiazole, isoxazole, thiadiazole any of which is optionallysubstituted. In some embodiments, R² is selected from isoxazole,oxazole, thiadiazole, pyrazole, oxadiazole, thiazole, isoxazole,thiadiazole any of which is optionally substituted.

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), (Id), substituents on R² are independentlyselected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, and —CN; C₁₋₆ alkyloptionally substituted with one or more substituents independentlyselected from halogen, —OR¹⁰, —N(R¹⁰)₂, —NO₂, and —CN; and optionallysubstituted C₃₋₁₀ carbocycle. In some embodiments, R² is a heteroaryl,e.g., 5-membered heteroaryl, optionally substituted with one or moresubstituents selected from halogen, —OR¹⁰, and —N(R¹⁰)₂; C₁₋₄ alkyloptionally substituted with one or more substituents independentlyselected from halogen; and optionally substituted C₃₋₁₀ carbocycle,e.g., optionally substituted phenyl or optionally substituted cycloalkylsuch as cyclopropyl.

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), (Id), R² is selected from:

any one of which is optionally substituted. In some embodiments, R² isselected from:

any one of which is optionally substituted. In some embodiments, R² isselected from:

any one of which is optionally substituted.

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), (Id), R² is selected from optionally substituted6-membered heteroaryl. In some embodiments, R² may be selected from6-membered heteroaryls, such as pyridine, pyridazine, pyrimidine,pyrazine, triazene and N-oxides thereof. In some embodiments, R² isselected from optionally substituted pyridyl, optionally substitutedpyrimidyl, optionally substituted pyridyl N-oxide, and optionallysubstituted pyrimidyl N-oxide. In some embodiments, R² is selected fromoptionally substituted pyridyl and optionally substituted pyrimidyl. Incertain embodiments, for a compound or salt of any one of Formula (I),(Ia), (Ib), (Ic), (Id), R² is a 6-membered heteroaryl, e.g., pyridinylor pyrimidinyl, optionally substituted with halogen, —OR¹⁰, —SR¹⁰,—N(R¹⁰)₂, —NO₂, and —CN; C₁₋₆ alkyl optionally substituted with one ormore substituents independently selected from halogen, —OR¹⁰, —SR¹⁰,—N(R¹⁰)₂, —NO₂, and —CN; and optionally substituted C₃₋₁₀ carbocycle. Incertain embodiments, for a compound or salt of any one of Formula (I),(Ia), (Ib), (Ic), (Id), R² is a 6-membered heteroaryl, e.g., pyridinylor pyrimidinyl, optionally substituted with halogen, —OR¹⁰, —SR¹⁰, and—N(R¹⁰)₂; and C₁₋₄ alkyl optionally substituted with one or moresubstituents independently selected from halogen and —OR¹⁰. In someembodiments, R² is selected from:

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), (Id), R² is selected from optionally substitutedpyridine, optionally substituted pyrazine, optionally substitutedpyridazine, and optionally substituted pyrimidine. In some embodiments,R² is selected from

any of which is optionally substituted with one or more substituentsindependently selected from: halogen, —OR¹⁰, —SR¹⁰, —CN, and asubstituent on a nitrogen atom of the pyridyl is optionally selectedfrom —O⁻; and C₁₋₆ alkyl optionally substituted with one or moresubstituents independently selected from halogen and —OR¹⁰. In someembodiments, R² is selected from:

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), (Id), R² is selected from optionally substitutedbicyclic heteroaryl. In some embodiments, R² is selected from optionallysubstituted 9-membered bicyclic heteroaryl, e.g., optionally substitutedbenzoxazole, benzothiazole, or benzimidazole. In certain embodiments,for a compound or salt of any one of Formula (I), (Ia), (Ib), (Ic),(Id), R² is a 9-membered bicyclic heteroaryl, e.g., benzoxazole,optionally substituted with halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, and—CN; C₁₋₆ alkyl optionally substituted with one or more substituentsindependently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, and—CN; and optionally substituted C₃₋₁₀ carbocycle. In some embodiments,R² is selected from optionally substituted benzoxazole. In someembodiments, R² is selected from:

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), (Id), R² is selected optionally substituted9-membered bicyclic heteroaryl. In some embodiments, R² is selected frombenzoxazole, benzothiazole, benzimidazole, indole, indazole, andimidazopyridine, any of which is optionally substituted. In someembodiments, R² is selected from benzoxazole, benzothiazole, indole,indazole, and imidazopyridine, any of which is optionally substituted.In some embodiments, R² is selected from benzoxazole, indazole, andimidazopyridine, any of which is optionally substituted. In someembodiments, R² is selected from optionally substituted benzoxazole. Insome embodiments, R² is selected from:

any of which is optionally substituted with one or more substituentsindependently selected from halogen, —OR¹⁰, —SR¹⁰, and —CN. In someembodiments, R² is selected from:

In some embodiments, for a compound or salt of any one of Formula (I),(Ia), (Ib), (Ic), (Id), when R² is substituted at either or both orthopositions of the heteroaryl ring relative to the point of connectivityto the rest of the molecule, each ortho substituent on R² isindependently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, —CN,and C₁₋₃ alkyl optionally substituted with one or more substituentsindependently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, and—CN. In some embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), (Id), when R² is substituted at either or bothortho positions of the heteroaryl ring relative to the point ofconnectivity to the rest of the molecule, each ortho substituent on R²is independently selected from halogen, —OH, —OCH₃, —OCF₃, and C₁₋₃alkyl optionally substituted with one or more substituents independentlyselected from halogen.

In some embodiments, for a compound or salt of any one of Formula (I),(Ia), (Ib), (Ic), (Id), R² is not substituted at either ortho positionof the heteroaryl ring relative to the point of connectivity to the restof the molecule. In some embodiments, for a compound or salt of any oneof Formula (I), (Ia), (Ib), (Ic), (Id), R² is not substituted by aheterocycle or carbocycle at either ortho position of the heteroarylring relative to the point of connectivity to the rest of the molecule.

In certain embodiments, for a compound or salt of Formula (I), each R³is selected from hydrogen, halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, —CN,and C₁₋₆ alkyl optionally substituted with one or more substituentsindependently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, and—CN. In some embodiments, R³ together with R¹ form a 5- to 6-memberedheterocycle or C₅₋₆ carbocycle, wherein the 5- to 6-membered heterocycleor C₅₋₆ carbocycle is optionally substituted with one or more R⁹. Insome embodiments, R³ is hydrogen.

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), (Id), R⁴ is independently selected from hydrogen;and C₁₋₆ alkyl optionally substituted with one or more substituentsindependently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, and—CN; or R⁴ together with R¹ form a 3- to 10-membered heterocycle, whichis optionally substituted with one or more R⁹. In some embodiments, R⁴is hydrogen.

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), (Id), each R⁵ and R⁶ is independently selectedfrom hydrogen, halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, —CN, and C₁₋₆alkyl optionally substituted with one or more substituents independentlyselected from halogen, —OR², —SR¹⁰, —N(R¹⁰)₂, —NO₂, and —CN.

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), (Id), each R⁷ and R⁸ is independently selectedfrom halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, —CN, and C₁₋₆ alkyloptionally substituted with one or more substituents independentlyselected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, and —CN. In certainembodiments, for a compound or salt of any one of Formula (I), (Ia),(Ib), (Ic), (Id), each R⁷ and R⁸ is independently selected from halogen,—OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, —CN, —CHF₂, —CF₃, —CH₂F, and C₂₋₆ alkyloptionally substituted with one or more substituents independentlyselected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, and —CN.

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), (Id), each R⁹ is independently selected fromhalogen, —OR¹⁰, —N(R¹⁰)₂, —NO₂, ═O, ═S, —CN; and C₁₋₃ alkyl, C₂₋₃alkenyl, C₂₋₃ alkynyl, each of which is optionally substituted with oneor more substituents independently selected from halogen, —OR¹⁰,—N(R¹⁰)₂, —NO₂, —CN. In some embodiments, R⁹ is a halogen. In someembodiments, R⁹ is an unsubstituted C₁₋₃ alkyl. In some embodiments, R⁹is ═O. In some embodiments, R⁹ is a haloalkyl. In some embodiments, R⁹is a C₁₋₃ alkyl substituted with one or more fluorine substituents.

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), (Id), each R¹⁰ is independently selected fromhydrogen; and C₁₋₆ alkyl optionally substituted with one or moresubstituents independently selected from halogen, —CN, —OH, —SH, —NO₂,—NH₂, ═O, ═S, —O—C₁₋₆ alkyl, —S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —NH(C₁₋₆alkyl), C₃₋₁₀ carbocycle, 3- to 10-membered heterocycle; and C₃₋₁₀carbocycle, and 3- to 10-membered heterocycle, each of which isoptionally substituted with one or more substituents independentlyselected from halogen, —CN, —OH, —SH, —NO₂, —NH₂, ═O, ═S, —O—C₁₋₆ alkyl,—S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —NH(C₁₋₆ alkyl), C₁₋₆ alkyl, C₃₋₁₀carbocycle, 3- to 10-membered heterocycle, and haloalkyl.

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), (Id), n is 0.

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), (Id), p is 0.

In one aspect, disclosed herein is a compound represented by Formula(Ie):

or a salt thereof, wherein:

-   X is independently selected from C(R³) and N;-   R¹ is selected from    -   C₁₋₆ alkyl optionally substituted with one or more substituents        independently selected from halogen, —OH, —SH, —NH₂, —NO₂, —CN,        C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle, wherein the        C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle are each        optionally substituted with one or more R⁹;-   R² is a heteroaryl, e.g., a 5-, 6-, or 9-membered heteroaryl,    optionally substituted with one or more substituents independently    selected from    -   halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, and —CN;    -   C₁₋₆ alkyl optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —NO₂, —CN; and    -   C₃₋₁₀ carbocycle optionally substituted with one or more R⁹;-   each R⁹ is independently selected from    -   halogen, —OR¹⁰, —N(R¹⁰)₂, —NO₂, —CN; and    -   C₁₋₃ alkyl optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —N(R¹⁰)₂, —NO₂, and        —CN; and-   each R¹⁰ is independently selected from    -   hydrogen; and    -   C₁₋₆ alkyl optionally substituted with one or more substituents        independently selected from halogen, —CN, —OH, —SH, —NO₂, —NH₂,        —O—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, and —NH(C₁₋₆ alkyl).

In certain embodiments, for a compound or salt of any one of Formula(I), (Ia), (Ib), (Ic), or (Id), R¹-A is further selected from hydrogen.For example, a compound of the disclosure may be represented by:

or a salt thereof.

In certain embodiments, for a compound or salt of Formula (I):

-   each X is N or N⁺(—O⁻), preferably each X is N;-   A is selected from —O—, —NR⁴—, or —CR⁵R⁶—, preferably A is —O—;-   R¹ is selected from C₁₋₅ alkyl optionally substituted with one or    more substituents independently selected from halogen, —OR¹⁰, —SR¹⁰,    C₃₋₅ carbocycle and 3- to 5-membered heterocycle, wherein the C₃₋₅    carbocycle and 3- to 5-membered heterocycle are each optionally    substituted with one or more R⁹, preferably R¹ is selected from C₁₋₃    alkyl optionally substituted with one or more substituents    independently selected from halogen;-   R² is selected from optionally substituted 5- or 6-membered    monocyclic heteroaryl and optionally substituted 9-membered bicyclic    heteroaryl, preferably R² is selected from optionally substituted    6-membered heteroaryl, wherein substituents on R² are independently    selected from halogen, —OR¹⁰, —SR¹⁰, —CN, C₁₋₃ alkyl and C₁₋₃    haloalkyl;-   R⁷ and R⁸ are independently selected from halogen, —OR¹⁰, —SR¹⁰,    —N(R¹⁰)₂, —NO₂, —CN, and C₁₋₃ alkyl optionally substituted with one    or more substituents independently selected from halogen;-   n is 0 or 1; and-   p is 0 or 1.

In certain embodiments, a compound of the disclosure is selected from acompound of Table 1 or a salt thereof.

In one aspect, disclosed herein is a compound represented by Formula(II):

or a salt thereof, wherein:

-   T is selected from —O—, —NR¹⁴—, —CR¹⁵R¹⁶—, —C(O)—, —S—, —S(O)—, and    —S(O)₂;-   R¹¹ is selected from:    -   C₁₋₅ haloalkyl optionally further substituted with one or more        substituents independently selected from —OR²⁰, —SR²⁰, —N(R²⁰)₂,        —NO₂, ═O, ═S, —CN, C₃₋₁₀ carbocycle and 3- to 10-membered        heterocycle, wherein the C₃₋₁₀ carbocycle and 3- to 10-membered        heterocycle are each optionally substituted with one or more        R¹⁹;-   R¹² is a heteroaryl optionally substituted with one or more    substituents independently selected from    -   halogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂, —C(O)R²⁰, —C(O)N(R²⁰)₂,        —N(R²⁰)C(O)R²⁰, —N(R²⁰)C(O)N(R²⁰)₂, —OC(O)N(R²⁰)₂,        —N(R²⁰)C(O)OR²⁰, —C(O)OR²⁰, —OC(O)R²⁰, —S(O)R²⁰, —S(O)₂R²⁰,        —NO₂, ═O, ═S, ═N(R²⁰), and —CN; and when R¹² is pyridyl or        pyrimidyl, a substituent on a nitrogen atom of the pyridyl or        pyrimidyl is optionally further selected from —O⁻;    -   C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂,        —C(O)R², —C(O)N(R²⁰)₂, —N(R²⁰)C(O)R²⁰, —N(R²⁰)C(O)N(R²⁰)₂,        —OC(O)N(R²⁰)₂, —N(R²⁰)C(O)OR²⁰, —C(O)OR²⁰, —OC(O)R²⁰, —S(O)R²⁰,        —S(O)₂R²⁰, —NO₂, ═O, ═S, ═N(R²⁰), —CN, C₃₋₁₀ carbocycle and 3-        to 10-membered heterocycle, wherein the C₃₋₁₀ carbocycle and 3-        to 10-membered heterocycle are each optionally substituted with        one or more R¹⁹; and    -   C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle, each of        which is optionally substituted with one or more —R¹⁹;    -   each R¹⁵ and R¹⁶ is independently selected from hydrogen,        halogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂, —NO₂, —CN, and C₁₋₆ alkyl        optionally substituted with one or more substituents        independently selected from halogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂,        —NO₂, and —CN;    -   R¹⁴ is independently selected from hydrogen, and C₁₋₆ alkyl        optionally substituted with one or more substituents        independently selected from halogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂,        —NO₂, and —CN;-   each R¹⁷ and R¹⁸ is independently selected from:    -   halogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂, —NO₂, —CN, and C₁₋₆ alkyl        optionally substituted with one or more substituents        independently selected from halogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂,        —NO₂, and —CN;-   each R¹⁹ is independently selected from:    -   halogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂, —C(O)R²⁰, —C(O)R²⁰,        —C(O)N(R²⁰)₂, —N(R²⁰)C(O)R²⁰, —N(R²⁰)C(O)N(R²⁰)₂, —OC(O)N(R²⁰)₂,        —N(R²⁰)C(O)OR²⁰, —C(O)OR²⁰, —OC(O)R²⁰, —S(O)R²⁰, —S(O)₂R²⁰,        —NO₂, ═O, ═S, ═N(R²⁰), —CN; and    -   C₁₋₃ alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂,        —C(O)R²⁰, —C(O)N(R²⁰)₂, —N(R²⁰)C(O)R²⁰, —N(R²⁰)C(O)N(R²⁰)₂,        —OC(O)N(R²⁰)₂, —N(R²⁰)C(O)OR²⁰, —C(O)OR²⁰, —OC(O)R²⁰, —S(O)R²⁰,        —S(O)₂R²⁰, —NO₂, ═O, ═S, ═N(R²⁰), and —CN;-   each R²⁰ is independently selected from:

hydrogen; and

-   -   C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —CN, —OH, —SH, —NO₂, —NH₂,        ═O, ═S, —O—C₁₋₆ alkyl, —S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —NH(C₁₋₆        alkyl), C₃₋₁₀ carbocycle, 3- to 10-membered heterocycle; and    -   C₃₋₁₀ carbocycle, and 3- to 10-membered heterocycle, each of        which is optionally substituted with one or more substituents        independently selected from halogen, —CN, —OH, —SH, —NO₂, —NH₂,        ═O, ═S, —O—C₁₋₆ alkyl, —S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —NH(C₁₋₆        alkyl), C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀        carbocycle, 3- to 10-membered heterocycle, and haloalkyl;

-   w is 0, 1, or 2; and

-   z is 0, 1, or 2.

In certain embodiments, for a compound or salt of Formula (II), T isselected from —O—, —NR¹⁴—, and —CR¹⁵R¹⁶—. In some embodiments, T is —O—.

In certain embodiments, for a compound or salt of Formula (II), R¹¹ isselected from C₁₋₅ haloalkyl optionally further substituted with one ormore substituents independently selected from —OH, —SH, —NH₂, —NO₂, ═O,═S, —CN, C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle, wherein theC₃₋₁₀ carbocycle and 3- to 10-membered heterocycle are each optionallysubstituted with one or more R¹⁹. In some embodiments, R¹¹ is selectedfrom C₁₋₃ haloalkyl optionally further substituted with one or moresubstituents independently selected from —OR²⁰, —SR²⁰, —N(R²⁰)₂, ═O,—CN, C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle. In certainembodiments, R¹¹ is C₁₋₃ alkyl substituted with one or more halogensubstituents. In some embodiments, R¹¹ is —CHF₂ or —CH₂CF₃.

In certain embodiments, for a compound or salt of any one of Formula(II), R¹¹ is selected from optionally substituted C₃-C₆ cycloalkyl, suchas cyclopropyl, cyclobutyl, cyclopentyl, bicyclopentyl, and spiropentyl,any of which is optionally substituted. In certain embodiments, R¹¹ isselected from alkyl, e.g., methyl, ethyl, propyl, iso-propyl, t-butyl,iso-butyl, sec-butyl, any of which may be optionally substituted. Incertain embodiments, R¹¹ is selected from:

In certain embodiments, R¹¹ is selected from:

In certain embodiments, R¹¹ is selected from optionally substituted

In some embodiments, for a compound of Formula (II), R¹² is anoptionally substituted 5-membered heteroaryl, 6-membered heteroaryl, ora 9-membered bicyclic heterocycle. In some embodiments, R¹² is anoptionally substituted 5-membered heteroaryl. In certain embodiments,R¹² is an optionally substituted 5-membered heteroaryl with at least oneendocyclic nitrogen or oxygen atom in the 5-membered heteroaryl, e.g.,oxazole, thiazole, pyrrole, pyrazole, furan, diazole, triazole,imidazole, oxadiazole, thiadiazole, isoxazole, isothiazole, andtetrazole. In certain embodiments, for a compound or salt of Formula(II), R¹² is selected from:

any one of which is optionally substituted. In some embodiments, R¹² isselected from:

any one of which is optionally substituted. In some embodiments, R¹² isselected from:

any one of which is optionally substituted. In some embodiments, R¹² isselected from:

any of which is optionally substituted. In some embodiments, R¹² isselected from:

In some embodiments, R¹² is selected from optionally substituted 5- or6-membered monocyclic heteroaryl and optionally substituted 9-memberedbicyclic heteroaryl. In some embodiments, R¹² is selected fromisoxazole, oxazole, thiadiazole, triazole, isothiazole, tetrazole,pyrazole, pyrrole, furan, imidazole, oxadiazole, thiazole, pyridine,pyridazine, pyrimidine, pyrazine, tetrazine, benzoxazole, benzothiazole,benzimidazole, indole, indazole, and imidazopyridine, any of which isoptionally substituted. In some embodiments, R¹² is selected fromisoxazole, oxazole, thiadiazole, triazole, pyrazole, imidazole,oxadiazole, thiazole, pyridine, pyrimidine, benzoxazole, benzimidazole,any of which is optionally substituted. In some embodiments, R¹² isselected from isoxazole, oxazole, thiadiazole, oxadiazole, pyrazole,tetrazole, thiazole, pyridine, benzoxazole, any of which is optionallysubstituted. In some embodiments, R¹² is not substituted at either orthoposition on R¹² relative to the point of connectivity to the rest of themolecule. In some embodiments, R¹² is not substituted at either orthoposition on R¹² with a carbocycle or heterocycle. In some embodiments,R¹² is selected from isoxazole, oxazole, thiadiazole, oxadiazole,pyrazole, tetrazole, and thiazole, any of which is optionallysubstituted.

In certain embodiments, for a compound of Formula (II), substituents onR¹² are independently selected from halogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂,—NO₂, and —CN; C₁₋₆ alkyl optionally substituted with one or moresubstituents independently selected from halogen, —OR²⁰, —SR¹⁰,—N(R²⁰)₂, —NO₂, and —CN; and optionally substituted C₃₋₁₀ carbocycle. Insome embodiments, R² is a heteroaryl, e.g., 5-membered heteroaryl,optionally substituted with one or more substituents selected fromhalogen, —OR¹⁰, and —N(R²⁰)₂; C₁₋₄ alkyl optionally substituted with oneor more substituents independently selected from halogen; and optionallysubstituted C₃₋₁₀ carbocycle, e.g., optionally substituted phenyl oroptionally substituted cycloalkyl such as cyclopropyl.

In certain embodiments, for a compound or salt of Formula (II), R¹² isselected from:

any one of which is optionally substituted. In some embodiments, R¹² isselected from:

any one of which is optionally substituted.

In certain embodiments, for a compound or salt of Formula (II), R¹² isselected from optionally substituted 6-membered heteroaryl. In someembodiments, R¹² may be selected from 6-membered heteroaryls, such aspyridine, pyridazine, pyrimidine, pyrazine, triazene and N-oxidesthereof. In some embodiments, R¹² is selected from optionallysubstituted pyridyl, optionally substituted pyrimidyl, optionallysubstituted pyridyl N-oxide, and optionally substituted pyrimidylN-oxide. In some embodiments, R¹² is selected from optionallysubstituted pyridyl and optionally substituted pyrimidyl. In certainembodiments, for a compound or salt of Formula (II), R¹² is a 6-memberedheteroaryl, e.g., pyridinyl or pyrimidinyl, optionally substituted withhalogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂, —NO₂, and —CN; C₁₋₆ alkyl optionallysubstituted with one or more substituents independently selected fromhalogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂, —NO₂, and —CN; and optionallysubstituted C₃₋₁₀ carbocycle. In certain embodiments, for a compound orsalt of Formula (II), R¹² is a 6-membered heteroaryl, e.g., pyridinyl orpyrimidinyl, optionally substituted with halogen, —OR²⁰, —SR²⁰, and—N(R²⁰)₂; and C₁₋₄ alkyl optionally substituted with one or moresubstituents independently selected from halogen and —OR²⁰. In someembodiments, R¹² is selected from:

In some embodiments, R¹² is selected from pyridine and pyrimidine any ofwhich is optionally substituted. In some embodiments, R¹² is selectedfrom:

any of which is optionally substituted.

In some embodiments, R¹² is selected from optionally substitutedbenzoxazole. In some embodiments, R¹² is optionally substituted

In certain embodiments, for a compound or salt of Formula (II), R¹² isselected from optionally substituted bicyclic heteroaryl. In someembodiments, R¹² is selected from optionally substituted 9-memberedbicyclic heteroaryl, e.g., optionally substituted benzoxazole,benzothiazole, or benzimidazole. In certain embodiments, for a compoundor salt of Formula (II), R¹² is a 9-membered bicyclic heteroaryl, e.g.,benzoxazole, optionally substituted with halogen, —OR²⁰, —SR²⁰,—N(R²⁰)₂, —NO₂, and —CN; C₁₋₆ alkyl optionally substituted with one ormore substituents independently selected from halogen, —OR²⁰, —SR²⁰,—N(R²⁰)₂, —NO₂, and —CN; and optionally substituted C₃₋₁₀ carbocycle. Insome embodiments, R¹² is selected from optionally substitutedbenzoxazole. In some embodiments, R¹² is selected from

In some embodiments, for a compound or salt of Formula (II), when R¹² issubstituted at either or both ortho positions of the heteroaryl ringrelative to the point of connectivity to the rest of the molecule, eachortho substituent on R¹² is independently selected from halogen, —OR²⁰,—SR²⁰, —N(R²⁰)₂, —NO₂, —CN, and C₁₋₃ alkyl optionally substituted withone or more substituents independently selected from halogen, —OR²⁰,—SR²⁰, —N(R²⁰)₂, —NO₂, and —CN. In some embodiments, for a compound orsalt of Formula (II), when R¹² is substituted at either or both orthopositions of the heteroaryl ring relative to the point of connectivityto the rest of the molecule, each ortho substituent on R¹² isindependently selected from halogen, —OH, —OCH₃, —OCF₃, and C₁₋₃ alkyloptionally substituted with one or more substituents independentlyselected from halogen.

In some embodiments, for a compound or salt of Formula (II), R¹² is notsubstituted at either ortho position of the heteroaryl ring relative tothe point of connectivity to the rest of the molecule. In someembodiments, for a compound or salt of Formula (II), R¹² is notsubstituted by a heterocycle or carbocycle at either ortho position ofthe heteroaryl ring relative to the point of connectivity to the rest ofthe molecule.

In certain embodiments, for a compound of Formula (II), R¹⁴ isindependently selected from hydrogen; and C₁₋₆ alkyl optionallysubstituted with one or more substituents independently selected fromhalogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂, —NO₂, and —CN. In some embodiments, R¹⁴is hydrogen.

In certain embodiments, for a compound of Formula (II), each R¹⁵ and R¹⁶is independently selected from hydrogen, halogen, —OR²⁰, —SR²⁰,—N(R²⁰)₂, —NO₂, —CN, and C₁₋₆ alkyl optionally substituted with one ormore substituents independently selected from halogen, —OR²⁰, —SR²⁰,—N(R²⁰)₂, —NO₂, and —CN.

In certain embodiments, for a compound of Formula (II), each R¹⁷ and R¹⁸is independently selected from halogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂, —NO₂,—CN, —CHF₂, —CF₃, —CH₂F, and C₂₋₆ alkyl optionally substituted with oneor more substituents independently selected from halogen, —OR²⁰, —SR²⁰,—N(R²⁰)₂, —NO₂, and —CN. In certain embodiments, for a compound ofFormula (II), each R¹⁷ and R¹⁸ is independently selected from halogen,—OR²⁰, —SR²⁰, —N(R²⁰)₂, —NO₂, —CN, and C₁₋₆ alkyl optionally substitutedwith one or more substituents independently selected from halogen,—OR²⁰, —SR²⁰, —N(R²⁰)₂, —NO₂, and —CN.

In certain embodiments, for a compound of Formula (II), each R¹⁹ isindependently selected from halogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂, —NO₂, ═O,═S, —CN; and C₁₋₃ alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl, each of which isoptionally substituted with one or more substituents independentlyselected from halogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂, —NO₂, —CN. In someembodiments, R¹⁹ is a halogen. In some embodiments, R¹⁹ is anunsubstituted C₁₋₃ alkyl. In some embodiments, R¹⁹ is ═O. In someembodiments, R¹⁹ is a haloalkyl. In some embodiments, R¹⁹ is a C₁₋₃alkyl substituted with one or more fluorine substituents.

In certain embodiments, for a compound of Formula (II), each R²⁰ isindependently selected from hydrogen; and C₁₋₆ alkyl optionallysubstituted with one or more substituents independently selected fromhalogen, —CN, —OH, —SH, —NO₂, —NH₂, ═O, ═S, —O—C₁₋₆ alkyl, —S—C₁₋₆alkyl, —N(C₁₋₆ alkyl)₂, —NH(C₁₋₆ alkyl), C₃₋₁₀ carbocycle, 3- to10-membered heterocycle; and C₃₋₁₀ carbocycle, and 3- to 10-memberedheterocycle, each of which is optionally substituted with one or moresubstituents independently selected from halogen, —CN, —OH, —SH, —NO₂,—NH₂, ═O, ═S, —O—C₁₋₆ alkyl, —S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —NH(C₁₋₆alkyl), C₁₋₆ alkyl, C₃₋₁₀ carbocycle, 3- to 10-membered heterocycle, andhaloalkyl. In some embodiments, R²⁰ is a C₁₋₂ alkyl substituted with a4- to 6-membered heterocycle. In some embodiments, R²⁰ is hydrogen.

In certain embodiments, for a compound of Formula (II), w is 0.

In certain embodiments, for a compound of Formula (II), z is 0.

In one aspect, disclosed herein is a compound represented by Formula(IIa)

or a salt thereof, wherein,

-   R¹¹ is selected from:    -   C₁₋₅ haloalkyl optionally further substituted with one or more        substituents independently selected from —OH, —SH, —NH₂, —NO₂,        —CN, C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle, wherein        the C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle are each        optionally substituted with one or more R¹⁹;-   R¹² is a heteroaryl, e.g., a 5-, 6-, or 9-membered heteroaryl,    optionally substituted with one or more substituents independently    selected from:    -   halogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂, —NO₂, —CN; and    -   C₃₋₁₀ carbocycle optionally substituted with one or more —R¹⁹;-   each R¹⁹ is independently selected from:    -   halogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂, —NO₂, —CN; and    -   C₁₋₃ alkyl optionally substituted with one or more substituents        independently selected from halogen, —OR²⁰, —SR²⁰, —N(R²⁰)₂,        —NO₂, and —CN; and-   each R²⁰ is independently selected from:    -   hydrogen; and    -   C₁₋₆ alkyl optionally substituted with one or more substituents        independently selected from halogen, —CN, —OH, —SH, —NO₂, —NH₂,        ═O, ═S, —O—C₁₋₆ alkyl, —S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, and        —NH(C₁₋₆ alkyl).

In certain embodiments, for a compound or salt of any one of Formula(II) R¹¹-T is further selected from hydrogen. For example, a compound ofthe disclosure may be represented by:

or a salt thereof.

In certain embodiments, a compound of the disclosure is selected from acompound of Table 2 or a salt thereof.

Chemical entities having carbon-carbon double bonds or carbon-nitrogendouble bonds may exist in Z- or E-form (or cis- or trans-form).Furthermore, some chemical entities may exist in various tautomericforms. Unless otherwise specified, compounds described herein areintended to include all Z-, E- and tautomeric forms as well.

A “tautomer” refers to a molecule wherein a proton shift from one atomof a molecule to another atom of the same molecule is possible. Thecompounds presented herein, in certain embodiments, exist as tautomers.In circumstances where tautomerization is possible, a chemicalequilibrium of the tautomers will exist. The exact ratio of thetautomers depends on several factors, including physical state,temperature, solvent, and pH. Some examples of tautomeric equilibriuminclude:

The compounds disclosed herein, in some embodiments, are used indifferent enriched isotopic forms, e.g., enriched in the content of ²H,³H, ¹¹C, ¹³C and/or ¹⁴C. In one particular embodiment, the compound isdeuterated in at least one position. Such deuterated forms can be madeby the procedure described in U.S. Pat. Nos. 5,846,514 and 6,334,997. Asdescribed in U.S. Pat. Nos. 5,846,514 and 6,334,997, deuteration canimprove the metabolic stability and or efficacy, thus increasing theduration of action of drugs.

Unless otherwise stated, compounds described herein are intended toinclude compounds which differ only in the presence of one or moreisotopically enriched atoms. For example, compounds having the presentstructures except for the replacement of a hydrogen by a deuterium ortritium, or the replacement of a carbon by ¹³C- or ¹⁴C-enriched carbonare within the scope of the present disclosure.

The compounds of the present disclosure optionally contain unnaturalproportions of atomic isotopes at one or more atoms that constitute suchcompounds. For example, the compounds may be labeled with isotopes, suchas for example, deuterium (²H), tritium (³H), iodine-125 (¹²⁵I) orcarbon-14 (¹⁴C). Isotopic substitution with ²H, ¹¹C, ¹³C, ¹⁴C, ¹⁵C, ¹²N,¹³N, ¹⁵N, ¹⁶N, ¹⁶O, ¹⁷O, ¹⁴F, ¹⁵F, ¹⁶F, ¹⁷F, ¹⁸F, ³³S, ³⁴S, ³⁵S, ³⁶S,³⁵Cl, ³⁷Cl, ⁷⁹Br, ⁸¹Br, and ¹²⁵I are all contemplated. All isotopicvariations of the compounds of the present invention, whetherradioactive or not, are encompassed within the scope of the presentinvention.

In certain embodiments, the compounds disclosed herein have some or allof the ¹H atoms replaced with ²H atoms. The methods of synthesis fordeuterium-containing compounds are known in the art and include, by wayof non-limiting example only, the following synthetic methods.

Deuterium substituted compounds are synthesized using various methodssuch as described in: Dean, Dennis C.; Editor. Recent Advances in theSynthesis and Applications of Radiolabeled Compounds for Drug Discoveryand Development. [In: Curr., Pharm. Des., 2000; 6(10)] 2000, 110 pp;George W.; Varma, Rajender S. The Synthesis of Radiolabeled Compoundsvia Organometallic Intermediates, Tetrahedron, 1989, 45(21), 6601-21;and Evans, E. Anthony. Synthesis of radiolabeled compounds, J.Radioanal. Chem., 1981, 64(1-2), 9-32.

Deuterated starting materials are readily available and are subjected tothe synthetic methods described herein to provide for the synthesis ofdeuterium-containing compounds. Large numbers of deuterium-containingreagents and building blocks are available commercially from chemicalvendors, such as Aldrich Chemical Co.

Compounds of the present invention also include crystalline andamorphous forms of those compounds, pharmaceutically acceptable salts,and active metabolites of these compounds having the same type ofactivity, including, for example, polymorphs, pseudopolymorphs,solvates, hydrates, unsolvated polymorphs (including anhydrates),conformational polymorphs, and amorphous forms of the compounds, as wellas mixtures thereof.

Included in the present disclosure are salts, particularlypharmaceutically acceptable salts, of the compounds described herein.The compounds of the present disclosure that possess a sufficientlyacidic, a sufficiently basic, or both functional groups, can react withany of a number of inorganic bases, and inorganic and organic acids, toform a salt. Alternatively, compounds that are inherently charged, suchas those with a quaternary nitrogen, can form a salt with an appropriatecounterion, e.g., a halide such as bromide, chloride, or fluoride,particularly bromide.

The compounds described herein may in some cases exist as diastereomers,enantiomers, or other stereoisomeric forms. The compounds presentedherein include all diastereomeric, enantiomeric, and epimeric forms aswell as the appropriate mixtures thereof. Separation of stereoisomersmay be performed by chromatography or by forming diastereomers andseparating by recrystallization, or chromatography, or any combinationthereof (Jean Jacques, Andre Collet, Samuel H. Wilen, “Enantiomers,Racemates and Resolutions”, John Wiley And Sons, Inc., 1981, hereinincorporated by reference for this disclosure). Stereoisomers may alsobe obtained by stereoselective synthesis.

The methods and compositions described herein include the use ofamorphous forms as well as crystalline forms (also known as polymorphs).The compounds described herein may be in the form of pharmaceuticallyacceptable salts. As well, in some embodiments, active metabolites ofthese compounds having the same type of activity are included in thescope of the present disclosure. In addition, the compounds describedherein can exist in unsolvated as well as solvated forms withpharmaceutically acceptable solvents such as water, ethanol, and thelike. The solvated forms of the compounds presented herein are alsoconsidered to be disclosed herein.

In certain embodiments, compounds or salts of the compounds may beprodrugs, e.g., wherein a hydroxyl in the parent compound is presentedas an ester or a carbonate, or carboxylic acid present in the parentcompound is presented as an ester. The term “prodrug” is intended toencompass compounds which, under physiologic conditions, are convertedinto pharmaceutical agents of the present disclosure. One method formaking a prodrug is to include one or more selected moieties which arehydrolyzed under physiologic conditions to reveal the desired molecule.In other embodiments, the prodrug is converted by an enzymatic activityof the host animal such as specific target cells in the host animal. Forexample, esters or carbonates (e.g., esters or carbonates of alcohols orcarboxylic acids and esters of phosphonic acids) are preferred prodrugsof the present disclosure.

Prodrug forms of the herein described compounds, wherein the prodrug ismetabolized in vivo to produce a compound as set forth herein areincluded within the scope of the claims. In some cases, some of theherein-described compounds may be a prodrug for another derivative oractive compound.

Prodrugs are often useful because, in some situations, they may beeasier to administer than the parent drug. They may, for instance, bebioavailable by oral administration whereas the parent is not. Prodrugsmay help enhance the cell permeability of a compound relative to theparent drug. The prodrug may also have improved solubility inpharmaceutical compositions over the parent drug. Prodrugs may bedesigned as reversible drug derivatives, for use as modifiers to enhancedrug transport to site-specific tissues or to increase drug residenceinside of a cell.

In some embodiments, the design of a prodrug increases the lipophilicityof the pharmaceutical agent. In some embodiments, the design of aprodrug increases the effective water solubility. See, e.g., Fedorak etal., Am. J. Physiol., 269:G210-218 (1995); McLoed et al., Gastroenterol,106:405-413 (1994); Hochhaus et al., Biomed. Chrom., 6:283-286 (1992);J. Larsen and H. Bundgaard, Int. J. Pharmaceutics, 37, 87 (1987); J.Larsen et al., Int. J. Pharmaceutics, 47, 103 (1988); Sinkula et al., J.Pharm. Sci., 64:181-210 (1975); T. Higuchi and V. Stella, Pro-drugs asNovel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series; andEdward B. Roche, Bioreversible Carriers in Drug Design, AmericanPharmaceutical Association and Pergamon Press, 1987, all incorporatedherein for such disclosure). According to another embodiment, thepresent disclosure provides methods of producing the above-definedcompounds. The compounds may be synthesized using conventionaltechniques. Advantageously, these compounds are conveniently synthesizedfrom readily available starting materials.

Synthetic chemistry transformations and methodologies useful insynthesizing the compounds described herein are known in the art andinclude, for example, those described in R. Larock, ComprehensiveOrganic Transformations (1989); T. W. Greene and P. G. M. Wuts,Protective Groups in Organic Synthesis, 2d. Ed. (1991); L. Fieser and M.Fieser, Fieser and Fieser's Reagents for Organic Synthesis (1994); andL. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis (1995).

Therapeutic Applications

Methods of administration of a compound or salt of Formula (I), (Ia),(Ib), (Ic), (Id), (Ie), (II), or (IIa) discussed herein may be used forthe treatment of neuromuscular conditions and movement disorders.Examples of neuromuscular conditions include but are not limited toDuchenne Muscular Dystrophy, Becker muscular dystrophy, myotonicdystrophy 1, myotonic dystrophy 2, facioscapulohumeral musculardystrophy, oculopharyngeal muscular dystrophy, limb girdle musculardystrophies, tendinitis and carpal tunnel syndrome. Examples of movementdisorders include but are not limited to muscle spasticity disorders,spasticity associated with multiple sclerosis, Parkinson's disease,Alzheimer's disease, or cerebral palsy, or injury or a traumatic eventsuch as stroke, traumatic brain injury, spinal cord injury, hypoxia,meningitis, encephalitis, phenylketonuria, or amyotrophic lateralsclerosis. Also included are other conditions that may respond to theinhibition of skeletal myosin II, skeletal troponin C, skeletal troponinI, skeletal tropomyosin, skeletal troponin T, skeletal regulatory lightchains, skeletal myosin binding protein C or skeletal actin.

In some embodiments, disclosed herein are methods to treat neuromuscularand movement disorders by the administration of a compound or salt ofFormula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II), or (IIa). In someembodiments, disclosed herein are methods to treat neuromuscular andmovement disorders by the administration of a compound or salt ofFormula (III);

or a salt thereof, wherein:

-   each Y is independently selected from C(R³), N, and N⁺(—O⁻);-   A is selected from —O—, —NR⁴—, —CR⁵R⁶—, —C(O)—, —S—, —S(O)—, and    —S(O)₂—;-   R¹ is selected from:    -   C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰,        —N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —S(O)R¹⁰,        —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), —CN, C₃₋₁₀ carbocycle and 3-        to 10-membered heterocycle, wherein the C₃₋₁₀ carbocycle and 3-        to 10-membered heterocycle are each optionally substituted with        one or more R⁹; and    -   C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle, each of        which is optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰,        —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂,        —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰,        —NO₂, ═O, ═S, ═N(R¹⁰), and —CN; or    -   R¹ together with R³ form a 5- to 10-membered heterocycle or        C₅₋₁₀ carbocycle, wherein the 5- to 10-membered heterocycle or        C₅₋₁₀ carbocycle is optionally substituted with one or more R⁹;        or R¹ together with R⁵ form a 3- to 10-membered heterocycle or        C₃₋₁₀ carbocycle, wherein the 3- to 10-membered heterocycle or        C₃₋₁₀ carbocycle is optionally substituted with one or more R⁹;        or R¹ together with R⁴ form a 3- to 10-membered heterocycle,        wherein the 3- to 10-membered heterocycle is optionally        substituted with one or more R⁹;-   R² is a heteroaryl optionally substituted with one or more    substituents independently selected from    -   halogen, —OR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂,        —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂,        —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰,        —NO₂, ═O, ═S, ═N(R¹⁰), and —CN; and when R² is pyridyl or        pyrimidyl, a substituent on a nitrogen atom of the pyridyl or        pyrimidyl is optionally further selected from —O⁻;    -   C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂,        —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰,        —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), —CN, C₃₋₁₀ carbocycle and 3-        to 10-membered heterocycle, wherein the C₃₋₁₀ carbocycle and 3-        to 10-membered heterocycle are each optionally substituted with        one or more R⁹; and    -   C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle, each of        which is optionally substituted with one or more R⁹;-   each R³, R⁵, and R⁶ is independently selected from:    -   hydrogen, halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, —CN, and C₁₋₆        alkyl optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —NO₂, and —CN; or    -   R³ together with R¹ form a 5- to 10-membered heterocycle or        C₅₋₁₀ carbocycle, wherein the 5- to 10-membered heterocycle or        C₅₋₁₀ carbocycle is optionally substituted with one or more R⁹;        R⁵ together with R¹ form a 3- to 10-membered heterocycle or        C₃₋₁₀ carbocycle, wherein the 3- to 10-membered heterocycle or        C₃₋₁₀ carbocycle is optionally substituted with one or more R⁹;-   R⁴ is independently selected from:    -   hydrogen; and    -   C₁₋₆ alkyl optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —NO₂, and —CN; or R⁴ together with R¹ form a 3- to 10-membered        heterocycle, which is optionally substituted with one or more        R⁹;-   each R⁷ and R⁸ is independently selected from:    -   halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, —CN, and C₁₋₆ alkyl        optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —NO₂, and —CN;-   each R⁹ is independently selected from:    -   halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂,        —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂,        —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰,        —NO₂, ═O, ═S, ═N(R¹⁰), —CN; and    -   C₁₋₃ alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂,        —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰,        —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), and —CN;-   each R¹⁰ is independently selected from:    -   hydrogen; and    -   C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —CN, —OH, —SH, —NO₂, —NH₂,        ═O, ═S, —O—C₁₋₆ alkyl, —S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —NH(C₁₋₆        alkyl), C₃₋₁₀ carbocycle, 3- to 10-membered heterocycle; and    -   C₃₋₁₀ carbocycle, and 3- to 10-membered heterocycle, each of        which is optionally substituted with one or more substituents        independently selected from halogen, —CN, —OH, —SH, —NO₂, —NH₂,        ═O, ═S, —O—C₁₋₆ alkyl, —S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —NH(C₁₋₆        alkyl), C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀        carbocycle, 3- to 10-membered heterocycle, and haloalkyl;-   n is 0, 1, or 2; and-   p is 0, 1, or 2.

In certain embodiments, the disclosure provides a method of treatingactivity-induced muscle damage, comprising administering to a subject inneed thereof a compound or salt of Formula (III′):

or a salt thereof, wherein:

-   each Y is independently selected from C(R³), N, and N⁺(—O⁻);-   A is absent or selected from —O—, —NR⁴—, —CR⁵R⁶—, —C(O)—, —S—,    —S(O)—, and —S(O)₂—;-   R¹ is selected from:    -   C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂,        —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰,        —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), —CN, C₃₋₁₀ carbocycle, and 3-        to 10-membered heterocycle, wherein the C₃₋₁₀ carbocycle and 3-        to 10-membered heterocycle are each optionally substituted with        one or more R⁹; and    -   C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle, each of        which is optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂,        —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰,        —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), and —CN; or    -   R¹ together with R³ form a 5- to 10-membered heterocycle or        C₅₋₁₀ carbocycle, wherein the 5- to 10-membered heterocycle or        C₅₋₁₀ carbocycle is optionally substituted with one or more R⁹;        or R¹ together with R⁵ form a 3- to 10-membered heterocycle or        saturated C₃₋₁₀ carbocycle, wherein the 3- to 10-membered        heterocycle or saturated C₃₋₁₀ carbocycle is optionally        substituted with one or more R⁹; or R¹ together with R⁴ form a        3- to 10-membered heterocycle, wherein the 3- to 10-membered        heterocycle is optionally substituted with one or more R⁹; and    -   when A is —NR⁴—, R¹ is additionally selected from hydrogen, and        when A is —C(O)—, R¹ is additionally selected from —N(R¹⁰)₂ and        —OR¹⁰;    -   when A is absent R¹ is further selected from halogen, —OR¹⁰,        —SR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰,        —N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰,        —OC(O)R¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰, —NO₂, and —CN;-   R² is a heteroaryl optionally substituted with one or more    substituents independently selected from:    -   halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰), —C(O)R¹⁰, —C(O)N(R¹⁰)²,        —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂,        —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰,        —NO₂, ═O, ═S, ═N(R¹⁰), and —CN; and when R² is pyridyl or        pyrimidyl, a substituent on a nitrogen atom of the pyridyl or        pyrimidyl is optionally further selected from —O⁻;    -   C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂,        —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰,        —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), —CN, C₃₋₁₀ carbocycle and 3-        to 10-membered heterocycle, wherein the C₃₋₁₀ carbocycle and 3-        to 10-membered heterocycle are each optionally substituted with        one or more R⁹; and    -   C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle, each of        which is optionally substituted with one or more R⁹;-   each R³, R⁵, and R⁶ is independently selected from:    -   hydrogen, halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, —CN, and C₁₋₆        alkyl optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —NO₂, and —CN; or    -   R³ together with R¹ form a 5- to 10-membered heterocycle or        C₅₋₁₀ carbocycle, wherein the 5- to 10-membered heterocycle or        C₅₋₁₀ carbocycle is optionally substituted with one or more R⁹;        R⁵ together with R¹ form a 3- to 10-membered heterocycle or        C₃₋₁₀ carbocycle, wherein the 3- to 10-membered heterocycle or        C₃₋₁₀ carbocycle is optionally substituted with one or more R⁹;-   R⁴ is independently selected from:    -   hydrogen; and    -   C₁₋₆ alkyl optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —NO₂, and —CN; or R⁴ together with R¹ form a 3- to 10-membered        heterocycle, which is optionally substituted with one or more        R⁹;-   each R⁷ and R⁸ is independently selected from    -   halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, —CN, and C₁₋₆ alkyl        optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —NO₂, and —CN;-   each R⁹ is independently selected from    -   halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂,        —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂,        —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰,        —NO₂, ═O, ═S, ═N(R¹⁰), —CN; and    -   C₁₋₃ alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,        —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂,        —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰—, —S(O)R¹⁰,        —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), and —CN;-   each R¹⁰ is independently selected from    -   hydrogen; and    -   C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, each of which is        optionally substituted with one or more substituents        independently selected from halogen, —CN, —OH, —SH, —NO₂, —NH₂,        ═O, ═S, —O—C₁₋₆ alkyl, —S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —NH(C₁₋₆        alkyl), C₃₋₁₀ carbocycle, 3- to 10-membered heterocycle; and    -   C₃₋₁₀ carbocycle, and 3- to 10-membered heterocycle, each of        which is optionally substituted with one or more substituents        independently selected from halogen, —CN, —OH, —SH, —NO₂, —NH₂,        ═O, ═S, —OC₁₋₆ alkyl, —S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —NH(C₁₋₆        alkyl), C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀        carbocycle, 3- to 10-membered heterocycle, and haloalkyl;-   R³⁰ and R³¹ are independently selected from R¹⁰ or R³⁰ and R³¹ come    together to form a C₃₋₇ carbocycle, wherein the 3- to 7-membered    heterocycle, wherein C₃₋₇ carbocycle and 3- to 7-membered    heterocycle are optionally substituted with R⁹;-   n is 0, 1, or 2; and-   p is 0, 1, or 2.

In certain embodiments, for a compound or salt of Formula (III) or(III′), each Y is independently selected from C(R³) and N wherein atleast one Y is N. In some embodiments, one Y is N and one Y is C(R³). Insome embodiments, one Y is N⁺(—O⁻) and one Y is C(R³). In someembodiments, each Y is N. In some embodiments, one Y is N, and one Y isN⁺(—O⁻). In certain embodiments, for a compound or salt of Formula (III)or (III′), each Y is further selected from C(R³).

In certain embodiments, for a compound or salt of Formula (III) or(III′), A is selected from —O—, —CR⁵R⁶—, and —C(O)—. In someembodiments, A is selected from —O— and —NR⁴. In some embodiments, A is—O—.

In certain embodiments, for a compound or salt of Formula (III) or(III′), R¹ is C₁₋₆ alkyl optionally substituted with one or moresubstituents independently selected from halogen, —OR¹⁰, —SR¹⁰,—N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰), —C(O)OR¹⁰, —OC(O)R¹⁰,—N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰,—NO₂, ═O, ═S, ═N(R¹⁰), —CN, C₃₋₁₀ carbocycle and 3- to 10-memberedheterocycle, wherein the C₃₋₁₀ carbocycle and 3- to 10-memberedheterocycle are each optionally substituted with one or more R⁹. In someembodiments, R¹ is C₁₋₆ alkyl substituted with one or more substituentsindependently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰,—C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂,—OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰, —NO₂, ═O, ═S,═N(R¹⁰, —CN, C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle, whereinthe C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle are eachoptionally substituted with one or more R⁹. In some embodiments, R¹ isC₁₋₆ alkyl substituted with one or more substituents independentlyselected from halogen, —OR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂,—N(R¹⁰)C(O)R¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —NO₂, ═O, ═N(R¹⁰), —CN, C₃₋₁₀carbocycle and 3- to 10-membered heterocycle, wherein the C₃₋₁₀carbocycle and 3- to 10-membered heterocycle are each optionallysubstituted with one or more R⁹. In some embodiments, R¹ is selectedfrom C₁₋₃ alkyl optionally substituted with one or more substituentsindependently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, ═O,═S, ═N(R¹⁰), —CN, C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle,wherein the C₃₋₁₀ carbocycle and 3- to 10-membered heterocycle are eachoptionally substituted with one or more R⁹. In some embodiments, R¹ isC₁₋₃ alkyl substituted with one or more substituents independentlyselected from halogen, —OR¹⁰, —N(R¹⁰)₂, —NO₂, ═O, —CN, C₃₋₁₀ carbocycleand 3- to 10-membered heterocycle, wherein the C₃₋₁₀ carbocycle and 3-to 10-membered heterocycle are each optionally substituted with one ormore R⁹. In some embodiments, R¹ is C₁₋₃ alkyl substituted with one ormore halogen substituents. In some embodiments, R¹ is a C₁₋₃fluoroalkyl. In some embodiments, R¹ is selected from —CHF₂ and —CH₂CF₃.

In certain embodiments, for a compound or salt of Formula (III) or(III′), R¹ is selected from optionally substituted C₃-C₆ cycloalkyl,such as cyclopropyl, cyclobutyl, cyclopentyl, bicyclopentyl, andspiropentyl, any of which is optionally substituted. In certainembodiments, R¹ is selected from alkyl, e.g., methyl, ethyl, propyl,iso-propyl, t-butyl, iso-butyl, sec-butyl, any of which may beoptionally substituted. In certain embodiments, R¹ is selected from:

In certain embodiments, R¹ is selected from optionally substituted

In certain embodiments, for a compound or salt of Formula (III) or(III′), R¹ together with R³ form a 5- to 10-membered heterocycle orC₅₋₁₀ carbocycle, wherein the 5- to 10-membered heterocycle or C₅₋₁₀carbocycle is optionally substituted with one or more R⁹. In someembodiments, R¹ together with R³ form a C₅₋₁₀ carbocycle or 5- to10-membered heterocycle, such as a C₅₋₆ carbocycle or 5- to 6-memberedheterocycle, for example:

In certain embodiments, for a compound or salt of Formula (III) or(III′), R¹ together with R⁵ form a 3- to 10-membered heterocycle orC₃₋₁₀ carbocycle, wherein the 3- to 10-membered heterocycle or C₃₋₁₀carbocycle is optionally substituted with one or more R⁹. In someembodiments, R¹ together with R⁵ form a 3- to 10-membered heterocycle orC₃₋₁₀ carbocycle, for example:

In certain embodiments, for a compound or salt of Formula (III) or(III′), R¹ together with R⁴ form a 3- to 10-membered heterocycle,wherein the 3- to 10-membered heterocycle is optionally substituted withone or more R⁹. In some embodiments, R¹ together with R⁴ form a 3- to10-membered heterocycle, for example:

In some embodiments, for a compound or salt of Formula (III) or (III′),R² is an optionally substituted 5-membered heteroaryl, 6-memberedheteroaryl, or a 9-membered bicyclic heterocycle. In some embodiments,R² is an optionally substituted 5-membered heteroaryl. In certainembodiments, R² is an optionally substituted 5-membered heteroaryl withat least one endocyclic nitrogen or oxygen atom in the 5-memberedheteroaryl, e.g., oxazole, isoxazole, thiazole, pyrrole, pyrazole,furan, diazole, triazole, imidazole, oxadiazole, thiadiazole, isoxazole,isothiazole, and tetrazole. In certain embodiments, for a compound orsalt Formula (III) or (III′), R² is selected from:

any one of which is optionally substituted. In some embodiments, R² isselected from:

any one of which is optionally substituted. In some embodiments, R² isselected from:

any one of which is optionally substituted.

In certain embodiments, for a compound or salt of Formula (III) or(III′), substituents on R² are independently selected from halogen,—OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, and —CN; C₁₋₆ alkyl optionally substitutedwith one or more substituents independently selected from halogen,—OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, and —CN; and optionally substituted C₃₋₁₀carbocycle. In some embodiments, R² is a heteroaryl, e.g., 5-memberedheteroaryl, optionally substituted with one or more substituentsselected from halogen, —OR¹⁰, and —N(R¹⁰)₂; C₁₋₄ alkyl optionallysubstituted with one or more substituents independently selected fromhalogen; and optionally substituted C₃₋₁₀ carbocycle, e.g., optionallysubstituted phenyl or optionally substituted cycloalkyl such ascyclopropyl.

In certain embodiments, for a compound or salt of Formula (III) or(III′), R² is selected from:

any one of which is optionally substituted. In some embodiments, R² isselected from:

any one of which is optionally substituted.

In certain embodiments, for a compound or salt of Formula (III) or(III′), R² is selected from optionally substituted 6-memberedheteroaryl. In some embodiments, R² may be selected from 6-memberedheteroaryls, such as pyridine, pyridazine, pyrimidine, pyrazine,triazene and N-oxides thereof. In some embodiments, R² is selected fromoptionally substituted pyridyl, optionally substituted pyrimidyl,optionally substituted pyridyl N-oxide, and optionally substitutedpyrimidyl N-oxide. In some embodiments, R² is selected from optionallysubstituted pyridyl and optionally substituted pyrimidyl. In certainembodiments, for a compound or salt of Formula (III) or (III′), R² is a6-membered heteroaryl, e.g., pyridinyl or pyrimidinyl, optionallysubstituted with halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, and —CN; C₁₋₆alkyl optionally substituted with one or more substituents independentlyselected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, and —CN; andoptionally substituted C₃₋₁₀ carbocycle. In certain embodiments, for acompound or salt of Formula (III) or (III′), R² is a 6-memberedheteroaryl, e.g., pyridinyl or pyrimidinyl, optionally substituted withhalogen, —OR¹⁰, —SR¹⁰, and —N(R¹⁰)₂; and C₁₋₄ alkyl optionallysubstituted with one or more substituents independently selected fromhalogen and —OR¹⁰. In some embodiments, R² is selected from:

In certain embodiments, for a compound or salt of Formula (III) or(III′), R² is selected from optionally substituted bicyclic heteroaryl.In some embodiments, R² is selected from optionally substituted9-membered bicyclic heteroaryl, e.g., optionally substitutedbenzoxazole, benzothiazole, or benzimidazole. In certain embodiments,for a compound or salt of Formula (III) or (III′), R² is a 9-memberedbicyclic heteroaryl, e.g., benzoxazole, optionally substituted withhalogen, —OR¹⁶, —SR¹⁰, —N(R¹⁰)₂, —NO₂, and —CN; C₁₋₆ alkyl optionallysubstituted with one or more substituents independently selected fromhalogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, and —CN; and optionallysubstituted C₃₋₁₀ carbocycle. In some embodiments, R² is selected fromoptionally substituted benzoxazole. In some embodiments, R² is selectedfrom:

In certain embodiments, for a compound or salt of Formula (III) or(III′), each R³ is selected from hydrogen, halogen, —OR¹⁰, —SR¹⁰,—N(R¹⁰)₂, —NO₂, —CN, and C₁₋₆ alkyl optionally substituted with one ormore substituents independently selected from halogen, —OR¹⁰, —SR¹⁰,—N(R¹⁰)₂, —NO₂, and —CN. In some embodiments, R³ together with R¹ form a5- to 6-membered heterocycle or C₅₋₆ carbocycle, wherein the 5- to6-membered heterocycle or C₅₋₆ carbocycle is optionally substituted withone or more R⁹. In some embodiments, R³ is hydrogen.

In certain embodiments, for a compound or salt of Formula (III) or(III′), R⁴ is independently selected from hydrogen; and C₁₋₆ alkyloptionally substituted with one or more substituents independentlyselected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, and —CN; or R⁴together with R¹ form a 3- to 10-membered heterocycle, which isoptionally substituted with one or more R⁹. In some embodiments, R⁴ ishydrogen.

In certain embodiments, for a compound or salt of Formula (III) or(III′), each R⁵ and R⁶ is independently selected from hydrogen, halogen,—OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, —CN, and C₁₋₆ alkyl optionally substitutedwith one or more substituents independently selected from halogen,—OR¹⁰, —SR¹⁰—N(R¹⁰)₂, —NO₂, and —CN.

In certain embodiments, for a compound or salt of Formula (III) or(III′) each R⁷ and R⁸ is independently selected from halogen, —OR¹⁰,—SR¹⁰, —N(R¹⁰)₂, —NO₂, —CN, and C₁₋₆ alkyl optionally substituted withone or more substituents independently selected from halogen, —OR¹⁰,—SR¹⁰, —N(R¹⁰)₂, —NO₂, and —CN. In certain embodiments, for a compoundor salt of Formula (III) or (III′) each R⁷ and R⁸ is independentlyselected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, —CN, —CHF₂, —CF₃,—CH₂F, and C₂₋₆ alkyl optionally substituted with one or moresubstituents independently selected from halogen, —OR¹⁰, —SR¹⁰,—N(R¹⁰)₂, —NO₂, and —CN.

In certain embodiments, for a compound or salt of Formula (III) or(III′), each R⁹ is independently selected from halogen, —OR¹⁰, —SR¹⁰,—N(R¹⁰)₂, —NO₂, ═O, ═S, —CN; and C₁₋₃ alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl,each of which is optionally substituted with one or more substituentsindependently selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, —CN.In some embodiments, R⁹ is a halogen. In some embodiments, R⁹ is anunsubstituted C₁₋₃ alkyl. In some embodiments, R⁹ is ═O. In someembodiments, R⁹ is a haloalkyl. In some embodiments, R⁹ is a C₁₋₃ alkylsubstituted with one or more fluorine substituents.

In certain embodiments, for a compound or salt of Formula (III) or(III′), each R¹⁰ is independently selected from hydrogen; and C₁₋₆ alkyloptionally substituted with one or more substituents independentlyselected from halogen, —CN, —OH, —SH, —NO₂, —NH₂, ═O, ═S, —O—C₁₋₆ alkyl,—S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —NH(C₁₋₆ alkyl), C₃₋₁₀ carbocycle, 3- to10-membered heterocycle; and C₃₋₁₀ carbocycle, and 3- to 10-memberedheterocycle, each of which is optionally substituted with one or moresubstituents independently selected from halogen, —CN, —OH, —SH, —NO₂,—NH₂, ═O, ═S, —O—C₁₋₆ alkyl, —S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —NH(C₁₋₆alkyl), C₁₋₆ alkyl, C₃₋₁₀ carbocycle, 3- to 10-membered heterocycle, andhaloalkyl.

In certain embodiments, for a compound or salt of Formula (III) or(III′), n is 0.

In certain embodiments, for a compound or salt of Formula (III) or(III′), p is 0.

In certain embodiments, for a compound or salt of Formula (III) or(III′), R¹-A is further selected from hydrogen. For example, a compoundof the disclosure is represented by:

or a salt thereof.

Presented herein are methods to treat neuromuscular and movementdisorders by reduction of skeletal muscle contraction. Treatment ofsubjects with neuromuscular and movement disorders with a selective fastskeletal muscle (type II) myosin inhibitor of a compound or salt ofFormula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′)may reduce muscle breakdown by preventing excessive uncoordinated musclecontractures resulting in less muscle damage. Furthermore, methods ofthe disclosure may reduce muscle damage while minimizing the impact onphysical function in subjects. Preservation of function may occur bothby limiting damaging levels of force generation in type II fibers and byincreasing reliance on healthier type I fibers. Reduction of skeletalmuscle contraction or uncoordinated muscle contractures can be reducedby the inhibition of skeletal myosin II. In certain embodiments, theinhibitor of skeletal myosin II is a compound or salt of Formula (I),(Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′) as disclosedherein.

In some embodiments, disclosed herein is a method of inhibiting musclemyosin II, comprising administering a compound or salt of Formula (I),(Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′) to a subjectin need thereof. In some embodiments, the compound or salt does notappreciably inhibit cardiac muscle contraction. In some embodiments,wherein the compound or salt does not appreciably inhibit cardiac musclecontraction. In some embodiments, the compound or salt reduces cardiacmuscle force by less than 10%.

In some aspects, methods of treating neuromuscular conditions ormovement disorders may comprise administering a compound or salt ofFormula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′)to inhibit skeletal muscle contraction. In some embodiments, thecompound or salt of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II),(IIa), (III), or (III′) does not significantly inhibit cardiac musclecontraction. In some embodiments, cardiac muscle contraction isinhibited by 20% or less. In some embodiments, cardiac musclecontraction is inhibited by 15% or less. In some embodiments, cardiacmuscle contraction is inhibited by 10% or less. In some embodiments,cardiac muscle contraction is inhibited by 9% or less. In someembodiments, cardiac muscle contraction is inhibited by 8% or less. Insome embodiments, cardiac muscle contraction is inhibited by 7% or less.In some embodiments, cardiac muscle contraction is inhibited by 6% orless. In some embodiments, cardiac muscle contraction is inhibited by 5%or less. In some embodiments, cardiac muscle contraction is inhibited by4% or less. In some embodiments, cardiac muscle contraction is inhibitedby 3% or less. In some embodiments, cardiac muscle contraction isinhibited by 2% or less. In some embodiments, cardiac muscle contractionis inhibited by 1% or less.

A subject's activities of daily life (ADL) or habitual physical activitymay be monitored prior to and following the treatment with a compound orsalt of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III),or (III′). ADL or habitual physical activity is subject-dependent andmay range from simple walking to extensive exercise depending on thesubject's ability and routine. Treatment options and dosages of theskeletal muscle contraction inhibitors discussed herein may bepersonalized to a subject such that the ADL and habitual physicalactivity remains unchanged.

In some aspects, methods of treating neuromuscular conditions ormovement disorders may comprise administering a compound or salt ofFormula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′)to inhibit skeletal muscle contraction. A compound or salt of Formula(I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′) may begiven in an amount relative to the amount needed to reduce skeletalmuscle contraction by 50%. The compound or salt of Formula (I), (Ia),(Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′) may beadministered in an amount less than the amount needed to reduce skeletalmuscle contraction by 50% relative to pre-treatment skeletal musclecontraction capacity of the subject. The compound or salt of Formula(I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′) may beadministered in an amount that reduces skeletal muscle contraction by 5%to 45% relative to pre-treatment skeletal muscle contraction capacity ofsaid subject. In some cases, the compound or salt of Formula (I), (Ia),(Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′) may beadministered in an amount that reduces skeletal muscle contraction byless than 10%, less than 15%, less than 20%, less than 25%, less than30%, less than 35%, less than 40%, less than 45% or even less than 50%relative to pre-treatment skeletal muscle contraction capacity of saidsubject. In certain embodiments, the compound or salt of Formula (I),(Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′) may beadministered in an amount that reduces skeletal muscle contraction from1% to 50% relative to pre-treatment skeletal muscle contraction capacityof said subject.

In some aspects, methods of treating neuromuscular conditions ormovement disorders may comprise administering a compound or salt ofFormula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′)to inhibit type I skeletal muscle contraction. The inhibitor of type Iskeletal muscle contraction may be given in an amount relative to theamount needed to reduce type I skeletal muscle contraction by 20%. Theinhibitor of type I skeletal muscle contraction may be administered inan amount less than the amount needed to reduce type I skeletal musclecontraction by 20% relative to pre-treatment type I skeletal musclecontraction capacity of the subject. The inhibitor of type I skeletalmuscle contraction may be administered in an amount that reduces type Iskeletal muscle contraction by 0.01% to 20% relative to pre-treatmenttype I skeletal muscle contraction capacity of said subject. In somecases, the inhibitor may be administered in an amount that reduces typeI skeletal muscle contraction by less than 0.01%, less than 0.1%, lessthan 0.5%, less than 1%, less than 5%, less than 10%, less than 15% orless than 20% relative to pre-treatment type I skeletal musclecontraction capacity of said subject. In certain embodiments, theinhibitor may be administered in an amount that reduces type I skeletalmuscle contraction from 0.01% to 20% relative to pre-treatment type Iskeletal muscle contraction capacity of said subject.

In some aspects, methods of treating neuromuscular conditions ormovement disorders may comprise administering a compound or salt ofFormula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′)to inhibit type II skeletal muscle contraction. The inhibitor of type IIskeletal muscle contraction may be given in an amount relative to theamount needed to reduce type II skeletal muscle contraction by 90%. Theinhibitor of type II skeletal muscle contraction may be administered inan amount less than the amount needed to reduce type II skeletal musclecontraction by 90% relative to pre-treatment type II skeletal musclecontraction capacity of the subject. The inhibitor of type II skeletalmuscle contraction may be administered in an amount that reduces type IIskeletal muscle contraction by 5% to 75% relative to pre-treatment typeII skeletal muscle contraction capacity of said subject. In some cases,the inhibitor may be administered in an amount that reduces type IIskeletal muscle contraction by less than 10%, less than 15%, less than20%, less than 25%, less than 30%, less than 35%, less than 40%, lessthan 45%, less than 50%, less than 55%, less than 60%, less than 65%,less than 70%, less than 75%, less than 80%, less than 85% or even lessthan 90% relative to pre-treatment type II skeletal muscle contractioncapacity of said subject. In certain embodiments, the inhibitor may beadministered in an amount that reduces type II skeletal musclecontraction by from 1% to 50% relative to pre-treatment type II skeletalmuscle contraction capacity of said subject.

In some aspects, methods of treating contraction-induced injury inskeletal muscle fiber may comprise administering a compound or salt ofFormula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′)to inhibit skeletal muscle contraction and/or skeletal muscle myosin II.In certain embodiments, the inhibitor does not appreciably inhibitcardiac muscle contraction.

In some aspects, methods of treating metabolic myopathies, e.g.McArdle's syndrome, may comprise administering a compound or salt ofFormula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or(III′).

In certain embodiments, the contraction-induced injury in skeletalmuscle fiber is from involuntary skeletal muscle contraction. Theinvoluntary skeletal muscle contraction may be associated with aneuromuscular condition or spasticity-associated condition. In certainembodiments, the contraction-induced injury in skeletal muscle fiber maybe from voluntary skeletal muscle contraction, e.g., physical exercise.

In certain embodiments, the administration of a compound or salt ofFormula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′)to a subject modulates one or more biomarkers associated with musclecontraction. Examples of biomarkers include but are not limited tocreatinine kinase (CK), Troponin T (TnT), Troponin C (TnC), Troponin I(TnI), pyruvate kinase (PK), lactate dehydrogenase (LDH), myoglobin,isoforms of TnI (such as cardiac, slow skeletal, fast skeletal muscles)and inflammatory markers (IL-1, IL-6, IL-4, TNF-α). Biomarkers may alsoinclude measures of muscle inflammation for example, edema. The level ofbiomarkers described herein may increase after the administration of theinhibitor relative to pre-treatment level of the biomarkers.Alternatively, the level of biomarkers may decrease after theadministration of the inhibitor relative to pre-treatment level of thebiomarkers. The modulation of one or more biomarkers with an inhibitordescribed herein may indicate treatment of a neuromuscular conditionsuch as those described herein.

Levels of CK in a subject increase when the subject is active ascompared to when the subject is inactive (e.g., sleeping) and thereforeCK is a potential metric for evaluating skeletal muscle breakdown causedby skeletal muscle contraction. In certain embodiments, a compound orsalt of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III),or (III′) may be administered to a subject prior to mild, moderate orstrenuous activity to reduce or prevent skeletal muscle breakdown fromthe activity. Moderate to strenuous activity may be dependent on asubject's abilities and may include physical exercise that increases theheart rate by at least 20% or more, such as about 50% or more relativeto the subject's resting heart rate. Examples of moderate to strenuousactivity include walking, running, weight lifting, biking, swimming,hiking, etc.

In certain embodiments, a compound or salt of Formula (I), (Ia), (Ib),(Ic), (Id), (Ie), (II), (IIa), (III), or (III′) is administered priorto, during, or after moderate or strenuous activity to reduce or preventskeletal muscle breakdown from the activity. The compound or salt ofFormula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′)may reduce the subject's level of CK relative to the untreated subjectperforming the same activity. The level of CK may be measured in theperipheral blood of the subject during or after the activity. Theadministration of an inhibitor described herein may reduce the level ofCK by 5% to 90% in an active subject relative to the untreated subjectperforming the same activity, thereby reducing or preventing skeletalmuscle breakdown from the activity. The administration of an inhibitordescribed herein may modulate the level of CK by about 5% to about 90%relative to the untreated subject performing the same activity, therebyreducing or preventing skeletal muscle breakdown from the activity. Theadministration of an inhibitor described herein may reduce the level ofCK by at least about 5% relative to the untreated subject performing thesame activity thereby reducing or preventing skeletal muscle breakdownfrom the activity. The administration of an inhibitor described hereinmay modulate the level of CK by at most about 90% relative to theuntreated subject performing the same activity. The administration of aninhibitor described herein may reduce the level of CK by about 5% toabout 15%, about 5% to about 25%, about 5% to about 35%, about 5% toabout 45%, about 5% to about 55%, about 5% to about 65%, about 5% toabout 75%, about 5% to about 85%, about 5% to about 90%, about 15% toabout 25%, about 15% to about 35%, about 15% to about 45%, about 15% toabout 55%, about 15% to about 65%, about 15% to about 75%, about 15% toabout 85%, about 15% to about 90%, about 25% to about 35%, about 25% toabout 45%, about 25% to about 55%, about 25% to about 65%, about 25% toabout 75%, about 25% to about 85%, about 25% to about 90%, about 35% toabout 45%, about 35% to about 55%, about 35% to about 65%, about 35% toabout 75%, about 35% to about 85%, about 35% to about 90%, about 45% toabout 55%, about 45% to about 65%, about 45% to about 75%, about 45% toabout 85%, about 45% to about 90%, about 55% to about 65%, about 55% toabout 75%, about 55% to about 85%, about 55% to about 90%, about 65% toabout 75%, about 65% to about 85%, about 65% to about 90%, about 75% toabout 85%, about 75% to about 90%, or about 85% to about 90% relative tothe untreated subject performing the same activity, thereby reducing orpreventing skeletal muscle breakdown from the activity. Theadministration of an inhibitor described herein may modulate the levelof CK by about 5%, about 15%, about 25%, about 35%, about 45%, about55%, about 65%, about 75%, about 85%, or about 90% relative to theuntreated subject performing the same activity, thereby reducing orpreventing skeletal muscle breakdown from the activity.

The administration of a compound or salt of Formula (I), (Ia), (Ib),(Ic), (Id), (Ie), (II), (IIa), (III), or (III′) to a subject maymodulate the levels of inflammatory markers, e.g., reduce the level ofone or more inflammatory markers relative to the untreated subject orthe subject prior to treatment. The level of inflammatory markers may bemeasured in the peripheral blood of the subject. Examples ofinflammatory markers may include but are not limited to IL-1, IL-6 andTNF-α. Inflammatory markers may also be in the form of conditions suchas edema which may be measured using magnetic resonance imaging. Thelevel of inflammatory markers in the peripheral blood may increase afterthe administration of the inhibitor relative to pre-treatment level ofinflammatory marker for the subject. Alternatively, the level ofinflammatory markers in the peripheral blood may decrease after theadministration of the inhibitor relative to pre-treatment level ofinflammatory marker for the subject. The administration of an inhibitordescribed herein may modulate the level of inflammatory markers by 5% to90% relative to pre-treatment level of inflammatory marker for thesubject. In some cases, the level of inflammatory markers may bemodulated by about 5% to about 90% relative to pre-treatment level ofinflammatory markers of the subject. In some cases, the level ofinflammatory markers may be modulated by at least about 5% relative topre-treatment level of inflammatory markers of the subject. In somecases, the level of inflammatory markers may be modulated by at mostabout 90% relative to pre-treatment level of inflammatory markers of thesubject. In some cases, the level of inflammatory markers may bemodulated by about 5% to about 15%, about 5% to about 25%, about 5% toabout 35%, about 5% to about 45%, about 5% to about 55%, about 5% toabout 65%, about 5% to about 75%, about 5% to about 85%, about 5% toabout 90%, about 15% to about 25%, about 15% to about 35%, about 15% toabout 45%, about 15% to about 55%, about 15% to about 65%, about 15% toabout 75%, about 15% to about 85%, about 15% to about 90%, about 25% toabout 35%, about 25% to about 45%, about 25% to about 55%, about 25% toabout 65%, about 25% to about 75%, about 25% to about 85%, about 25% toabout 90%, about 35% to about 45%, about 35% to about 55%, about 35% toabout 65%, about 35% to about 75%, about 35% to about 85%, about 35% toabout 90%, about 45% to about 55%, about 45% to about 65%, about 45% toabout 75%, about 45% to about 85%, about 45% to about 90%, about 55% toabout 65%, about 55% to about 75%, about 55% to about 85%, about 55% toabout 90%, about 65% to about 75%, about 65% to about 85%, about 65% toabout 90%, about 75% to about 85%, about 75% to about 90%, or about 85%to about 90% relative to pre-treatment level of inflammatory markers ofthe subject. In some cases, the level of inflammatory markers may bemodulated by about 5%, about 15%, about 25%, about 35%, about 45%, about55%, about 65%, about 75%, about 85%, or about 90% relative topre-treatment level of inflammatory markers of the subject.

The administration of a compound or salt of Formula (I), (Ia), (Ib),(Ic), (Id), (Ie), (II), (IIa), (III), or (III′) to a subject maymodulate the levels of circulating fast skeletal muscle Troponin I(fS-TnI). The level of fS-TnI may be measured in the peripheral blood.The level of fS-TnI in the peripheral blood may increase after theadministration of the inhibitor relative to pre-treatment level offS-TnI for the subject. Alternatively, the level of fS-TnI in theperipheral blood may decrease after the administration of the inhibitorrelative to pre-treatment level of fS-TnI for the subject. Theadministration of an inhibitor described herein may modulate the levelof fS-TnI by 5% to 90% relative to pre-treatment level of fS-TnI for thesubject. In some cases, the level of fS-TnI may be modulated by at leastabout 5% relative to pre-treatment level of fS-TnI of the subject. Insome cases, the level of fS-TnI may be modulated by at most about 90%relative to pre-treatment level of fS-TnI of the subject. In some cases,the level of fS-TnI may be modulated by about 5% to about 15%, about 5%to about 25%, about 5% to about 35%, about 5% to about 45%, about 5% toabout 55%, about 5% to about 65%, about 5% to about 75%, about 5% toabout 85%, about 5% to about 90%, about 15% to about 25%, about 15% toabout 35%, about 15% to about 45%, about 15% to about 55%, about 15% toabout 65%, about 15% to about 75%, about 15% to about 85%, about 15% toabout 90%, about 25% to about 35%, about 25% to about 45%, about 25% toabout 55%, about 25% to about 65%, about 25% to about 75%, about 25% toabout 85%, about 25% to about 90%, about 35% to about 45%, about 35% toabout 55%, about 35% to about 65%, about 35% to about 75%, about 35% toabout 85%, about 35% to about 90%, about 45% to about 55%, about 45% toabout 65%, about 45% to about 75%, about 45% to about 85%, about 45% toabout 90%, about 55% to about 65%, about 55% to about 75%, about 55% toabout 85%, about 55% to about 90%, about 65% to about 75%, about 65% toabout 85%, about 65% to about 90%, about 75% to about 85%, about 75% toabout 90%, or about 85% to about 90% relative to pre-treatment level offS-TnI of the subject. In some cases, the level of fS-TnI may bemodulated by about 5%, about 15%, about 25%, about 35%, about 45%, about55%, about 65%, about 75%, about 85%, or about 90% relative topre-treatment level of fS-TnI of the subject.

Isoforms of troponin may be measured in a subject prior to and followingthe administration a compound or salt of Formula (I), (Ia), (Ib), (Ic),(Id), (Ie), (II), (IIa), (III), or (III′). Inhibition of skeletal musclecontraction may not inhibit some isoforms of troponin, such as cardiactroponin I (cTnI) or slow skeletal troponin I (ssTnI). In some cases,the inhibition of skeletal muscle contraction may not appreciablyinhibit cTnI or ssTnI. As used herein with regard to cTnI or ssTnI, thephrase not appreciably refers to the cTnI or ssTnI reduced by less than10%, less than 8%, less than 6%, less than 4%, less than 2%, less than1%, less than 0.5% or even less than 0.1% relative to the cTnI or ssTnIprior to the administration of the inhibitor.

The administration of a compound or salt of Formula (I), (Ia), (Ib),(Ic), (Id), (Ie), (II), (IIa), (III), or (III′) may reduce involuntarymuscle contractions. Involuntary muscle contractions may be reduced by20% to 90% relative to involuntary muscle contractions prior to theadministration of the inhibitor. In some cases, involuntary musclecontractions may be reduced by at least about 20% relative topre-treatment involuntary muscle contractions. In some cases,involuntary muscle contractions may be reduced by at most about 90%relative to pre-treatment involuntary muscle contractions. In somecases, involuntary muscle contractions may be reduced by about 20% toabout 25%, about 20% to about 30%, about 20% to about 40%, about 20% toabout 50%, about 20% to about 70%, about 20% to about 75%, about 20% toabout 80%, about 20% to about 85%, about 20% to about 90%, about 25% toabout 30%, about 25% to about 40%, about 25% to about 50%, about 25% toabout 70%, about 25% to about 75%, about 25% to about 80%, about 25% toabout 85%, about 25% to about 90%, about 30% to about 40%, about 30% toabout 50%, about 30% to about 70%, about 30% to about 75%, about 30% toabout 80%, about 30% to about 85%, about 30% to about 90%, about 40% toabout 50%, about 40% to about 70%, about 40% to about 75%, about 40% toabout 80%, about 40% to about 85%, about 40% to about 90%, about 50% toabout 70%, about 50% to about 75%, about 50% to about 80%, about 50% toabout 85%, about 50% to about 90%, about 70% to about 75%, about 70% toabout 80%, about 70% to about 85%, about 70% to about 90%, about 75% toabout 80%, about 75% to about 85%, about 75% to about 90%, about 80% toabout 85%, about 80% to about 90%, or about 85% to about 90% relative topre-treatment involuntary muscle contractions. In some cases,involuntary muscle contractions may be reduced by about 20%, about 25%,about 30%, about 40%, about 50%, about 70%, about 75%, about 80%, about85%, or about 90% relative to pre-treatment involuntary musclecontractions.

A compound or salt of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II),(IIa), (III), or (III′) may be used to improve activities of dailyliving (ADL) or habitual physical activity in a subject as mature,functional undamaged muscle may be restored. Examples of ADL or habitualactivities include but are not limited to stair climb, time to get up,timed chair rise, habitual walk speed, North Star Ambulatory assessment,incremental/endurance shuttle walk and 6 minute walk distance tests. ADLor habitual physical activity levels or capacity may be measured priorto and following the administration of a skeletal muscle inhibitor.Inhibition of skeletal muscle contraction may not affect ADL or habitualphysical activity. In some cases, the inhibition of skeletal musclecontraction may not appreciably affect ADL or habitual physicalactivity. As used herein with regard to ADL or habitual physicalactivity, the phrase not appreciably refers to the level of ADL orhabitual activity reduced by less than 20%, less than 15%, less than10%, less than 8%, less than 6%, less than 4%, less than 2%, less than1%, less than 0.5% or even less than 0.1% relative to the ADL orhabitual activity prior to the administration of the inhibitor. Skeletalmuscle contraction or force in a subject may be measured prior to andfollowing the administration of the compound or salt of Formula (I),(Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′). Suchmeasurements may be performed to generate a dose response curve for thecompound or salt of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II),(IIa), (III), or (III′). Dosage of the compound or salt of Formula (I),(Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′) may beadjusted by about 5% to 50% relative to a dose that reduces type IIskeletal muscle contraction by 90%. In some cases, dosage of theskeletal muscle contraction inhibitor may be adjusted by at least about5% relative to a dose that reduces type II skeletal muscle contractionby 90%. In some cases, dosage of the skeletal muscle contractioninhibitor may be adjusted by at most about 50% relative to a dose thatreduces type II skeletal muscle contraction by 90%. In some cases,dosage of the skeletal muscle contraction inhibitor may be adjusted byabout 5% to about 10%, about 5% to about 15%, about 5% to about 20%,about 5% to about 25%, about 5% to about 30%, about 5% to about 35%,about 5% to about 40%, about 5% to about 50%, about 10% to about 15%,about 10% to about 20%, about 10% to about 25%, about 10% to about 30%,about 10% to about 35%, about 10% to about 40%, about 10% to about 50%,about 15% to about 20%, about 15% to about 25%, about 15% to about 30%,about 15% to about 35%, about 15% to about 40%, about 15% to about 50%,about 20% to about 25%, about 20% to about 30%, about 20% to about 35%,about 20% to about 40%, about 20% to about 50%, about 25% to about 30%,about 25% to about 35%, about 25% to about 40%, about 25% to about 50%,about 30% to about 35%, about 30% to about 40%, about 30% to about 50%,about 35% to about 40%, about 35% to about 50%, or about 40% to about50% relative to a dose that reduces type II skeletal muscle contractionby 90%. In some cases, dosage of the skeletal muscle contractioninhibitor may be adjusted by about 10%, about 12%, about 15%, about 18%,about 20%, about 25%, about 30%, about 35%, about 40%, about 45% orabout 50% relative to a dose that reduces type II skeletal musclecontraction by 90%. Skeletal muscle contraction may be measured by amuscle force test after nerve stimulation using surface electrodes(e.g., foot plantar flexion after peroneal nerve stimulation in theleg), isolated limb assay, heart rate monitor or an activity monitor orequivalents thereof prior to and following the administration of askeletal muscle contraction inhibitor.

Cardiac muscle force or cardiac muscle contraction of a subject may bemeasured prior to and following the administration of a compound or saltof Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or(III′). Inhibition of skeletal muscle contraction may not inhibitcardiac muscle contraction or cardiac muscle force. In some embodiments,the inhibition of skeletal muscle contraction may not appreciablyinhibit cardiac muscle contraction. In certain embodiments with regardto cardiac muscle contraction, the phrase not appreciably refers tocardiac muscle force reduced by less than 10%, less than 8%, less than6%, less than 4%, less than 2%, less than 1%, less than 0.5% or evenless than 0.1% relative to the cardiac muscle force prior to theadministration of the inhibitor. Cardiac muscle force or cardiac musclecontraction of a subject following the administration of a compound orsalt of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III),or (III′) may be within 0.1% to 10% of the cardiac muscle contraction orcardiac muscle force prior to the administration of the inhibitor. Insome embodiments, administration of a compound or salt of Formula (I),(Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′) may inhibitskeletal muscle contraction and cardiac muscle contraction or cardiacmuscle force. In some embodiments, cardiac muscle force reduced by morethan 0.1%, more than 0.5%, more than 1%, more than 2%, more than 4%,more than 6%, more than 8%, or more than 10%. In some embodiments, areduction of skeletal muscle contraction and cardiac muscle contractionare described by a ratio to one another. For example, in someembodiments, the ratio of the reduction in skeletal muscle contractionto reduction in cardiac muscle contraction is from about 1:1 to about100:1, about 2:1 to about 50:1, about 3:1 to about 40:1, about 4:1 toabout 30:1, about 5:1 to about 20:1, about 7:1 to about 15:1, or about8:1 to about 12:1. Cardiac muscle force or cardiac muscle contractionmay be measured using an echocardiogram (fractional shortening) or otherequivalent tests.

Tidal volume in lung in a subject may be measured prior to and followingthe administration of a compound or salt of Formula (I), (Ia), (Ib),(Ic), (Id), (Ie), (II), (IIa), (III), or (III′). Administration may notinhibit tidal volume in a lung. In some cases, administration may notappreciably inhibit tidal volume in a lung. In certain embodiments withregard to tidal lung volume in a lung, the phrase not appreciably refersto the tidal volume in a lung reduced by less than 10%, less than 8%,less than 6%, less than 4%, less than 2%, less than 1%, less than 0.5%or less than 0.1% relative to the tidal volume in a lung prior to theadministration of the inhibitor. Tidal volume in a lung in a subject maybe measured using forced volume in one second test (FEV1) or forcedvital capacity test (FVC) or equivalent tests thereof.

Smooth muscle contraction in a subject may be measured prior to andfollowing the administration of a skeletal muscle contraction inhibitor.Inhibition of skeletal muscle contraction may not inhibit smooth musclecontraction. In some cases, the inhibition of skeletal musclecontraction may not appreciably inhibit smooth muscle contraction. Asused herein with regard to smooth muscle contraction, the phrase notappreciably refers to the smooth muscle contraction reduced by less than10%, less than 8%, less than 6%, less than 4%, less than 2%, less than1%, less than 0.5% or even less than 0.1% relative to the smooth musclecontraction prior to the administration of the inhibitor. Smooth musclecontraction in a subject may be evaluated by measuring a subject's bloodpressure.

Neuromuscular coupling in a subject may be measured prior to andfollowing the administration of a compound or salt of Formula (I), (Ia),(Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′). Inhibition ofskeletal muscle contraction, with an inhibitor described herein, may notimpair nerve conduction, neurotransmitter release or electricaldepolarization of skeletal muscle in a subject. In some cases, theinhibition of skeletal muscle contraction may not appreciably impairneuromuscular coupling in a subject. As used herein with regard toneuromuscular coupling, the phrase not appreciably refers to a level ofneuromuscular coupling in the subject reduced by less than 10%, lessthan 8%, less than 6%, less than 4%, less than 2%, less than 1%, lessthan 0.5% or less than 0.1% relative to the level of neuromuscularcoupling in the subject prior to the administration of the inhibitor.Neuromuscular coupling in a subject may be evaluated by measuring nerveinduced electrical depolarization of skeletal muscle by the recording ofelectrical activity produced by skeletal muscles after electrical orvoluntary stimulation with electromyography (EMG) using surface orneedle electrodes.

In some aspects, the method of treating a neuromuscular condition ormovement disorder can comprise administering a compound or salt ofFormula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′)wherein the compound or salt of Formula (I), (Ia), (Ib), (Ic), (Id),(Ie), (II), (IIa), (III), or (III′) may inhibit myosin ATPase activity,native skeletal muscle myofibril ATPase (calcium regulated) or areconstituted S1 with actin, tropomyosin and troponin. In vitro assaysmay be used to test the effect of the test compound or inhibitor on themyosin ATPase activity. Test compounds can be screened for assessingtheir inhibitory activity of muscle contraction. Inhibitory activity canbe measured using an absorbance assay to determine actin-activatedATPase activity. Rabbit muscle myosin sub-fragment 1 (S1) can be mixedwith polymerized actin and distributed into wells of assay plateswithout nucleotides. Test compounds can then be added into the wellswith a pin array. The reaction can be initiated with MgATP. The amountof ATP consumption over a defined time period in the test vessel may becompared to the amount of ATP consumption in a control vessel. Thedefined period of time may be 5 minutes to 20 minutes. The ATPconsumption can be determined by direct or indirect assays. The testcompounds that reproducibly and strongly inhibited the myosin S1 ATPaseactivity can be evaluated further in dose response assay to determineIC50 for the compound ex vivo on dissected muscles. The assay maymeasure ATPase activity indirectly by coupling the myosin to pyruvatekinase and lactate dehydrogenase to provide an absorbance detectionmethod at 340 nm based upon the conversion of NADH to NAD+ driven by ADPaccumulation. In some cases, wherein ATP consumption is decreased by atleast 20% in said test vessel than said control vessel, said testcompound may be selected as a compound or salt of Formula (I), (Ia),(Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′). A test compoundmay be selected when there is at least 20% greater inhibition of NAD+generation in a kinetic assay.

The inhibitor or test compound selected may not inhibit cardiac musclemyosin S1 ATPase in in vitro assays. In some cases, the cardiac musclemyosin S1 ATPase or cardiac myofibrils or reconstituted system may beinhibited by less than 10%, less than 8%, less than 5%, less than 3%,less than 2%, less than 1% or less than 0.5% when a test compound orcompound or salt of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II),(IIa), (III), or (III′) is tested in an in-vitro assay.

Test compounds of skeletal muscle contraction may be tested on skinnedfibers. Single skeletal muscle fibers, treated so as to remove membranesand allow for a direct activation of contraction after calciumadministration may be used. An inhibitor compound or salt of Formula(I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′) mayinhibit contraction of a single skeletal muscle fiber by about 5% toabout 90% relative to pre-treatment value or an untreated control singleskeletal muscle fiber. An inhibitor may inhibit contraction of a singleskeletal muscle fiber by at least about 5% relative to pre-treatmentvalue or an untreated control single skeletal muscle fiber. An inhibitormay inhibit contraction of a single skeletal muscle fiber by at mostabout 90% relative to pre-treatment value or an untreated control singleskeletal muscle fiber. An inhibitor may inhibit contraction of a singleskeletal muscle fiber by about 5% to about 10%, about 5% to about 20%,about 5% to about 30%, about 5% to about 40%, about 5% to about 50%,about 5% to about 60%, about 5% to about 70%, about 5% to about 80%,about 5% to about 90%, about 10% to about 20%, about 10% to about 30%,about 10% to about 40%, about 10% to about 50%, about 10% to about 60%,about 10% to about 70%, about 10% to about 80%, about 10% to about 90%,about 20% to about 30%, about 20% to about 40%, about 20% to about 50%,about 20% to about 60%, about 20% to about 70%, about 20% to about 80%,about 20% to about 90%, about 30% to about 40%, about 30% to about 50%,about 30% to about 60%, about 30% to about 70%, about 30% to about 80%,about 30% to about 90%, about 40% to about 50%, about 40% to about 60%,about 40% to about 70%, about 40% to about 80%, about 40% to about 90%,about 50% to about 60%, about 50% to about 70%, about 50% to about 80%,about 50% to about 90%, about 60% to about 70%, about 60% to about 80%,about 60% to about 90%, about 70% to about 80%, about 70% to about 90%,or about 80% to about 90% relative to pre-treatment capacity or anuntreated control single skeletal muscle fiber. An inhibitor may inhibitcontraction of a single skeletal muscle fiber by about 5%, about 10%,about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about80%, or about 90% relative to pre-treatment capacity or an untreatedcontrol single skeletal muscle fiber.

An inhibitor compound or salt of Formula (I), (Ia), (Ib), (Ic), (Id),(Ie), (II), (IIa), (III), or (III′) may inhibit contraction of a singleskeletal muscle by about 5% to about 90% relative to pre-treatment valueor an untreated control single skeletal muscle. An inhibitor may inhibitcontraction of a single skeletal muscle by at least about 5% relative topre-treatment value or an untreated control single skeletal muscle. Aninhibitor may inhibit contraction of a single skeletal muscle by at mostabout 90% relative to pre-treatment value or an untreated control singleskeletal muscle. An inhibitor may inhibit contraction of a singleskeletal muscle by about 5% to about 10%, about 5% to about 20%, about5% to about 30%, about 5% to about 40%, about 5% to about 50%, about 5%to about 60%, about 5% to about 70%, about 5% to about 80%, about 5% toabout 90%, about 10% to about 20%, about 10% to about 30%, about 10% toabout 40%, about 10% to about 50%, about 10% to about 60%, about 10% toabout 70%, about 10% to about 80%, about 10% to about 90%, about 20% toabout 30%, about 20% to about 40%, about 20% to about 50%, about 20% toabout 60%, about 20% to about 70%, about 20% to about 80%, about 20% toabout 90%, about 30% to about 40%, about 30% to about 50%, about 30% toabout 60%, about 30% to about 70%, about 30% to about 80%, about 30% toabout 90%, about 40% to about 50%, about 40% to about 60%, about 40% toabout 70%, about 40% to about 80%, about 40% to about 90%, about 50% toabout 60%, about 50% to about 70%, about 50% to about 80%, about 50% toabout 90%, about 60% to about 70%, about 60% to about 80%, about 60% toabout 90%, about 70% to about 80%, about 70% to about 90%, or about 80%to about 90% relative to pre-treatment capacity or an untreated controlsingle skeletal muscle. An inhibitor may inhibit contraction of a singleskeletal muscle by about 5%, about 10%, about 20%, about 30%, about 40%,about 50%, about 60%, about 70%, about 80%, or about 90% relative topre-treatment capacity or an untreated control single skeletal muscle.

The effect of a test compound on slow type I skeletal muscle fibers,cardiac muscle bundles or lung muscle fibers, may be evaluated. A testcompound or inhibitor compound or salt of Formula (I), (Ia), (Ib), (Ic),(Id), (Ie), (II), (IIa), (III), or (III′) may be selected so as not toappreciably modulate the function of slow type I skeletal muscle fibers,cardiac muscle bundles or lung muscle fibers and be specific for type IIskeletal muscles. As used herein, the term “appreciably modulate” canrefer to the contraction capacity of muscles following the inhibitoradministration to be reduced less than 10%, less than 8%, less than 6%,less than 4%, less than 2%, less than 1%, less than 0.5% or even lessthan 0.1% relative to the muscle force/contraction prior to theadministration of the inhibitor.

In some aspects, a method of treating a neuromuscular condition or amovement disorder may comprise administering to a subject in needthereof a compound or salt of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie),(II), (IIa), (III), or (III′) wherein the compound or salt of Formula(I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′) reducesskeletal muscle contraction by 5% to 90% in an ex vivo assay. The exvivo assays used may be mouse models. The mouse models used may bedystrophy mouse models such as an mdx mouse. The mdx mouse has a pointmutation in its dystrophin gene, changing the amino acid coding for aglutamine to a threonine producing a nonfunctional dystrophin proteinresulting in DMD where there is increased muscle damage and weakness.Extensor digitorum longus muscles may be dissected from mdx mice andmounted on a lever arm. The muscles may be bathed in an oxygenated Krebssolution to maintain muscle function. A test compound or compound orsalt of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III),or (III′) may be applied to the muscles. An isometric (fixed length)contraction step may then be performed wherein the muscles arestimulated with a series of electrical pulses. An eccentric(lengthening) contraction step may be performed wherein the muscles arestretched to 10%, 15%, 20%, 25%, or 30% greater than its rested length,while relaxed or while stimulated with an electrical pulse. In someembodiments, the eccentric contraction step is repeated from 2 to 50times. In some embodiments, the eccentric contraction step is repeatedfrom 2 to 40 times. In some embodiments, the eccentric contraction stepis repeated from 2 to 30 times. In some embodiments, the eccentriccontraction step is repeated from 2 to 20 times. In some embodiments,the eccentric contraction step is repeated from 2 to 10 times. In someembodiments, the eccentric contraction step is repeated 4, 5, 6, 7, 8,9, 10, 11, 12, 13, 14, or 15 times to cause muscle fiber injury. In someembodiments, the electric pulses may have a frequency of about 1 Hz toabout 500 Hz. In some embodiments, the electric pulses may have afrequency of about 1 Hz to about 400 Hz. In some embodiments, theelectric pulses may have a frequency of about 1 Hz to about 300 Hz. Insome embodiments, the electric pulses may have a frequency of about 1 Hzto about 200 Hz. In some embodiments, the electric pulses may have afrequency of about 1 Hz to about 100 Hz. The electric pulse may have afrequency of about 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105,110, 115, 120, 125, 130, 135, 140, 145 or 150 Hz. A series of electricpulses may comprise of individual pulses of different frequencies. Thetime period of each pulse in the series of electric pulses may bebetween 0.1 second to 0.5 seconds for each pulse. The time for eachpulse may be 0.1, 0.2, 0.3, 0.35, 0.4 or 0.5 seconds. Muscle membranedamage may also be measured by incubating muscles in procion orangeafter the isometric or eccentric contraction. Procion orange is afluorescent dye that is taken up by muscle fibers with injuredmembranes. The number or proportion of dye-positive fibers may thenquantified by histology. When the test force drop and/or proportion ofdye-positive fibers may be at least 20% less than the control force dropand/or dye uptake, the test compound may be selected as a compound orsalt of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III),or (III′).

Using an isometric or eccentric set of contractions, the force generatedby the muscle may be measured. The change in force generated by themuscle before and after an isometric or eccentric set of contractionsmay be calculated as the test force drop. The calculations may becompared to the change in force generated by the muscle contraction fromthe first pulse to the last pulse in a control sample without exposureto the test compound (control force drop). Force drop can be used as asurrogate of muscle injury and a test compound or inhibitor compound orsalt of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III),or (III′) may be selected when the test force drop is at least 20% lessthan the control force drop.

Pharmaceutical Formulations

The compositions and methods described herein may be considered usefulas pharmaceutical compositions for administration to a subject in needthereof. Pharmaceutical compositions may comprise at least the acompound or salt of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II),(IIa), (III), or (III′) described herein and one or morepharmaceutically acceptable carriers, diluents, excipients, stabilizers,dispersing agents, suspending agents, and/or thickening agents.

Pharmaceutical compositions comprising a compound or salt of Formula(I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′) may beformulated using one or more physiologically-acceptable carrierscomprising excipients and auxiliaries. Formulation may be modifieddepending upon the route of administration chosen. Pharmaceuticalcompositions comprising a compound, salt or conjugate may bemanufactured, for example, by lyophilizing the compound, salt orconjugate, mixing, dissolving, emulsifying, encapsulating or entrappingthe conjugate. The pharmaceutical compositions may also include thecompounds, salts or conjugates in a free-base form orpharmaceutically-acceptable salt form.

Methods for formulation of a compound or salt of Formula (I), (Ia),(Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′) may includeformulating any of the compounds, salts or conjugates with one or moreinert, pharmaceutically-acceptable excipients or carriers to form asolid, semi-solid, or liquid composition. Solid compositions mayinclude, for example, powders, tablets, dispersible granules andcapsules, and in some aspects, the solid compositions further containnontoxic, auxiliary substances, for example wetting or emulsifyingagents, pH buffering agents, and other pharmaceutically-acceptableadditives. Alternatively, the compounds, salts or conjugates may belyophilized or in powder form for re-constitution with a suitablevehicle, e.g., sterile pyrogen-free water, before use.

Pharmaceutical compositions comprising a compound or salt of Formula(I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′) maycomprise at least one active ingredient (e.g., a compound, salt orconjugate and other agents). The active ingredients may be entrapped inmicrocapsules prepared, for example, by coacervation techniques or byinterfacial polymerization (e.g., hydroxymethylcellulose or gelatinmicrocapsules and poly-(methylmethacylate) microcapsules, respectively),in colloidal drug-delivery systems (e.g., liposomes, albuminmicrospheres, microemulsions, nano-particles and nanocapsules) or inmacroemulsions.

The compositions and formulations may be sterilized. Sterilization maybe accomplished by filtration through sterile filtration.

The compositions comprising a compound or salt of Formula (I), (Ia),(Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′) may be formulatedfor administration as an injection. Non-limiting examples offormulations for injection may include a sterile suspension, solution oremulsion in oily or aqueous vehicles. Suitable oily vehicles mayinclude, but are not limited to, lipophilic solvents or vehicles such asfatty oils or synthetic fatty acid esters, or liposomes. Aqueousinjection suspensions may contain substances which increase theviscosity of the suspension. The suspension may also contain suitablestabilizers. Injections may be formulated for bolus injection orcontinuous infusion. Alternatively, the compositions may be lyophilizedor in powder form for reconstitution with a suitable vehicle, e.g.,sterile pyrogen-free water, before use.

For parenteral administration, a compound or salt of Formula (I), (Ia),(Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′) may be formulatedin a unit dosage injectable form (e.g., solution, suspension, emulsion)in association with a pharmaceutically acceptable parenteral vehicle.Such vehicles may be inherently non-toxic, and non-therapeutic. Vehiclesmay be water, saline, Ringer's solution, dextrose solution, and 5% humanserum albumin. Non-aqueous vehicles such as fixed oils and ethyl oleatemay also be used. Liposomes may be used as carriers. The vehicle maycontain minor amounts of additives such as substances that enhanceisotonicity and chemical stability (e.g., buffers and preservatives).

In one embodiment the invention relates to methods and compositions ofFormula (I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′)formulated for oral delivery to a subject in need. In one embodiment acomposition is formulated so as to deliver one or more pharmaceuticallyactive agents to a subject through a mucosa layer in the mouth oresophagus. In another embodiment the composition is formulated todeliver one or more pharmaceutically active agents to a subject througha mucosa layer in the stomach and/or intestines.

In one embodiment compositions of Formula (I), (Ia), (Ib), (Ic), (Id),(Ie), (II), (IIa), (III), or (III′) are provided in modified releasedosage forms. Suitable modified release dosage vehicles include, but arenot limited to, hydrophilic or hydrophobic matrix devices, water-solubleseparating layer coatings, enteric coatings, osmotic devices,multi-particulate devices, and combinations thereof. The compositionsmay also comprise non-release controlling excipients.

In another embodiment compositions of Formula (I), (Ia), (Ib), (Ic),(Id), (Ie), (II), (IIa), (III), or (III′) are provided in enteric coateddosage forms. These enteric coated dosage forms can also comprisenon-release controlling excipients. In one embodiment the compositionsare in the form of enteric-coated granules, as controlled-releasecapsules for oral administration. The compositions can further comprisecellulose, disodium hydrogen phosphate, hydroxypropyl cellulose,pyridazine, lactose, mannitol, or sodium lauryl sulfate. In anotherembodiment the compositions are in the form of enteric-coated pellets,as controlled-release capsules for oral administration. The compositionscan further comprise glycerol monostearate 40-50, hydroxypropylcellulose, pyridazine, magnesium stearate, methacrylic acid copolymertype C, polysorbate 80, sugar spheres, talc, or triethyl citrate.

In another embodiment the compositions of Formula (I), (Ia), (Ib), (Ic),(Id), (Ie), (II), (IIa), (III), or (III′) are enteric-coatedcontrolled-release tablets for oral administration. The compositions canfurther comprise carnauba wax, crospovidone, diacetylatedmonoglycerides, ethylcellulose, hydroxypropyl cellulose, pyridazinephthalate, magnesium stearate, mannitol, sodium hydroxide, sodiumstearyl fumarate, talc, titanium dioxide, or yellow ferric oxide.

Sustained-release preparations comprising a compound or salt of Formula(I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′) may bealso be prepared. Examples of sustained-release preparations may includesemipermeable matrices of solid hydrophobic polymers that may containthe compound, salt or conjugate, and these matrices may be in the formof shaped articles (e.g., films or microcapsules). Examples ofsustained-release matrices may include polyesters, hydrogels (e.g.,poly(2-hydroxyethyl-methacrylate), or poly(vinyl alcohol)),polylactides, copolymers of L-glutamic acid and y ethyl-L-glutamate,non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolicacid copolymers such as the LUPRON DEPO™ (i.e., injectable microspherescomposed of lactic acid-glycolic acid copolymer and leuprolide acetate),and poly-D-(−)-3-hydroxybutyric acid.

Pharmaceutical formulations comprising a compound or salt of Formula(I), (Ia), (Ib), (Ic), (Id), (Ie), (II), (IIa), (III), or (III′) may beprepared for storage by mixing a compound, salt or conjugate with apharmaceutically acceptable carrier, excipient, and/or a stabilizer.This formulation may be a lyophilized formulation or an aqueoussolution. Acceptable carriers, excipients, and/or stabilizers may benontoxic to recipients at the dosages and concentrations used.Acceptable carriers, excipients, and/or stabilizers may include bufferssuch as phosphate, citrate, and other organic acids; antioxidantsincluding ascorbic acid and methionine; preservatives, polypeptides;proteins, such as serum albumin or gelatin; hydrophilic polymers; aminoacids; monosaccharides, disaccharides, and other carbohydrates includingglucose, mannose, or dextrins; chelating agents such as EDTA; sugarssuch as sucrose, mannitol, trehalose or sorbitol; salt-formingcounter-ions such as sodium; metal complexes; and/or non-ionicsurfactants or polyethylene glycol.

In another embodiment the compositions of Formula (I), (Ia), (Ib), (Ic),(Id), (Ie), (II), (IIa), (III), or (III′) can further comprise calciumstearate, crospovidone, hydroxypropyl methylcellulose, iron oxide,mannitol, methacrylic acid copolymer, polysorbate 80, povidone,propylene glycol, sodium carbonate, sodium lauryl sulfate, titaniumdioxide, and triethyl citrate.

In another embodiment compositions of Formula (I), (Ia), (Ib), (Ic),(Id), (Ie), (II), (IIa), (III), or (III′) are provided in effervescentdosage forms. These effervescent dosage forms can also comprisenon-release controlling excipients.

In another embodiment compositions of Formula (I), (Ia), (Ib), (Ic),(Id), (Ie), (II), (IIa), (III), or (III′) can be provided in a dosageform that has at least one component that can facilitate the immediaterelease of an active agent, and at least one component that canfacilitate the controlled release of an active agent. In a furtherembodiment the dosage form can be capable of giving a discontinuousrelease of the compound in the form of at least two consecutive pulsesseparated in time from 0.1 up to 24 hours. The compositions can compriseone or more release controlling and non-release controlling excipients,such as those excipients suitable for a disruptable semi-permeablemembrane and as swellable substances.

In another embodiment compositions of Formula (I), (Ia), (Ib), (Ic),(Id), (Ie), (II), (IIa), (III), or (III′) are provided in a dosage formfor oral administration to a subject, which comprise one or morepharmaceutically acceptable excipients or carriers, enclosed in anintermediate reactive layer comprising a gastric juice-resistantpolymeric layered material partially neutralized with alkali and havingcation exchange capacity and a gastric juice-resistant outer layer.

In some embodiments, the compositions of Formula (I), (Ia), (Ib), (Ic),(Id), (Ie), (II), (IIa), (III), or (III′) provided herein can be inunit-dosage forms or multiple-dosage forms. Unit-dosage forms, as usedherein, refer to physically discrete units suitable for administrationto human or non-human animal subjects and packaged individually. Eachunit-dose can contain a predetermined quantity of an activeingredient(s) sufficient to produce the desired therapeutic effect, inassociation with the required pharmaceutical carriers or excipients.Examples of unit-dosage forms include, but are not limited to, ampoules,syringes, and individually packaged tablets and capsules. In someembodiments, unit-dosage forms may be administered in fractions ormultiples thereof. A multiple-dosage form is a plurality of identicalunit-dosage forms packaged in a single container, which can beadministered in segregated unit-dosage form. Examples of multiple-dosageforms include, but are not limited to, vials, bottles of tablets orcapsules, or bottles of pints or gallons. In another embodiment themultiple dosage forms comprise different pharmaceutically active agents.

In some embodiments, the compositions of Formula (I), (Ia), (Ib), (Ic),(Id), (Ie), (II), (IIa), (III), or (III′) may also be formulated as amodified release dosage form, including immediate-, delayed-, extended-,prolonged-, sustained-, pulsatile-, controlled-, extended, accelerated-and fast-, targeted-, programmed-release, and gastric retention dosageforms. These dosage forms can be prepared according to known methods andtechniques (see, Remington: The Science and Practice of Pharmacy, supra;Modified-Release Drug Delivery Technology, Rathbone et al., Eds., Drugsand the Pharmaceutical Science, Marcel Dekker, Inc.: New York, N.Y.,2002; Vol. 126, which are herein incorporated by reference in theirentirety).

Combination Therapies

Also contemplated herein are combination therapies, for example,co-administering a disclosed compound and an additional active agent, aspart of a specific treatment regimen intended to provide the beneficialeffect from the co-action of these therapeutic agents. The beneficialeffect of the combination includes, but is not limited to,pharmacokinetic or pharmacodynamic co-action resulting from thecombination of therapeutic agents. Administration of these therapeuticagents in combination typically is carried out over a defined timeperiod (usually hours, days, weeks, months or years depending upon thecombination selected). Combination therapy is intended to embraceadministration of multiple therapeutic agents in a sequential manner,that is, wherein each therapeutic agent is administered at a differenttime, as well as administration of these therapeutic agents, or at leasttwo of the therapeutic agents, in a substantially simultaneous manner.

Substantially simultaneous administration is accomplished, for example,by administering to the subject a single formulation or composition,(e.g., a tablet or capsule having a fixed ratio of each therapeuticagent or in multiple, single formulations (e.g., capsules) for each ofthe therapeutic agents. Sequential or substantially simultaneousadministration of each therapeutic agent is effected by any appropriateroute including, but not limited to, oral routes, intravenous routes,intramuscular routes, and direct absorption through mucous membranetissues. The therapeutic agents are administered by the same route or bydifferent routes. For example, a first therapeutic agent of thecombination selected is administered by intravenous injection while theother therapeutic agents of the combination are administered orally.Alternatively, for example, all therapeutic agents are administeredorally or all therapeutic agents are administered by intravenousinjection.

The components of the combination are administered to a patientsimultaneously or sequentially. It will be appreciated that thecomponents are present in the same pharmaceutically acceptable carrierand, therefore, are administered simultaneously. Alternatively, theactive ingredients are present in separate pharmaceutical carriers, suchas, conventional oral dosage forms, that are administered eithersimultaneously or sequentially.

In certain embodiments, a compound or salt of the disclosure may beadministered in combination with an oral corticosteroid. In certainembodiments, a compound or salt of the disclosure is administered incombination with deflazacort. In certain embodiments, a compound or saltof the disclosure is administered in combination with prednisone. Incertain embodiments, a compound or salt of the disclosure isadministered in combination with a morpholino antisense oligomer. Incertain embodiments, a compound or salt of the disclosure isadministered in combination with and exon skipping therapy. In certainembodiments, the additional therapeutic agent is eteplirsen or ataluren.

In certain embodiments, a compound or salt of the disclosure is used incombination with a gene therapy. In certain embodiments, the compound orsalt of the disclosure is used in combination with adeno-associatedvirus (AAV) containing genes encoding replacement proteins, e.g.,dystrophin, or truncated version thereof, e.g., microdystrophin. Incertain embodiments, a compound or salt of the disclosure isadministered in combination with vamorolone.

EXAMPLES

The invention now being generally described, it will be more readilyunderstood by reference to the following examples which are includedmerely for purposes of illustration of certain aspects and embodimentsof the present invention, and are not intended to limit the invention inany way.

The following synthetic schemes are provided for purposes ofillustration, not limitation. The following examples illustrate thevarious methods of making compounds described herein. It is understoodthat one skilled in the art may be able to make these compounds bysimilar methods or by combining other methods known to one skilled inthe art. It is also understood that one skilled in the art would be ableto make, in a similar manner as described below by using the appropriatestarting materials and modifying the synthetic route as needed. Ingeneral, starting materials and reagents can be obtained from commercialvendors or synthesized according to sources known to those skilled inthe art or prepared as described herein.

Example 1. General Scheme—Synthesis of2-((3-ethylisoxazol-5-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazine-3(2H)-one(Compound 36)

Example 2. Exemplary Scheme—Synthesis of2-((3-ethylisoxazol-5-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazine-3(2H)-one(Compound 36)

Step 1: Substitution of Pyridine, Pyrimidine, or Phenyl Groups

Bromofluoropyrimidine was combined with an alcohol (e.g.2,2,2-trifluoroethanol), cesium carbonate and a non-protic solvent (e.g.DMF). The mixture was heated gently if necessary to increase the rate offluoro displacement. Isolation of the major product provided thecorresponding 2-substituted pyrimidines.

Steps 2-3: Cross Coupling of Pyridine, Pyrimidine, or Phenyl Groups withPyrizidinones

A Suzuki reaction at the C-4 bromo position using a palladium catalyst(e.g. [1,1-bis(diphenylphosphino)ferrocene]dichloropalladium (II)) and amild base (e.g. potassium acetate) in dioxane/water produced the bi-arylcores in good yield.

Step 4: Alkylation of Compounds

The nitrogen was cleanly alkylated using a wide variety ofheteroarylmethylbromides or heteroarylmethylchlorides (e.g.5-(chloromethyl)-3-ethylisoxazole) and inorganic base in polar aproticsolvents (e.g. DMF). Alternatively, the nitrogen of the pyridizinonecould be functionalized using Mitsunobu methodology. This required ahydroxymethylheteroaryl compound, triphenylphosphine and a carbodiimidereagent (e.g. DEAD). Both alternatives were utilized in preparation ofdesired products depending on the availability of the appropriatecoupling partners. Examples 1 and 2 may be modified as appropriate toprepare compounds described in Tables 1 and 2 herein.

Example 3:6-[2-[(3-fluorooxetan-3-yl)methoxy]pyrimidin-5-yl]-2-[(5-phenyl-1,3,4-thiadiazol-2-yl)methyl]-2,3-dihydropyridazin-3-one(Compound 36)

Step 1: 5-bromo-2-((3-fluorooxetan-3-yl)methoxy)pyrimidine

Following step 1 in example 2 gave the title as a solid 160 mg (58.8%).LC/MS (ESI): 263 [M+H]⁺.

Step 2/3:6-(2-((3-fluorooxetan-3-yl)methoxy)pyrimidin-5-yl)pyridazine-3(2H)-one

Following step 2 in example 2 afforded the title compound as a whitesolid (500 mg, 32.8%). LC/MS (ESI): 279 [M+H]⁺.

Step 4:6-[2-[(3-fluorooxetan-3-yl)methoxy]pyrimidin-5-yl]-2-[(5-phenyl-1,3,4-thiadiazol-2-yl)methyl]-2,3-dihydropyridazin-3-one

To a stirred solution of6-[2-[(3-fluorooxetan-3-yl)methoxy]pyrimidin-5-yl]-2,3-dihydropyridazin-3-one(100 mg, 0.36 mmol) and (5-phenyl-1,3,4-thiadiazol-2-yl)methanol (69.0mg, 0.36 mmol) in THF (1.5 mL) were added PPh₃ (188 mg, 0.72 mmol) andDEAD (94.0 mg, 0.54 mmol). The reaction was stirred at 25° C. for 2 h.The mixture was concentrated under vacuum to give a residue, which waspurified by Prep-HPLC to afford the title compound as a white solid (24mg, 14.8%). ¹H NMR (DMSO-d6, 300 MHz): δ 9.14 (s, 2H), 8.20 (d,J_(\)=9.6 Hz, 1H), 8.00-7.97 (m, 2H), 7.59-7.53 (m, 3H), 7.26 (d,J_(\)=9.9 Hz, 1H), 5.83 (s, 2H), 4.88-4.71 (m, 6H); LC/MS (ESI): 453[M+H]⁺.

Example 4:6-[2-[(3-fluorooxetan-3-yl)methoxy]pyrimidin-5-yl]-2-[[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]methyl]-2,3-dihydropyridazin-3-one(Compound 90)

Step 1:6-[2-[(3-fluorooxetan-3-yl)methoxy]pyrimidin-5-yl]-2-[[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]methyl]-2,3-dihydropyridazin-3-one

To a solution of6-[2-[(3-fluorooxetan-3-yl)methoxy]pyrimidin-5-yl]-2,3-dihydropyridazin-3-one(100 mg, 0.036 mmol) in DMF (1 mL) were added Cs₂CO₃ (351 mg, 0.11 mmol)and 5-(chloromethyl)-3-(4-fluorophenyl)-1,2,4-oxadiazole (76.4 mg, 0.036mmol). The resulting mixture was stirred for 1 hr at 0° C. The resultingmixture was purified by Prep-HPLC to afford the title compound as awhite solid (10 mg, 6.1%). ¹H NMR (CD₃OD, 300 MHz): δ 9.13 (s, 2H),8.17-8.05 (m, 3H), 7.30-7.21 (m, 3H), 5.80 (s, 2H), 5.03-4.75 (m, 6H);LC/MS (ESI): 456 [M+H]⁺.

The following compound was synthesized following Example 4:

Cmpd No. Structure Name NMR/ MS 91

6-(2-((3-fluorooxetan-3- yl)methoxy)pyrimidin- 5-yl)-2-(3-phenyl-1,2,4-oxadiazol-5- yl)methyl)pyridazine- 3(2H)-one ¹H NMR (DMSO-d6, 300MHz): δ 9.13 (s, 2H), 8.24 (d, J = 9.6 Hz, 1H), 8.00-7.97 (m, 2H),7.60-7.56 (m, 3H), 7.27 (d, J = 9.6 Hz, 1H), 5.80 (s, 2H), 4.88-4.71 (m,6H); LC/MS (ESI): 437 [M + H]+

Example 5:6-(6-(difluoromethoxy)pyridazi-3-yl)-2-((5-phenyl-1,3,4-thiadiazol-2-yl)methyl)pyridazine-3(2H)-one(Compound 22)

Step 1/2: 6-(6-(difluoromethoxy)pyridazi-3-yl)pyridazine-3(2H)-one

Following steps 1 and 2 in example 2 afforded the title compound as awhite solid (3.5 g, 72.1%). LC/MS (ESI): 240 [M+H]⁺.

Step 3: ethyl 2-(2-benzoylhydrazineyl)-2-oxoacetate

To a solution of benzohydrazide (1.00 g, 7.35 mmol) in DCM (5.0 mL) wereadded ethyl oxalochloridate (1.00 g, 7.32 mmol). The resulting mixturewas stirred for 1 hr at 25° C. The reaction was concentrated to give aresidue, which was purified by chromatography on silica gel (Flash 40 g,30-80% EA:PE) to give the title compound as a white solid (0.5 g,28.8%). LC/MS (ESI): 237 [M+H]⁺.

Step 4: ethyl 5-phenyl-1,3,4-thiadiazole-2-carboxylate

A mixture of ethyl ethyl 2-(2-benzoylhydrazineyl)-2-oxoacetate (480 mg,2.03 mmol), Lawesson reagent (1.49 g, 4.06 mmol) in Toluene (5.0 mL) wasstirred for 2 hr at 80° C. The resulting mixture was concentrated undervacuum to give a residue, which was purified by chromatography on silicagel (Flash 40 g, 20-50% EA:PE) to give the title compound as a whitesolid (390 mg, 81.9%). LC/MS (ESI): 235 [M+H]⁺.

Step 5: (5-phenyl-1,3,4-thiadiazol-2-yl)methanol

To a solution of ethyl 5-phenyl-1,3,4-thiadiazole-2-carboxylate (440 mg,1.888 mmol) in MeOH (5.0 mL) was added NaBH₄ (142 mg, 3.76 mmol). Theresulting solution was stirred for 1 hr at 25° C. The resulting mixturewas concentrated to give a residue, which was purified by chromatographyon silica gel (Flash 40 g, 50-80% EA:PE) to give the title compound as awhite solid (300 mg, 83.1%). LC/MS (ESI): 193 [M+H]⁺.

Step 6:6-[2-[(3-fluorooxetan-3-yl)methoxy]pyrimidin-5-yl]-2-[(5-phenyl-1,3,4-thiadiazol-2-yl)methyl]-2,3-dihydropyridazin-3-one

Following step 4 in example 8 afford the title compound as a white solid(38.8 mg, 22.5%). ¹H NMR (DMSO-d6, 400 MHz): δ 8.81 (d, J_(\)=2.4 Hz,1H), 8.42 (dd, J₁=8.4 Hz, J₂=2.4 Hz, 1H), 8.21 (d, J_(\)=10.0 Hz, 1H),7.99-7.97 (m, 2H), 7.79 (t, J=73.2 Hz, 1H), 7.59-7.53 (m, 3H), 7.27-7.24(m, 2H), 5.83 (s, 2H); LC/MS (ESI): 414 [M+H]⁺.

The following compounds were synthesized following Example 5 (viaMitsunobo or Substitution):

Compound No. Structure Name NMR/MS 17

6-(6- (difluoromethoxy)pyridazi- 3-yl)-2-((5-(4- fluorophenyl)-1,3,4-thiadiazol-2- yl)methyl)pyridazine- 3(2H)-one ¹H NMR (DMSO-d6, 300 MHz):δ 8.81 (d, J_(\) = 2.4 Hz, 1H), 8.42 (dd, J₁ = 8.7 Hz, J₂ = 2.7 Hz, 1H),8.20 (d, J_(\) = 9.9 Hz, 1H), 8.07-8.04 (m, 2H), 7.78 (t, J = 72.6 Hz,1H), 7.39-7.37 (m, 2H), 7.27-7.23 (m, 2H), 5.82 (s, 2H); LC/MS (ESI):432 [M + H]⁺ 10

6-(6- (difluoromethoxy)pyridazi- 3-yl)-2-(pyridazi-3-ylmethyl)pyridazine- 3(2H)-one ¹H NMR (DMSO-d6, 300 MHz): δ 8.78 (d,J_(\) = 2.1 Hz, 1H), 8.65 (s, 1H), 8.52 (d, J = 3.9 Hz, 1H), 8.40 (dd,J₁ = 8.7 Hz, J₂ = 2.4 Hz, 1H), 8.13 (d, J_(\) = 9.6 Hz, 1H), 7.83-7.80(m, 1H), 7.77 (t, J = 72.3 Hz, 1H), 7.41-7.37 (m, 1H), 7.24-7.17 (m,2H), 5.38 (s, 2H); LC/MS (ESI): 331 [M + H]+  9

6-(6- (difluoromethoxy)pyridazi- 3-yl)-2-((5-fluoropyridin-3-yl)methyl)pyridazine- 3(2H)-one ¹H NMR (DMSO-d6, 300 MHz): δ 8.79 (d,J_(\) = 2.1 Hz, 1H), 8.54-8.53 (m, 2H), 8.40 (dd, J₁ = 8.7 Hz, J₂ = 2.4Hz, 1H), 8.14 (d, J_(\) = 9.9 Hz, 1H), 7.78 (t, J = 72.3 Hz, 1H),7.77-7.33 (m, 1H), 7.25-7.14 (m, 2H), 5.42 (s, 2H); LC/MS (ESI): 349[M + H]+  2

2-((5-chloropyridin-3- yl)methyl)-6-(6- (difluoromethoxy)pyridazi-3-yl)pyridazine-3(2H)-one ¹H NMR (DMSO-d6, 300 MHz): δ 8.78 (s, 1H),8.61- 8.59 (s, 2H), 8.40 (dd, J1 = 8.7 Hz, J2 = 2.4 Hz, 1H), 8.15 (d, J\= 9.9 Hz, 1H), 7.96-7.95 (m, 1H), 7.77 (t, J = 72.6 Hz, 1H), 7.25-7.14(m, 2H), 5.40 (s, 2H); LC/MS (ESI): 365 [M + H]+

Example 6:2-[(4-chlorophenyl)methyl]-6-[2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl]-2,3-dihydropyridazin-3-one(Compound 1)

Step 1: 5-bromo-2-(2,2,2-trifluoroethoxy)pyrimidine

To a mixture of 5-bromo-2-chloropyrimidine (10 g, 0.021 mol, 1.0 equiv)in DMSO (10 mL) were added 2,2,2-trifluoroethan-1-ol (6.21 g, 0.025 mol,1.20 equiv) and Cs₂CO₃ (25.27 g, 0.062 mol, 3.0 equiv) at roomtemperature. The reaction mixture was stirred for 2 h at 70° C. Thesolution was diluted with water and extracted with EtOAc (30 mL×3). Thecombined organic layers were washed with brine, dried over Na₂SO₄ andthe solvent removed in vacuo. Purification by chromatography on silicagel (Flash 300 g, 0-40% EtOAc:cyclohexane) afforded the title compoundas yellow oil (10.0 g, 94.08%). LC/MS (ESI): 257 [M+H]⁺.

Step 2: [2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl]boronic acid

To a mixture of 5-bromo-2-(2,2,2-trifluoroethoxy)pyrimidine (5.0 g,19.45 mmol, 1.0 equiv) in dioxane (40 mL) were added4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(7.41 g, 29.18 mmol, 1.5 equiv), KOAc (5.73 g, 58.36 mmol, 3.0 equiv)and Pd(dppf)Cl₂ (1.42 g, 1.94 mmol, 0.1 equiv). Into the flask purgedand maintained with an inert atmosphere of nitrogen. The reactionmixture was stirred for 4 h at 80° C. and confirmed by LCMS. Thereaction was used directly in the next step without workup.

Step 3:6-[2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl]-2,3-dihydropyridazin-3-one

To a mixture of [2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl]boronic acid(4.2 g, 18.93 mmol, 1.0 equiv) in dioxane (40 mL) were added6-bromo-2,3-dihydropyridazin-3-one (3.31 g, 18.916 mmol, 1.00 equiv),Pd(dppf)Cl₂ (0.69 g, 0.943 mmol, 0.05 equiv), K₂CO₃ (3.92 g, 28.387mmol, 1.5 equiv) and H₂O (4 mL). Into the flask purged and maintainedwith an inert atmosphere of nitrogen. The resulting solution was stirredfor 2 h at 90° C. The solution was diluted with water and extracted withEtOAc (30 mL×3). The combined organics were washed with brine, driedover Na₂SO₄ and the solvent removed in vacuo. Purification bychromatography on silica gel (Flash 300 g, 50-100% EtOAc:cyclohexane)afforded the title compound as brown solid (3.0 g, 58.24%). LC/MS (ESI):273 [M+H]⁺.

Step 4:2-[(5-chloropyridin-3-yl)methyl]-6-[2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl]-2,3-dihydropyridazin-3-one

To a mixture of6-[2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl]-2,3-dihydropyridazin-3-one(1.0 g, 3.67 mmol, 1.0 equiv) in DMF (10 mL) were added3-(bromomethyl)-5-chloropyridine (0.82 g, 0.004 mmol, 1.0 equiv) andCs₂CO₃ (2.39 g, 0.007 mmol, 2.0 equiv) at room temperature. Theresulting solution was stirred for 2 h at room temperature.

The following compounds were synthesized following Example 6:

Cmpd No. Structure Name NMR/MS 88

2-((3-(4-fluorophenyl)-1,2,4- oxadiazol-5-yl)methyl)-6-(2- (2,2,2-trifluoroethoxy)pyrimidin-5- yl)pyridazine-3(2H)-one ¹H NMR (300 MHz,DMSO-d6): δ 9.15 (s, 2H), 8.13 (d, J = 6.3 Hz, 1H), 8.11-8.05 (m, 2H),7.30- 7.21 (m, 3H), 5.81 (s, 2H), 5.03 (q, J = 8.7 Hz, 2H); LC/MS (ESI):449 [M + H]+ 89

2-((3-phenyl-1,2,4-oxadiazol- 5-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5- yl)pyridazine-3(2H)-one ¹H NMR (300 MHz,DMSO-d6): δ 9.16 (s, 2H), 8.15 (d, J = 9.9 Hz, 1H), 8.06-8.02 (m, 2H),7.59- 7.48 (m, 3H), 7.23 (d, J = 9.9 Hz, 1H), 5.81 (s, 2H), 5.03 (q, J =8.4 Hz, 2H); LC/MS (ESI): 432 [M + H]+  1

2-((5-chloropyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5- yl)pyridazine-3(2H)-one ¹H NMR (300 MHz,DMSO-d₆): δ 9.18 (s, 2H), 8.61 (dd, J = 8.7, 1.5 Hz, 2H), 8.15 (d, J =9.9 Hz, 1H), 7.99 (s, 1H), 7.18 (d, J = 9.6 Hz, 1H), 5.39 (s, 2H), 5.12(q, J = 9.0 Hz, 2H); LC/MS (ESI): 398 [M + H]⁺  6

2-((5-fluoropyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5- yl)pyridazine-3(2H)-one ¹H NMR (300 MHz,DMSO-d₆): δ 9.18 (s, 2H), 8.55-8.54 (m, 2H), 8.15 (d, J = 9.6 Hz, 1H),7.81-7.77 (m, 1H), 7.19 (d, J = 9.9 Hz, 1H), 5.41 (s, 2H), 5.12 (q, J =9.0 Hz, 2H); LC/MS (ESI): 382 [M + H]⁺

Example 7:6-[4-(difluoromethoxy)phenyl]-2-[(3-methyl-1,2-oxazol-5-yl)methyl]-2,3-dihydropyridazin-3-one(Compound 204)

Step 1: 6-[4-(difluoromethoxy)phenyl]-2,3-dihydropyridazin-3-one

To a mixture of 6-bromo-2,3-dihydropyridazin-3-one (1.69 g, 9.67 mmol,1.0 equiv) in in Dioxane (20 mL) were added[4-(difluoromethoxy)phenyl]boronic acid (2.0 g, 10.64 mmol, 1.1 equiv),K₂CO₃ (4.0 g, 29.0 mmol, 3.0 equiv), Pd(dppf)Cl₂ (707.51 mg, 0.97 mmol,0.1 equiv) and H₂O (2 mL). The reaction mixture was stirred for 4 h at90° C. under Argon atmosphere. The solution was diluted with water andextracted with EtOAc (30 mL×3). The combined organics were washed withbrine, dried over Na₂SO₄ and the solvent removed in vacuo. Purificationby chromatography on silica gel (Flash 300 g, 50-90% EtOAc:cyclohexane)afforded the title compound as an off-white solid (1.55 g, 67.30%).LC/MS (ESI): 239 [M+H]⁺.

Step 2:6-[4-(difluoromethoxy)phenyl]-2-[(3-methyl-1,2-oxazol-5-yl)methyl]-2,3-dihydropyridazine-3-one

To a mixture of 6-[4-(difluoromethoxy)phenyl]-2,3-dihydropyridazin-3-one(100 mg, 0.42 mmol, 1.0 equiv) in DMF (2 mL) were added5-(bromomethyl)-3-methyl-1,2-oxazole (81.28 mg, 0.462 mmol, 1.1 equiv)and Cs₂CO₃ (411.63 mg, 1.259 mmol, 3.0 equiv). The reaction mixture wasstirred for 4 h at room temperature. The reaction was quenched by theaddition of saturated aqueous sodium bicarbonate solution. The solutionwas diluted with water and extracted with EtOAc (30 mL×3). The combinedorganics were washed with brine, dried over Na₂SO₄ and the solventremoved in vacuo. The residue was purified by Prep-HPLC to afford awhite solid (76 mg, 54.31%). ¹H NMR (400 MHz, DMSO-d₆): δ 8.11 (d,J=10.0 Hz, 1H), 7.94 (d, J=8.0 Hz, 2H), 7.52-7.12 (m, 4H), 6.34 (s, 1H),5.46 (s, 2H), 2.21 (s, 3H); LC/MS (ESI): 334 [M+H]⁺

The following compounds were synthesized following Example 7:

Cmpd No. Structure Name NMR/MS 204

6-(4-(difluoromethoxy)phenyl)-2- ((3-methylisoxazol-5-yl)methyl)pyridazine-3(2H)-one ¹H NMR (400 MHz, DMSO-d₆): δ 8.11 (d, J =10.0 Hz, 1H), 7.94 (d, J = 8.0 Hz, 2H), 7.52-7.12 (m, 4H), 6.34 (s, 1H),5.46 (s, 2H), 2.21 (s, 3H); LC/MS (ESI): 334 [M + H]⁺ 205

6-(4-(difluoromethoxy)phenyl)-2- ((4-methylthiazol-2-yl)methyl)pyridazine-3(2H)-one ¹H NMR (300 MHz, DMSO-d₆): δ 8.14-7.95 (d, J = 9.9Hz, 1H), 7.98-7.95 (m, 2H), 7.58-7.09 (m, 5H), 5.58 (s, 2H), 2.34 (s,3H); LC/MS (ESI): 350 [M + H]⁺ 206

2-((3-cyclopropylisoxazol-5- yl)methyl)-6-(4- (difluoromethoxy)phenyl)pyridazine-3(2H)-one ¹H NMR (300 MHz, DMSO-d₆): δ 8.11 (d, J = 9.6 Hz,1H), 7.97-7.92 (m, 2H), 7.58-7.09 (m, 4H), 6.24 (s, 1H), 5.42 (s, 2H),2.02-1.93 (m, 1H), 1.01- 0.95 (m, 2H), 0.77-0.74 (m, 2H); LC/MS (ESI):360 [M + H]⁺ 203

2-(benzo[d]oxazol-2-ylmethyl)-6- (4-(difluoromethoxy)phenyl)pyridazine-3(2H)-one ¹H NMR (300 MHz, DMSO-d₆): δ 8.17 (d, J = 9.9 Hz,1H), 7.97-7.94 (m, 2H), 7.75-7.71 (m, 2H), 7.58-7.09 (m, 6H), 5.69 (s,2H); LC/MS (ESI): 370 [M + H]⁺ 208

2((3-cyclopropyl-1,2,4-oxadiazol- 5-yl)methyl)-6-(4-(difluoromethoxy)phenyl) pyridazine-3(2H)-one ¹H NMR (300 MHz, DMSO-d₆):δ 8.15 (d, J = 9.9 Hz, 1H), 7.96-7.93 (m, 2H), 7.58-7.09 (m, 4H), 5.62(s, 2H), 2.16-2.07 (m, 1H), 1.09-1.00 (m, 2H), 0.88-0.86 (m, 2H); LC/MS(ESI): 361 [M + H]⁺ 210

2-((4-cyclopropylthiazol-2- yl)methyl)-6-(4- (difluoromethoxy)phenyl)pyridazine-3(2H)-one ¹H NMR (300 MHz, DMSO-d₆): δ 8.13 (d, J = 9.9 Hz,1H), 7.96 (d, J = 8.7 Hz, 2H), 7.60-7.05 (m, 5H), 5.55 (s, 2H),2.10-2.01 (m, 1H), 0.91-0.76 (m, 4H); LC/MS (ESI): 376 [M + H]⁺ 202

6-(4-(difluoromethoxy)phenyl)-2- ((3-phenyl-1,2,4-oxadiazol-5-yl)methyl)pyridazine-3(2H)-one ¹H NMR (300 MHz, DMSO-d₆): δ 8.20 (d, J =9.6 Hz, 1H), 7.98 (d, J = 7.6 Hz, 4H), 7.60-7.53 (m, 3H), 7.46-7.16 (m,4H), 5.79 (s, 3H); LC/MS (ESI): 397 [M + H]⁺

Example 8:6′-(bicyclo[1.1.1]pentan-1-ylamino)-1-(pyridazi-3-ylmethyl)-[3,3′-bipyridin]-6(1H)-one(Compound 71)

Step 1: N-(bicyclo[1.1.1]pentan-1-yl)-5-bromopyridin-2-amine

A mixture of 5-bromo-2-fluoropyridine (200 mg, 1.136 mmol),bicyclo[1.1.1]pentan-1-amine (141.72 mg, 1.705 mmol), Cs₂CO₃ (1.11 g,3.409 mmol) in DMSO (3 mL) was stirred for 2 hr at 120° C. The residuewas applied onto a silica gel column eluted with ethyl acetate/petroleumether (1:2). This resulted in the title compound as a solid 110 mg(40.48%). MS m/z: 239 [M+H]⁺

Step 2:N-(bicyclo[1.1.1]pentan-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridazi-2-amine

To a mixture of N-(bicyclo[1.1.1]pentan-1-yl)-5-bromopyridin-2-amine(110 mg, 0.46 mmol, 1.0 equiv) in dioxane (1.1 mL) were added4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(175 mg, 0.69 mmol, 1.5 equiv), KOAc (135 mg, 1.38 mmol, 3.0 equiv) andPd(dppf)Cl₂ (37 mg, 0.05 mmol, 0.1 equiv). Into the flask purged andmaintained with an inert atmosphere of nitrogen. The reaction mixturewas stirred for 4 h at 80° C. and confirmed by LCMS. The reaction wasused in next step directly without workup.

Step 3:2-[3-[6-([bicyclo[1.1.1]pentan-1-yl]amino)pyridazi-3-yl]-6-oxo-1,6-dihydropyridazin-1-yl]-N-ethylacetamide

To a mixture ofN-(bicyclo[1.1.1]pentan-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridazi-2-amine(131 mg, 0.46 mmol, 1.0 equiv) in dioxane (1.1 mL) were added6-bromo-2-(pyridazi-3-ylmethyl)pyridazine-3(2H)-one (122 mg, 0.46 mmol,1.00 equiv), Pd(dppf)Cl₂ (23 mg, 0.03 mmol, 0.05 equiv), K₂CO₃ (95 mg,0.69 mmol, 1.5 equiv) and H₂O (0.1 mL). Into the flask purged andmaintained with an inert atmosphere of nitrogen. The resulting solutionwas stirred for 2 h at 90° C. The solution was diluted with water andextracted with EtOAc (×3). The combined organics were washed with brine,dried over Na₂SO₄ and the solvent removed in vacuo. Purification bychromatography on silica gel (Flash 300 g, 50-100% EtOAc:cyclohexane)afforded crude product. The crude product was purified by RP-HPLC toafford a white solid. ¹H NMR (DMSO-d6, 300 MHz): δ 8.54 (d, J=2.1 Hz,1H), 8.10 (t, J=5.1 Hz, 1H), 8.00 (d, J=9.9 Hz, 1H), 7.88 (dd, J₁=8.7Hz, J₁=2.4 Hz 1H), 7.59 (s, 1H), 7.04 (d, J=9.9 Hz, 1H), 6.59 (d, J=8.7Hz, 1H), 4.67 (s, 2H), 3.16-3.07 (m, 2H), 2.47 (s, 1H), 2.10 (s, 6H),1.04 (t, J=7.2 Hz, 3H); LC/MS R_(t)=0.848 min; MS m/z: 340 [M+H]⁺

The following compounds were synthesized following Example 8:

Cmpd No. Structure Name NMR/MS 71

6-(6-(bicyclo[1.1.1]pentan-1- ylamino)pyridazi-3-yl)-2-(pyridazi-3-ylmethyl)pyridazine-3(2H)-one ¹H NMR (300 MHz, Methanol-d₄) δ 8.68 (s,1H), 8.51-8.49 (m, 2H), 8.02-7.94 (m, 3H), 7.47-7.43 (m, 1H), 7.07 (d, J= 9.9 Hz, 1H), 6.73 (d, J = 9.0 Hz, 1H), 5.46 (s, 2H), 2.50 (s, 1H),2.18 (s, 6H); LC/MS Rt = 0.732 min; MS m/z: 346 [M + H]⁺ 64

6-(2-(bicyclo[1.1.1]pentan-1- ylamino)pyrimidin-5-yl)-2-((5-fluoropyridin-3- yl)methyl)pyridazine-3(2H)-one ¹H NMR (300 MHz, DMSO-d6) δ 8.81 (s, 2H), 8.54-8.52 (m, 2H), 8.30 (s, 1H),8.02 (d, J = 9.9 Hz,1H), 7.77-7.72 (m, 1H), 7.08 (d, J = 9.9 Hz, 1H), 5.36 (s, 2H), 2.46 (s,1H), 2.09 (s, 6H); LC/MS Rt = 1.556 min; MS m/z: 365 [M + H]⁺ 97

2-((5-fluoropyridin-3-yl)methyl)-6- (2-(2-(trifluoromethoxy)ethoxy)pyrimidin-5-yl)pyridazine- 3(2H)-one ¹H NMR (300 MHz, DMSO- d6) δ 9.12(s, 2H), 8.54 (d, J = 2.4 Hz, 2H), 8.13 (d, J = 9.9 Hz, 1H), 7.83-7.73(m, 1H), 7.17 (d, J = 9.9 Hz, 1H), 5.40 (s, 2H), 4.63 (t, J = 3.9 Hz,2H), 4.52-4.43 (m, 2H); LC/MS Rt = 1.677 min; MS m/z: 412 [M+ H]⁺ 351

2-((5-((5 -3-yl)methyl)-6- (2-methylpyrimidin-5-yl) pyridazine-3(2H)-one¹H NMR (400 MHz, DMSO- d6) δ 9.18 (s, 2H), 8.55-8.53 (m, 2H), 8.17 (d, J= 10.0 Hz, 1H), 7.79-7.76 (m, 1H), 7.18 (d, J = 9.8 Hz, 1H), 5.42 (s,2H), 2.68 (s, 3H); LC/MS Rt = 1.082 min; MS m/z: 298 [M + H]⁺ 102

2-((5-((5-fluoropyridin-3-yl)methyl)-6-(2-(2-(methylthio)ethoxy)pyrimidin- 5-yl)pyridazine-3(2H)-one ¹H NMR(400 MHz, DMSO- d6) δ 9.11 (s, 2H), 8.54 (d, J = 3.2 Hz, 2H), 8.12 (d, J= 10.0 Hz, 1H), 7.98-7.76 (m, 1H), 7.17 (d, J = 9.6 Hz, 1H), 5.40 (s,2H), 4.54 (t, J = 6.4 Hz 2H), 2.90 (t, J = 6.8 Hz, 2H), 2.16 (s, 3H);LC/MS Rt = 1.424 min; MS m/z: 374 [M + H]⁺ 103

2((5-fluoropyridin-3-yl)methyl)-6- (2-(oxetan-3-ylmethoxy)pyrimidin-5-yl)pyridazine-3(2H)-one ¹H NMR (300 MHz, DMSO- d6) δ 9.11 (s, 2H),8.54 (d, J = 3.0 Hz, 2H), 8.13 (d, J = 9.9 Hz, 1H), 7.78 (dt, J = 9.4,2.3 Hz, 1H), 7.17 (d, J = 9.9 Hz, 1H), 5.40 (s, 2H), 4.72 (dd, J = 7.8,6.1 Hz, 2H), 4.60 (d, J = 6.9 Hz, 2H), 4.45 (t, J = 6.0 Hz, 2H),3.49-3.39 (m, 1H); LC/MS Rt = 1.021 min; MS m/z: 370.3 [M + H]⁺ 104

2((5-fluoropyridin-3-yl)methyl)-6- (2-(neopentyloxy)pyrimidin-5-yl)pyridazine-3(2H)-one ¹H NMR (400 MHz, DMSO- d6) δ 9.08 (s, 2H),8.57-8.50 (m, 2H), 8.13 (d, J = 9.7 Hz, 1H), 7.79-7.75 (m, 1H), 7.17 (d,J = 9.6 Hz, 1H), 5.41 (s, H), 4.08 (s, 2H), 1.02 (s, 9H); LC/MS Rt =1.721 min; MS m/z: 370 [M + H]⁺ 121

6-(2-(2-fluoro-2- methylpropoxy)pyrimidin-5-yl)-2- ((5-f1uoropyridin-3-yl)methyl)pyridazine-3(2H)-one ¹H NMR (300 MHz, DMSO- d6) δ 9.11 (s,2H), 8.54 (d, J = 3.0 Hz, 2H), 8.13 (d, J = 6.6 Hz, 1H), 7.80-7.76 (m,1H), 7.17 (d, J = 6.6 Hz, 1H), 5.41 (s, 2H), 4.47, 4.40 (d, J = 41.4 Hz,2H), 1.48 (s, 3H), 1.41 (s, 3H); LC/MS Rt = 0.985 min; MS m/z: 374 [M +H]⁺

Example 9:2-((5-fluoropyridin-3-yl)methyl)-6-(2-(2-methoxyethoxy)pyrimidin-5-yl)pyridazine-3(2H)-one(Compound 70)

Step 1:2-((5-fluoropyridin-3-yl)methyl)-6-(2-(2-methoxyethoxy)pyrimidin-5-yl)pyridazin-3(2H)-one

To a stirred mixture of2-((5-fluoropyridin-3-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazine-3(2H)-one(100.00 mg, 0.272 mmol, 1.00 equiv) in 2-methoxy-ethanol (1 mL) wasadded K₂CO₃ (112.89 mg, 0.817 mmol, 3 equiv) in portions, the solutionwas stirred at 70° C. for 2 h. The resulting mixture was concentratedunder reduced pressure. The crude product (120 mg) was purified byPrep-HPLC to afford the title compound as a white solid (35 mg, 35.97%).¹H NMR (DMSO-d₆, 400 MHz) δ 9.10 (s, 2H), 8.54 (d, J=2.4 Hz, 2H), 8.12(d, J=10.0 Hz, 1H), 7.82-7.74 (m, 1H), 7.16 (d, J=9.6 Hz, 1H), 5.40 (s,2H), 4.52-4.45 (m, 2H), 3.73-3.66 (m, 2H), 3.31 (s, 3H). LC/MS: Rt=0.810min, MS m/z: 358 [M+H]⁺.

The following compounds were synthesized following Example 9:

Cmpd No. Structure Name NMR/MS 67

2-((5-f1uoropyridin-3-yl)methyl)-6- (2-propoxypyrimidin-5-yl)pyridazine-3(2H)-one ¹H NMR (400 MHz, DMSO-d6) δ 9.09 (s, 2H),8.55-8.54 (m, 2H), 8.12 (d, J = 10 Hz, 1H),7.79-7.76 (m, 1H), 7.17 (d, J= 9.6 Hz, 1H), 5.40 (s, 2H), 4.33 (t, J = 6.4 Hz, 2H), 1.80-1.75 (m,2H), 0.99 (t, J = 7.2 Hz, 3H); MS m/z: 328 [M + H]⁺ 68

6-(2-ethoxypyrimidin-5-yl)-2- ((5-fluoropyridin-3-yl)methyl)pyridazine-3(2H)-one ¹H NMR (300 MHz, DMSO-d₆) δ 9.09 (s, 2H),8.54 (d, J = 2.4 Hz, 2H), 8.11 (d, J = 9.9 Hz, 1H), 7.80-7.75 (m, , 1H),7.16 (d, J = 9.9 Hz, 1H), 5.40 (s, 2H), 4.42 (q, J = 6.9, 7.2 Hz, 2H),1.36 (t, J = 6.9 Hz, 3H); LC/MS Rt = 0.850 min; MS m/z: 328 [M + H]⁺ 69

2-((5-fluoropyridin-3-yl)methyl)- 6-(2-methoxypyrimidin-5-yl)pyridazine-3(2H)-one ¹HNMR (400 MHz, DMSO-d₆) δ 9.05 (s, 2H), 8.49(d,J = 2.8 Hz, 2H), 8.05 (d, J = 9.6 Hz, 1H), 7.75-7.71 (m, 1H), 7.12 (d, J= 9.6 Hz, 1H), 5.39 (s, 2H), 3.97 (s, 3H); LC/MS Rt = 2.684 min; MS m/z:314 [M + H]⁺ 106

6-(2-(2,2- difluoroethoxy)pyrimidin-5-yl)- 2-((5-fluoropyridin-3-yl)methyl)pyridazine-3(2H)-one ¹H NMR (DMSO-d6,400 MHz) δ 9.15 (s, 2H),8.54 (d, J = 2.4 Hz, 2H), 8.14 (d, J = 9.6 Hz, 1H), 7.83-7.75 (m, 1H),7.18 (d, J = 9.6 Hz, 1H), 6.45 (t, J = 3.2 Hz, 0H), 5.41 (s, 2H), 4.70(td, J = 15.2, 3.6 Hz, 2H); LC/MS Rt = 1.228 min; MS m/z: 364 [M + H]+108

2-((5-fluoropyridin-3-yl)methyl)- 6-(2-((methylthio)methoxy)pyrimidin-5-yl)pyridazine-3(2H)-one ¹H NMR (300 MHz, DMSO-d6) δ 9.14 (s, 2H), 8.54(d, J = 2.7 Hz, 2H), 8.13 (d, J = 9.9 Hz, 1H), 7.79 (d, J = 9.6 Hz, 1H),7.17 (d, J = 9.6 Hz, 1H), 5.58 (s, 2H), 5.40 (s, 2H), 2.27 (s, 3H);LC/MS Rt = 5.971 min; MS m/z: 360 [M + H]+ 110

2-((5-fluoropyridin-3-yl)methyl)- 6-(2-isobutoxypyrimidin-5-yl)pyridazine-3(2H)-one ¹H NMR (300 MHz, DMSO-d6) δ 9.09 (s, 2H),8.55-8.53 (m, 2H), 8.12 (d, J = 9.9 Hz, 1H), 7.80- 7.76 (m, 1H), 7.17(d, J = 9.6 Hz, 1H), 5.40 (s, 2H), 4.16 (d, J = 6.9 Hz, 2H), 2.12-2.03(m, 1H), 0.99 (d, J = 6.6 Hz, 6H); LC/MS Rt = 1.317 min; MS m/z: 356[M + H]+ 113

6-(2-(2,2- difluoropropoxy)pyrimidin-5-yl)- 2-((5-fluoropyridin-3-yl)methyl)pyridazine-3(2H)-one ¹H NMR (DMSO-d6,300 MHz) δ 9.15 (s, 2H),8.54 (d, J = 2.4 Hz, 2H), 8.15 (d, J = 9.9 Hz, 1H), 7.84-7.73 (m, 1H),7.18 (d, J = 9.9 Hz, 1H), 5.41 (s, 2H), 4.69 (t, J = 13.2Hz, 2H),1.83-1.70 (t, J = 19.5 Hz, 3H); LC/MS Rt = 1.271 min; MS m/z: 378 [M+H]+ 115

2-((5-f1uoropyridin-3-yl)methyl)- 6-(2-isopropoxypyrimidin-5-yl)pyridazine-3(2H)-one ¹H NMR (DMSO-d6,300 MHz) δ 9.08 (s, 2H), 8.54(d, J = 3.3 Hz, 2H), 8.11 (d, J = 9.9 Hz, 1H), 7.78 (m, 1H), 7.16 (d, J= 9.6 Hz, 1H), 5.40 (s, 2H), 5.27 (m, 1H), 1.36 (s, 3H), 1.34 (s, 3H);LC/MS Rt = 1.318 min; MS m/z: 342 [M + H]+ 117

2-((5-f1uoropyridin-3-yl)methyl)- 6-(2-(3,3,3-trifluoropropoxy)pyrimidin-5- yl)pyridazine-3(2H)-one 1H NMR (300 MHz,DMSO-d6) δ 9.13 (s, 2H), 8.54 (d, J = 3.0 Hz, 2H), 8.13 (d, J = 9.6 Hz,1H), 7.81-7.76 (m, 1H), 7.17 (d, J = 9.9 Hz, 1H), 5.40 (s, 2H), 4.60 (t,J = 6.0 Hz, 2H), 2.95-2.73 (m, 2H); LC/MS Rt = 1.315 min; MS m/z: 396[M + H]+ 119

6-(2- (cyclopropylmethoxy)pyrimidin- 5-yl)-2-((5-fluoropyridin-3-yl)methyl)pyridazine-3(2H)-one 1H NMR (300 MHz, DMSO-d6) δ 9.09 (s, 2H),8.54 (d, J = 2.7 Hz, 2H), 8.12 (d, J = 9.6 Hz, 1H), 7.80-7.77 (m, 1H),7.17 (d, J = 9.9 Hz, 1H), 5.40 (s, 2H), 4.21 (d, J = 7.5 Hz, 2H),1.34-1.25 (m, 1H), 0.64-0.52 (m, 2H), 0.43- 0.32 (m, 2H); LC/MS Rt =1.280 min; MS m/z: 354 [M + H]+ 120

(S)-6-(2-(sec-butoxy)pyrimidin- 5-yl)-2((5-fluropyridin-3-yl)methyl)pyridazine-3(2H)-one 1H NMR (400 MHz, DMSO-d6) δ 9.07 (s, 2H),8.11 (d, J = 10.0 Hz, 1H), 2H), 8.54 (d, J = 2.8 Hz, 7.77 (d, J = 9.6Hz, 1H), 7.16 (d, J = 9.6 Hz, 1H), 5.39 (s, 2H), 5.15-5.07 (m, 1H),1.77-1.62 (m, 2H), 1.31 (d, J = 6.0 Hz, 3H), 0.92 (t, J = 7.2 Hz, 3H);LC/MS Rt = 1.674 min; MS m/z: 356 [M + H]+

Example 10:2-((5-(methylthio)pyridazi-3-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazine-3(2H)-one(Compound 111)

Step 1: methyl 5-(methylthio)nicotinate

A solution/mixture of methyl 5-bromopyridine-3-carboxylate (216.00 mg,1.000 mmol, 1.00 equiv) and sodium thiomethoxide (70.08 mg, 1.000 mmol,1.00 equiv) in DMF was stirred for overnight at 80 degrees C. undernitrogen atmosphere. The reaction was monitored by LCMS. The mixture wasallowed to cool down to room temperature. The reaction was quenched withWater at 0 degrees C. The resulting mixture was extracted with EtOAc.The combined organic layers were washed with water, dried over anhydrousNa₂SO₄. After filtration, the filtrate was concentrated under reducedpressure. The residue was purified by silica gel column chromatography,eluted with PE/EtOAc to afford methyl 5-(methylthio)nicotinate (150 mg,81.88%) as a solid.

Step 2: (5-(methylthio)pyridazi-3-yl)methanol

Under N₂ atmosphere, to a solution of methyl 5-(methylthio)nicotinate(150 mg, 0.82 mmol) in THF (3 mL) was added LAH (63 mg, 1.64 mmol) inseveral batches at 0° C. The resulting mixture was stirred for 1.5 h at25° C. The reaction was then quenched by the addition of 4 mL of waterand 10 mL of EA was added to mixture. The organic phase was separated,dried over Na₂SO₄, filtered and concentrated to give a residue, whichwas purified by silica gel chromatography to give the title compound asa solid (100 mg, 78.7%).

Step 3: 3-(chloromethyl)-5-(methylthio)pyridine

A solution of (5-(methylthio)pyridazi-3-yl)methanol (100 mg, 0.64 mmol)and SOCl₂ (152 mg, 1.29 mmol, 2.00 equiv) in DCM was stirred forovernight at room temperature under nitrogen atmosphere. The reactionwas monitored by LCMS. Desired product could be detected by LCMS. Themixture was concentrated under vacuum and the crude product was used innext step without further purification.

Step 4:2-((5-(methylthio)pyridazi-3-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazine-3(2H)-one

To a stirred solution of6-[2-[(3-fluorooxetan-3-yl)methoxy]pyrimidin-5-yl]-2,3-dihydro-pyridazin-3-one(174 mg, 0.64 mmol) and 3-(chloromethyl)-5-(methylthio)pyridine (111 mg,0.64 mmol) in DMF (2 mL) were added K₂CO₃ (177 mg, 1.28 mmol, 2 equiv.)in portions. The reaction was stirred at 25° C. for 2 h. The resultingmixture was extracted with EtOAc and water. The combined organic layerswere washed with brine, dried over anhydrous Na₂SO₄. After filtration,the filtrate was concentrated under reduced pressure. The residue waspurified by Prep-HPLC to afford the title compound as a white solid (45mg, 17.2%). ¹HNMR (300 MHz, Methanol-d₄) δ 9.14 (s, 2H), 8.41 (dd,J=12.9, 2.1 Hz, 2H), 8.06 (d, J=9.6 Hz, 1H), 7.87 (t, J=2.1 Hz, 1H),7.16 (d, J=9.9 Hz, 1H), 5.47 (s, 2H), 5.04 (q, J=8.7 Hz, 2H), 2.55 (s,3H). LC/MS Rt=2.406 min; MS m/z: 410 [M+H]⁺.

Example 11:2-((3-methylisoxazol-5-yl)methyl)-6-(2-(methylthio)pyrimidin-5-yl)pyridazine-3(2H)-one(Compound 65)

Step 1: 6-(2-(methylthio)pyrimidin-5-yl)pyridazine-3(2H)-one

A solution/mixture of6-[2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl]-2H-pyridazin-3-one (300.00mg, 1.102 mmol, 1.00 equiv) and (methylsulfanyl)sodium (231.72 mg, 3.307mmol, 3.00 equiv) in DMF (3.00 mL) was stirred for 1 h at 70° C. Thereaction was quenched with sat. NH₄Cl (aq.) at 25° C. The resultingmixture was diluted with EtOAc (50 mL). The resulting mixture was washedwith 5×10 mL of water. The residue was purified by reverse flashchromatography with the following conditions: column, C18 silica gel;mobile phase, MeOH in water, 10% to 50% gradient in 10 min; detector, UV254 nm. The residue was purified by silica gel column chromatography,eluted with PE/EtOAc (1:1) to afford6-[2-(methylsulfanyl)pyrimidin-5-yl]-2H-pyridazin-3-one (280 mg,115.34%) as a white solid. MS m/z: 221 [M+H]⁺

Step 2:2-((3-methylisoxazol-5-yl)methyl)-6-(2-(methylthio)pyrimidin-5-yl)pyridazine-3(2H)-one

A mixture of 6-[2-(methylsulfanyl)pyrimidin-5-yl]-2H-pyridazin-3-one(200.00 mg, 0.908 mmol, 1.00 equiv),5-(bromomethyl)-3-methyl-1,2-oxazole (191.80 mg, 1.090 mmol, 1.20 equiv)and K₂CO₃ (376.50 mg, 2.724 mmol, 3.00 equiv) in DMF (2.00 mL) wasstirred for 2 h at 25° C. The resulting mixture was diluted with EtOAc(50 mL) and washed with 2×10 mL of water. The residue was purified byreverse flash chromatography with the following conditions: column, C18silica gel; mobile phase, MeOH in water, 10% to 50% gradient in 10 min;detector, UV 254 nm. To afford2-[(3-methyl-1,2-oxazol-5-yl)methyl]-6-[2-(methylsulfanyl)pyrimidin-5-yl]pyridazine-3-one(52.3 mg, 17.70%) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.09 (s,2H), 8.15 (d, J=9.6 Hz, 1H), 7.21-7.19 (m, 1H), 6.39 (s, 1H), 5.46 (s,2H), 2.58 (s, 3H), 2.21 (s, 3H). LC/MS Rt=1.219 min; MS m/z: 316 [M+H]⁺.

The following compounds were synthesized following Example 11:

Cmpd No. Structure Name NMR/MS 66

6-(2-((3-fluorooxetan-3- yl)methoxy)pyrimidin-5-yl)-2((5-fluoropyridin-3- yl)methyl)pyridazine- 3(2H)-one ¹H NMR(DMSO-d₆, 400 MHz,) δ 9.13 (s, 2H), 8.54 (d, J = 2.8 Hz, 2H), 8.14 (d, J= 9.6 Hz, 1H), 7.78 (dd, J = 9.6, 2.8Hz, 1H), 7.17 (d, J = 9.6 Hz, 1H),5.41 (s, 2H), 4.87 (s, 1H), 4.81 (s, 1H), 4.77 (s, 2H).,4.72 (s, 2H);LC/MS R = 0.929 min, MS m/z: 388 [M + H]⁺ 101

2-((5-methylpyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazine-3(2H)-one ¹H NMR (DMSO-d₆,300 MHz) δ 9.17 (s, 2H), 8.46 (d, J = 3.0 Hz, 1H), 8.35 (d, J = 3.0 Hz,1H), 8.14 (d, J = 9.6 Hz, 1H), 7.63 (t, J = 2.4 Hz, 1H), 7.17 (d, J =9.6 Hz, 1H), 5.33 (s, 2H), 5.12 (m, 2H), 2.28 (s, 3H); LC/MS Rt = 0.734min; MS m/z: 378 [M + H]⁺

Example 12:2-((2-ethylthiazol-5-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazine-3(2H)-one(Compound 99) and2-((2-ethylthiazol-5-yl)methyl)-6-(2-propoxypyrimidin-5-yl)pyridazine-3(2H)-one(Compound 112)

Step 1: ethyl 2-ethylthiazole-5-carboxylate

Into a 100-mL round-bottom flask, were placed ethyl2-chloro-3-oxopropanoate (2.00 g, 13.284 mmol, 1.00 equiv), EtOH (20.00mL), propanethioamide (1184.38 mg, 13.284 mmol, 1.00 equiv) and MgSO₄(7994.69 mg, 66.419 mmol, 5.00 equiv). The resulting solution wasstirred for 16 hr at 80° C. The mixture was cooled to 25° C. andfiltered over celite, the filtrate was concentrated under vacuum, theresidue was applied onto a silica gel column with ethylacetate/petroleum ether (1:1) to afford 1 g (40.64%) of ethyl2-ethyl-1,3-thiazole-5-carboxylate as a light yellow oil. MS m/z: 186[M+H]⁺

Step 2: (2-ethylthiazol-5-yl)methanol

To a solution of ethyl 2-ethyl-1,3-thiazole-5-carboxylate (20.00 g,107.968 mmol, 1.00 equiv) in THF (300.00 mL) at 0° C. was added LiAlH₄(4.10 g, 107.968 mmol, 1.00 equiv) partwise, the mixture was stirred at0° C. for 1 h, 4 g of Na₂SO₄10H₂O was added partwise and then 2 g ofNa₂SO₄ was added, the mixture was stirred for 30 mins and filteredthrough celite, the filtrate was concentrated under vacuum to get crudeproduct 15 g (97.02%) as light yellow oil. MS m/z: 144 [M+H]⁺

Step 3: 5-(chloromethyl)-2-ethylthiazole

To a solution of (2-ethyl-1,3-thiazol-5-yl)methanol (10.00 g, 69.832mmol, 1.00 equiv) in DCM (100.00 mL) was added dropwise SOCl₂ (10.13 mL,85.161 mmol, 2.00 equiv) at 0° C., the mixture was stirred for 1 h. Themixture was concentrated under vacuum and the residue was dissolved in100 mL water and adjust PH=8 with saturated Na₂CO₃ solution, thenextracted with 3×100 mL of EA, the organic layer was dried over Na₂SO₄and concentrated under vacuum to get crude product which was purified bysilica gel column to get light yellow oil 6 g (53.15%). MS m/z: 162[M+H]⁺

Step 4:2-((2-ethylthiazol-5-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazine-3(2H)-one

Into a 250-mL round-bottom flask, was placed6-[2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl]-2H-pyridazin-3-one (10.00 g,36.739 mmol, 1.00 equiv), DMF (100.00 mL),5-(chloromethyl)-2-ethyl-1,3-thiazole (7126.72 mg, 44.087 mmol, 1.20equiv), K₂CO₃ (15232.78 mg, 110.218 mmol, 3.00 equiv). The resultingsolution was stirred for 1 hr at 50° C. The residue was applied onto asilica gel column with ethyl acetate/petroleum ether (1:1). Thecollected fractions were combined and concentrated under vacuum to getproduct which was purified by Combiflash (Reversed phase: 0.05%ammonia/I) to afford 5.1 g (34.93%) of2-[(2-ethyl-1,3-thiazol-5-yl)methyl]-6-[2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl]pyridazine-3-oneas a white solid. ¹H NMR (400 MHz, DMSO-d₆): δ 9.16 (s, 2H), 8.12 (d,J=9.6 Hz, 1H), 7.75 (s, 1H), 7.17 (d, J=9.6 Hz, 1H), 5.48 (s, 2H), 5.12(q, J=8.8 Hz, 2H), 2.92 (q, J=7.6 Hz, 2H), 1.24 (t, J=7.6 Hz, 3H). LC/MSRt=1.873 min; MS m/z: 398 [M+H]⁺.

Step 5:2-((2-ethylthiazol-5-yl)methyl)-6-(2-propoxypyrimidin-5-yl)pyridazine-3(2H)-one

To a stirred solution of2-[(2-ethyl-1,3-thiazol-5-yl)methyl]-6-[2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl]pyridazine-3-one(100.00 mg, 0.252 mmol, 1.00 equiv) in DMF was added K₂CO₃ (104.34 mg,0.755 mmol, 3.00 equiv) in portions at 25° C. under nitrogen atmosphere.To the above mixture was added propanol (302.46 mg, 5.033 mmol, 20.00equiv) in portions at 25° C. The resulting mixture was stirred foradditional 4 h at 25° C. The resulting mixture was concentrated undervacuum. The residue was purified by silica gel column chromatography,eluted with hexane/EtOAc (1:1) to afford2-[(2-ethyl-1,3-thiazol-5-yl)methyl]-6-(2-propoxypyrimidin-5-yl)pyridazine-3-one(13.2 mg, 14.46%) as a light yellow solid. ¹H NMR (DMSO-d₆, 300 MHz) δ9.08 (s, 2H), 8.10 (d, J=9.6 Hz, 1H), 7.75 (s, 1H), 7.16 (d, J=9.6 Hz,1H), 5.48 (s, 2H), 4.33 (t, J=6.9 Hz, 2H), 2.93 (q, J=7.5 Hz, 2H),1.812-1.742 (m, 2H), 1.25 (t, J=7.5 Hz, 3H), 0.99 (t, J=7.5 Hz, 3H).LC/MS Rt=1.349 min; MS m/z: 358 [M+H]⁺.

The following compounds were synthesized following Example 12:

Cmpd No. Structure Name NMR 105

2-((2- (difluoromethypthiazol-5- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5- yl)pyridazine-3(2H)-one ¹H NMR (DMSO-d₆,400 MHz) δ 9.18 (s, 2H), 8.16 (d, J = 9.6 Hz, 2H), 7.21 (d, J = 10.0 Hz,1H), 7.44, 7.30, 7.17 (t, J = 54 Hz, 1H), 5.62 (s, 2H), 5.13 (q, J = 8.8Hz, 2H); LC/MS Rt = 1.653 min; MS m/z: 420 [M + H]⁺] 100

2-((2-cyclopropylthiazol-5- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5- yl)pyridazine-3(2H)-one ¹H NMR (DMSO-d₆,300 MHz) δ 9.17 (s, 2H), 8.13 (d, J = 9.9 Hz, 1H), 7.68 (s, 1H), 7.18(d, J = 9.9 Hz, 1H), 5.45 (s, 2H), 5.13 (q, J = 9.0 Hz, 2H), 2.39-2.30(m, 1H), 1.10-1.01 (m, 2H), 0.94-0.89 (m, 2H); LC/MS Rt = 1.370 min; MSm/z: 410 [M + H]⁺ 116

2-((2-propylthiazol-5- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5- yl)pyridazine-3(2H)-one ¹H NMR (DMSO-d₆,300 MHz) δ 9.17 (s, 2H), 8.13 (d, J = 9.6 Hz, 1H), 7.76 (s, 1H), 7.18(d, J = 9.9 Hz, 1H), 5.49 (s, 2H), 5.13 (q, J = 9.0 Hz, 2H), 2.88 (t, J= 7.5 Hz, 2H), 1.76-1.63 (m, 2H), 0.92 (t, J = 7.2 Hz, 3H); LC/MS Rt =1.432 min; MS m/z: 412 [M + H]⁺ 114

2-((2-isopropylthiazol-5- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5- yl)pyridazine-3(2H)-one ¹H NMR (DMSO-d₆,300 MHz) δ 9.17 (s, 2H), 8.13 (d, J = 9.9 Hz 1H), 7.77 (s, 1H), 7.18 (d,J = 9.6 Hz, 1H), 5.49 (s, 2H), 5.13 (q, J = 9.0 Hz, 2H), 3.29-3.15 (m,1H), 1.28 (d, J = 6.9 Hz, 6H); LC/MS Rt = 2.462 min; MS m/z 412 [M + H]⁺109

2-((2- ((methylthio)methyl)thiazol- 5-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5- yl)pyridazine-3(2H)-one ¹H NMR (DMSO-d₆,300 MHz) δ 9.17 (s, 2H), 8.14 (d, J = 9.6 Hz, 1H), 7.79 (s, 1H), 7.19(d, J = 9.6 Hz, 1H), 5.51 (s, 2H), 5.13 (q, J = 9.0 Hz, 2H), 4.00 (s,2H), 2.08 (s, 3H); Rt = 1.458 min; MS m/z: 430 [M + H]⁺

Example 13:2-((5-fluoropyridin-3-yl)methyl)-6-(6-(2-methylpropoxy-2-D)pyridazi-3-yl)pyridazine-3(2H)-one(EDG-006364)

Step 1: 5-bromo-2-(2-methylpropoxy-2-d)pyrimidine

Into a 8-mL vial, was placed 5-bromo-2-fluoropyrimidine (100.00 mg,0.565 mmol, 1.00 equiv), THF (2.00 mL), NaH (20.34 mg, 0.848 mmol, 1.5equiv), 2-methyl(2-2D)propan-1-ol (42.45 mg, 0.565 mmol, 1.00 equiv).The resulting solution was stirred for 1 hr at 0° C. The resultingmixture was concentrated. The residue was applied onto a silica gelcolumn with ethyl acetate/petroleum ether (1:4). This resulted in 110 mg(83.88%) of 5-bromo-2-[2-methyl(2-2H)propoxy]pyrimidine as a solid. MSm/z: 232 [M+H]⁺

Step 2:2-(2-methylpropoxy-2-d)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

Into a 25-mL round-bottom flask, was placed5-bromo-2-[2-methyl(2-2H)propoxy]pyrimidine (110.00 mg, 0.474 mmol, 1.00equiv), bis(pinacolato)diboron (180.53 mg, 0.711 mmol, 1.50 equiv),Dioxane (5.00 mL), KOAc (93.03 mg, 0.948 mmol, 2 equiv), Pd(dppf)Cl₂(34.68 mg, 0.047 mmol, 0.1 equiv). The resulting solution was stirredfor 2 hr at 80° C. and confirmed by LCMS. The reaction was used in nextstep directly without workup.

Step 3:2-((5-fluoropyridin-3-yl)methyl)-6-(6-(2-methylpropoxy-2-d)pyridazi-3-yl)pyridazine-3(2H)-one

Into a 8-mL vial, was placed2-[2-methyl(2-2H)propoxy]pyrimidin-5-ylboronic acid (110.00 mg, 0.558mmol, 1.00 equiv),6-chloro-2-[(5-fluoropyridin-3-yl)methyl]pyridazine-3-one (133.79 mg,0.558 mmol, 1.00 equiv), K₂CO₃ (154.33 mg, 1.117 mmol, 2 equiv), Dioxane(3.00 mL), H₂O (0.50 mg), Pd(dppf)Cl₂ (40.85 mg, 0.056 mmol, 0.1 equiv).The resulting solution was stirred for 2 hr at 90° C. The resultingmixture was concentrated. The residue was applied onto a silica gelcolumn with dichloromethane/methanol (20:1). This resulted in 100 mg(50.26%) of2-[(5-fluoropyridin-3-yl)methyl]-6-[2-[2-methyl(2-2H)propoxy]pyrimidin-5-yl]pyridazine-3-oneas a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.09 (s, 2H), 8.55-8.53(m, 2H), 8.12 (d, J=10.0 Hz, 1H), 7.77 (d, J=9.6 Hz, 1H), 7.16 (d,J=10.0 Hz, 1H), 5.40 (s, 2H), 4.15 (s, 2H), 0.98 (s, 6H). LC/MS Rt=1.676min; MS m/z: 357 [M+H]⁺

Example 14:2-((5-fluoropyridin-3-yl)methyl)-6-(2-propoxypyrimidin-5-yl)pyridazine-3(2H)-one(Compound 125)

Step 1:N-cyclobutyl-2-[3-[2-(2-methylpropoxy)pyrimidin-5-yl]-6-oxopyridazin-1-yl]acet-amide

To a stirred mixture of2-((5-fluoropyridin-3-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazine-3(2H)-one(1.98 g, 5.217 mmol, 1.00 equiv) in 2-methoxy-2-methylpropan-1-ol (20mL) was added K₂CO₃ (1.422 g, 10.435 mmol, 2.00 equiv) in portions, thesolution was stirred at 80° C. for 4 h. The resulting mixture wasconcentrated under reduced pressure. The crude product was purified byPrep-HPLC to afford the title compound as a white solid.

The following compound was synthesized following Example 14:

Compound No. Structure Name NMR 125

2-((5-fluoropyridin-3- yl)methyl)-6-(2-(2-methoxy-2-methylpropoxy)pyrimidin-5- yl)pyridazine-3(2H)-one 1H NMR (400 MHz,DMSO-d6) δ 9.09 (s, 2H), 8.55-8.53 (m, 2H), 8.14 (d, J = 10.0 Hz, 1H),7.78- 7.76 (m, 1H), 7.17 (d, J = 9.6 Hz, 1H), 5.40 (s, 2H), 4.28 (s,2H), 3.16 (s, 3H), 1.22 (s, 6H); LC/MS Rt = 1.151 min; MS m/z: 386 [M +H]⁺ 123

2((5-fluoropyridin-3- yl)methyl)-6-(2-(2- (methylthio)propoxy)pyrimidin-5-yl)pyridazine-3(2H)-one 1H NMR (300 MHz, DMSO-d6) δ 9.08 (s, 2H), 8.56(s, 1H), 8.45 (d, J = 2.7 Hz, 1H), 8.05 (d, J = 9.9 Hz, 1H), 7.80-7.75(m, 1H), 7.15 (d, J = 9.6 Hz, 1H), 5.52 (s 2H), 4.65 (dd, J1 = 10.8 Hz,J2 = 5.4 Hz, 1H), 4.37 (dd, J1 = 10.8 Hz, J2 = 7.8 Hz, 1H), 3.13 (m,2H), 2.2 (s, 3H), 1.38 (d, J = 6.9 Hz, 3H); LC/MS Rt = 1.137 min; MSm/z: 388 [M + H]⁺ 126

6-(2-(cyclobutylmethoxy) pyrimidin- 5-yl)-2-((5-fluoropyridin-3-yl)methyl)pyridazine- 3(2H)-one 1H NMR (300 MHz, DMSO-d6) δ 9.08 (s,2H), 8.54-8.53 (m, 2H), 8.15 (d, J = 9.9 Hz, 1H), 7.80-7.76 (m, 1H),7.16 (d, J = 9.6 Hz, 1H), 5.40 (s, 2H), 4.35 (d, J = 6.9 Hz, 2H),2.81-2.75 (m, 1H), 2.09-2.04 (m, 2H), 2.03-1.85 (m, 2H); LC/MS Rt =1.484 min; MS m/z: 368 [M + H]⁺ 127

I-6-(2-(sec-butoxy) pyrimidin-5- yl)-2-45-fluoropyridin-3-yl)methyl)pyridazine- 3(2H)-one 1H NMR (300 MHz, DMSO-d6) δ 9.07 (s,2H), 8.54 (t, J = 3.0 Hz, 2H), 8.11 (d, J = 9.9 Hz, 1H), 7.79-7.76 (m,1H), 7.16 (d, J = 9.9 Hz, 1H), 5.40 (s, 2H), 5.10-5.06 (m,1H), 1.78-1.58(m, 2H), 1.31 (d, J = 6.3 Hz, 3H), 0.93 (t, J = 7.5 Hz, 3H); LC/MS Rt =2.219 min; MS m/z: 356 [M + H]⁺ 138

6-(2-(benzyloxy)pyrimidin- 5- yl)-2-45-fluoropyridin-3-yl)methyl)pyridazine- 3(2H)-one 1H NMR (300 MHz, DMSO-d6) δ 9.13 (s,2H), 8.55-8.53 (m, 2H), 8.13 (d, J = 9.8 Hz, 1H), 7.86-7.71 (m, 1H),7.52-7.45 (m, 2H), 7.44- 7.31 (m, 3H), 7.17 (d, J = 9.8 Hz, 1H), 5.47(s, 2H), 5.40 (s, 2H); LC/MS Rt = 1.944 min; MS m/z: 390 [M + H]⁺

Example 15:2-((5-methoxypyridin-3-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazine-3(2H)-one(Compound 128)

Step 1:2-((5-methoxypyridin-3-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazine-3(2H)-one

A mixture of6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazine-3(2H)-one (2.00 g,7.348 mmol, 1.00 equiv), 3-(chloromethyl)-5-methoxypyridine (1.43 g,7.348 mmol, 1.00 equiv), potassium carbonate (2.54 g, 18.370 mmol, 2.5equiv) in dimethylformamide (20.00 mL) was added into a 40-mL flask andstirred for 48 h at 60° C. The mixture was purified by Pre-HPLC (0.05%NH₃H₂O—H₂O/I, 5% to 55% gradient, 30 min) to give2-((5-methoxy-pyridin-3-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazine-3(2H)-one(1.3 g, 45.02%) as an off-white solid. ¹H NMR (300 MHz, DMSO-d₆) δ 9.17(s, 2H), 8.25-8.23 (m, 2H), 8.15 (d, J=9.6 Hz, 1H), 7.42-7.41 (m, 1H),7.18 (d, J=9.6 Hz, 1H), 5.36 (s, 2H), 5.12 (q, J=9.0 Hz, 2H), 3.82 (s,3H). LC/MS Rt=1.301 min; MS m/z: 394 [M+H]⁺.

The following compounds were synthesized following Example 15:

Cmpd No. Structure Name NMR/MS 132

2-((6-methoxypyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazine-3(2H)-one 1H NMR (300 MHz,DMSO- d6) δ 9.17 (d, J = 6.0 Hz, 2H), 8.28 (d, J = 1.8 Hz, 1H), 8.12 (d,J = 9.6 Hz, 1H), 7.82-7.78 (m, 1H), 7.15 (d, J = 9.9 Hz, 1H), 6.81 (d, J= 8.7 Hz, 1H), 5.27 (s, 2H), 5.12 (q, J = 9.0 Hz, 2H), 3.82 (s, 3H);LC/MS Rt = 1.460 min; MS m/z: 394 [M + H]+ 133

2-((5-fluoro-6- methoxypyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazine-3(2H)-one 1H NMR (400 MHz,DMSO- d6) δ 9.18 (s, 2H), 8.16-8.08 (m, 2H), 7.78 (dd, J = 11.2, 2.0 Hz,1H), 7.16 (d, J = 9.6 Hz, 1H), 5.30 (s, 2H), 5.12 (q, J = 8.8 Hz, 2H),3.93 (s, 3H); LC/MS Rt = 1.298 min; MS m/z: 412 [M + H]+ 134

2-((6-methoxy-5- methylpyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazine-3(2H)-one 1H NMR (400 MHz,DMSO- d6) δ 9.17 (s, 2H), 8.11 (d, J = 9.6 Hz, 2H), 7.64-7.59 (m, 1H),7.14 (d, J = 9.6 Hz, 1H), 5.24 (s, 2H), 5.12 (q, J = 8.8 Hz, 2H), 3.85(s, 3H), 2.12 (s, 3H); LC/MS Rt = 1.961 min; MS m/z: 408 [M + H]+ 135

2-((5-isopropylpyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5- yl)pyridazine-3(2H)-one 1H NMR (300 MHz,DMSO- d6) δ 9.17 (s, 2H), 8.47-8.45 (m, 2H), 8.14 (d, J = 9.7 Hz, 1H),7.76 (d, J = 2.2 Hz, 1H), 7.18 (d, J = 9.7 Hz, 1H), 5.36 (s, 2H), 5.12(q, J = 8.9 Hz, 2H), 3.00- 2.91 (m, 1H), 1.21 (d, J = 6.9 Hz, 6H); LC/MSRt = 2.011 min; MS m/z: 406 [M + H]+ 136

2-((5-fluoro-2- methylpyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazine-3(2H)-one 1H NMR (400 MHz,DMSO- d6) δ 9.12 (s, 2H), 8.39 (d, J = 2.8 Hz, 1H), 8.17 (d, J = 9.6 Hz,1H), 7.51 (dd, J = 9.6, 2.9 Hz, 1H), 7.20 (d, J = 9.6 Hz, 1H), 5.38 (s,2H), 5.12 (q, J = 8.8 Hz, 2H), 2.57 (s, 3H); LC/MS Rt = 1.524 min; MSm/z: 396 [M + H]+ 137

2-((5-ethylpyridin-3- yl)methyl)-6-(2-(2,2,2- trifluoroethoxy)pyrimidin-5-yl)pyridazine-3(2H)-one 1H NMR (300 MHz, DMSO- d6) δ 9.17-9.16 (m,2H), 8.47 (d, J = 2.1 Hz, 1H), 8.39 (d, J = 2.1 Hz, 1H), 8.14 (d, J =9.9 Hz, 1H), 7.69 (t, J = 2.1 Hz, 1H), 7.17 (d, J = 9.9 Hz, 1H), 5.35(s, 2H), 5.16-5.08 (m, 2H), 2.61 (q, J = 7.5 Hz, 2H), 1.17 (td, J = 7.2Hz, 3H); LC/MS Rt = 0.704 min; MS m/z: 392 [M + H]+ 139

2-((6-ethyl-5- fluoropyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazine-3(2H)-one 1H NMR (300 MHz,DMSO- d6) 69.18 (s, 2H), 8.44 (s, 1H), 8.14 (d, J = 9.6 Hz, 1H), 7.74-7.64 (m, 1H), 7.17 (d, J = 9.9 Hz, 1H), 5.36 (s, 2H), 5.12 (q, J = 9.0Hz, 2H), 2.82-2.74 (m, 2H), 1.20 (t, J = 7.5 Hz, 3H); LC/MS Rt = 1.626min; MS m/z: 410 [M + H]+ 140

2-((1-methyl-1H-1,2,3- triazol-4-yl)methyl)-6-(2- (2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazine-3(2H)-one 1H NMR (300 MHz,DMSO- d6) δ 9.15 (s, 2H), 8.13-8.10 (m, 2H), 7.16 (d, J = 9.6Hz, 1H),5.39 (s, 2H), 5.16-5.07 (m, 2H), 4.01 (s, 3H); LC/MS Rt = 0.904 min; MSm/z: 368 [M + H]+

Example 16:2-((2-ethylthiazol-5-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazine-3(2H)-one(Compound 99) and2-((2-ethylthiazol-5-yl)methyl)-6-(2-isobutoxypyrimidin-5-yl)pyridazine-3(2H)-one(Compound 124)

Step 1: ethyl 2-ethylthiazole-5-carboxylate

Into a 100-mL round-bottom flask, were placed ethyl2-chloro-3-oxopropanoate (80.00 g, 0.531 mol, 1.00 equiv), EtOH (600.00mL), propanethioamide (49.74 mg, 0.558 mol, 1.05 equiv), MgSO₄ (128.00g, 1.062 mol, 2.00 equiv). The resulting solution was stirred for 16 hrat 80° C. The mixture was cooled to 25° C. and filtered over celite, thefiltrate was concentrated under vacuum, the residue was applied onto asilica gel column with ethyl acetate/petroleum ether (1:1) to afford60.00 g (60.96%) of ethyl 2-ethyl-1,3-thiazole-5-carboxylate as a lightyellow oil. MS m/z: 186 [M+H]³⁰

Step 2: (2-ethylthiazol-5-yl)methanol

To a solution of ethyl 2-ethyl-1,3-thiazole-5-carboxylate (20.00 g,107.968 mmol, 1.00 equiv) in THF (300.00 mL) at 0° C. was added LiAlH₄(4.10 g, 107.968 mmol, 1.00 equiv) partwise, the mixture was stirred at0° C. for 1 h, 4 g of Na₂SO₄10H₂O was added partwise and then 2 g ofNa₂SO₄ was added, the mixture was stirred for 30 mins and filteredthrough celite, the filtrate was concentrated under vacuum to get crudeproduct 15 g (97.02%) as light yellow oil. MS m/z: 144 [M+H]⁺

Step 3: 5-(chloromethyl)-2-ethylthiazole

To a solution of (2-ethyl-1,3-thiazol-5-yl)methanol (10.00 g, 69.832mmol, 1.00 equiv) in DCM (100.00 mL) was added dropwise SOCl₂ (10.13 mL,85.161 mmol, 2.00 equiv) at 0° C., the mixture was stirred for 1 h. Themixture was concentrated under vacuum and the residue was dissolved in100 mL water and adjust PH=8 with saturated Na₂CO₃ solution, thenextracted with 3×100 mL of EA, the organic layer was dried over Na₂SO₄and concentrated under vacuum to get crude product which was purified bysilica gel column to get light yellow oil 6 g (53.15%). MS m/z: 162[M+H]⁺

Step 4:2-((2-ethylthiazol-5-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazine-3(2H)-one

Into a 250-mL round-bottom flask, was placed6-[2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl]-2H-pyridazin-3-one (10.00 g,36.739 mmol, 1.00 equiv), DMF (100.00 mL),5-(chloromethyl)-2-ethyl-1,3-thiazole (7126.72 mg, 44.087 mmol, 1.20equiv), K₂CO₃ (15232.78 mg, 110.218 mmol, 3.00 equiv). The resultingsolution was stirred for 1 hr at 50° C. The residue was applied onto asilica gel column with ethyl acetate/petroleum ether (1:1). Thecollected fractions were combined and concentrated under vacuum to getproduct which was purified by Combiflash (Reversed phase: 0.05%ammonia/I) to afford 5.1 g (34.93%) of2-[(2-ethyl-1,3-thiazol-5-yl)methyl]-6-[2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl]pyridazine-3-oneas a white solid. ¹H NMR (400 MHz, DMSO-d₆): δ 9.16 (s, 2H), 8.12 (d,J=9.6 Hz, 1H), 7.75 (s, 1H), 7.17 (d, J=9.6 Hz, 1H), 5.48 (s, 2H), 5.12(q, J=8.8 Hz, 2H), 2.92 (q, J=7.6 Hz, 2H), 1.24 (t, J=7.6 Hz, 3H). LC/MSRt=1.873 min; MS m/z: 398 [M+H]⁺.

Step 5:2-((2-ethylthiazol-5-yl)methyl)-6-(2-isobutoxypyrimidin-5-yl)pyridazine-3(2H)-one

To a stirred solution of2-[(2-ethyl-1,3-thiazol-5-yl)methyl]-6-[2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl]pyridazine-3-one(1.00 g, 2.516 mmol, 1.00 equiv) in 2-methylpropan-1-ol (10 mL) wasadded K₂CO₃ (0.70 mg, 5.033 mmol, 2.00 equiv) in portions at 25° C.under nitrogen atmosphere. The resulting mixture was slowly warmed to70° C. and stirred for additional 6 h. The resulting mixture wasconcentrated under vacuum. The residue was purified by reverse flashchromatography with the following conditions: column, C18 silica gel;mobile phase, MeOH in water, 10% to 90% gradient in 40 min; detector, UV254 nm. To afford2-((2-ethyl-thiazol-5-yl)methyl)-6-(2-isobutoxypyrimidin-5-yl)pyridazine-3(2H)-one(800 mg, 85.58%) as a grey solid. ¹H NMR (300 MHz, DMSO-d₆) δ 9.08 (s,2H), 8.10 (d, J=9.9 Hz, 1H), 7.75 (s, 1H), 7.16 (d, J=9.9 Hz, 1H), 5.48(s, 2H), 4.16 (d, J=6.6 Hz, 2H), 2.93 (q, J=7.5 Hz, 2H), 2.13-2.02 (m,1H), 1.25 (t, J=7.5 Hz, 3H), 0.99 (d, J=6.7 Hz, 6H). LC/MS Rt=1.462 min;MS m/z: 372 [M+H]⁺.

The following compounds were synthesized following Example 16:

Cmpd No. Structure Name NMR/MS 122

2-((2-cyclobutylthiazol-5- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5- yl)pyridazine-3(2H)-one ¹H NMR (300 MHz,DMSO-d₆) δ 9.17 (s, 2H), 8.13 (d, J = 9.9 Hz, 1H), 7.78 (s, 1H), 7.18(d, J = 9.6 Hz, 1H), 5.49 (s, 2H), 5.13 (q, J = 9.0 Hz, 2H), 3.86-3.74(m, 1H), 2.40-1.80 (m, 6H); LC/MS Rt = 1.581 min; MS m/z: 424 [M + H]⁺129

6-(2-(2,2- difluoropropoxy)pyrimidin-5- yl)-2((2-ethylthiazol-5-yl)methyl)pyridazine-3(2H)-one ¹H NMR (300 MHz, DMSO-d₆) δ 9.14 (s, 2H),8.12 (d, J = 9.9 Hz, 1H), 7.76 (s, 1H), 7.17 (d, J = 9.9 Hz, 1H), 5.49(s, 2H), 4.70 (t, J = 13.2 Hz, 2H), 2.93 (q, J = 7.5 Hz, 2H), 1.77 (t, J= 19.5 Hz, 3H), 1.25 (t, J = 7.5 Hz, 3H); LC/MS Rt = 1.803 min; MS m/z:394 [M + H]+ 130

6-(2-isobutoxypyrimidin-5- yl)-2-((2-methylthiazol-5-yl)methyl)pyridazine-3(2H)-one ¹H NMR (300 MHz, DMSO-d₆) δ 9.08 (s, 2H),8.10 (d, J = 9.9 Hz, 1H), 7.72 (s, 1H), 7.16 (d, J = 9.9 Hz, 1H), 5.47(s, 2H), 4.16 (d, J = 6.6 Hz, 2H), 2.60 (s, 3H), 2.27- 2.04 (m, 1H),1.00 (d, J = 6.6 Hz, 6H); LC/MS Rt = 1.817 min; MS m/z: 358 [M + H]+

Example 17: 5:6-(2,4-dihydroxypyrimidin-5-yl)-2-((5-fluoropyridin-3-yl)methyl)pyridazine-3(2H)-one(Compound 353)

Step 1:6-(2,4-dimethoxypyrimidin-5-yl)-2-((5-fluoropyridin-3-yl)methyl)pyridazine-3(2H)-one

To a mixture of (2,4-dimethoxypyrimidin-5-yl)boronic acid (552 mg, 3mmol, 1.0 equiv) in dioxane (5 mL) were added6-chloro-2-((5-fluoropyridin-3-yl)methyl)pyridazine-3(2H)-one (717 mg, 3mmol, 1.00 equiv), Pd(dppf)Cl₂ (110 mg, 0.15 mmol, 0.05 equiv), K₂CO₃(621 mg, 4.5 mmol, 1.5 equiv) and H₂O (0.5 mL). Into the flask purgedand maintained with an inert atmosphere of nitrogen. The resultingsolution was stirred for 2 h at 90° C. The solution was diluted withwater and extracted with EtOAc (×3). The combined organics were washedwith brine, dried over Na₂SO₄ and the solvent removed in vacuo.Purification by chromatography on silica gel to afforded6-(2,4-dimethoxypyrimidin-5-yl)-2-((5-fluoro-pyridin-3-yl)methyl)pyridazine-3(2H)-oneas a solid (610 mg, 59.3%).

Step 2:6-(2,4-dihydroxypyrimidin-5-yl)-2-((5-fluoropyridin-3-yl)methyl)pyridazine-3(2H)-one

To a mixture of6-(2,4-dimethoxypyrimidin-5-yl)-2-((5-fluoro-pyridin-3-yl)methyl)pyridazine-3(2H)-one(172 mg, 0.5 mmol, 1.0 equiv) in MeOH (6 mL) were added 4M HCl (8 mL).The resulting solution was stirred for 2 h at 90° C. The mixture wasconcentrated under reduced pressure. The crude product was purified byRP-HPLC to afford a white solid (28 mg, 17.8%). ¹H NMR (300 MHz,DMSO-d6) δ 11.46 (s, 2H), 8.91-8.23 (m, 2H), 8.05-7.80 (m, 2H),7.74-7.69 (m, 1H), 7.00 (d, J=9.8 Hz, 1H), 5.34 (s, 2H). LC/MS Rt=0.721min; MS m/z: 316 [M+H]⁺.

Example 18. Skeletal Myofibril ATPase Assay

Overview: Myosin ATPase activity is assessed by using a coupled reactionsystem, in which ADP generated by the myosin ATPase function is coupledto the disappearance of NADH through the pyruvate kinase/lactatedehydrogenase (PK-LDH) system. Myosin ATPase activity produces ADP,which is used as a substrate for PK to produce pyruvate and regenerateATP. The pyruvate is then used as a substrate by LDH to oxidize NADH toNAD+. The rate of the reaction is monitored through the time-dependentdisappearance of NADH using absorbance at 340 nm. Inhibition of ATPaseactivity by the assayed compounds is indicated by a reduced rate of NADHloss, relative to vehicle-treated controls, over the experimental timewindow. To assess the selectivity of the assayed compounds for skeletalmyofibrils, the compounds are counter-screened in cardiac myofibrils.

Materials: The following stock solutions and reagents were used in theSkeletal Myofibril ATPase Assay:

Stock Solutions PIPES, 200 mM in H₂O, pH 7.0 MgCl₂ in H₂O, 200 mM PM12Buffer, 10X: 12 mM PIPES (from 200 mM stock), 20 mM MgCl₂ (from 200 mMstock) EGTA in H₂O, 500 mM CaCl2 in H₂O, 500 mM DTT in H₂O, 1M BSA inH₂O, 20 mg/mL KCl in H₂O, 600 mM ATP in 1X PM12, 100 mM NADH in 1X PM12,30 mM PEP in 1X PM12, 100 mM, pH 7.0 Antifoam 204, 1% in H₂O

Stock Solutions of pCa buffer. Combine PIPES, CaCl₂, and EGTA solutionswith 70 mL of water. Adjust pH to 7.0 and bring final volume to 100 mL.

PREPARATION OF STOCKS SOLUTIONS FOR 100 ML OF PCA BUFFER 200 mM PIPESApprox. Water pCA (mL) (mL) CaCl₂ EGTA 4.0 6 74 10.025 9.975 4.5 6 749.800 10.200 5.0 6 74 9.325 10.675 5.5 6 74 8.100 11.900 5.75 6 74 7.20012.800 6.0 6 74 6.000 14.000 6.25 6 74 4.500 15.500 6.5 6 74 3.02516.975 6.75 6 74 1.975 18.025 7.0 6 74 1.165 18.835 8.0 6 74 0.12619.874 10.0 6 74 0.001 19.999

Skeletal Myofibril ATPase Assay Procedure: BSA, ATP, NADH, PEP, and DTTsolutions were thawed at room temperature, then transferred to ice.Pellet-frozen myofibrils (approximately twice the required volume) weretransferred into a sufficiently large tube and capped. Myofibrils werethawed by rolling in a water bath for approximately 15 min at roomtemperature and cooled on ice. Buffers A and B were prepared byadjusting volumes as necessary for required number of wells and storedon ice. 0.5 μL of the compounds to be assayed were added into wells of a384-well plate. Buffers A and B were mixed by inversion immediatelyprior to use, then 25 μL of each was dispensed using a Multidropdispenser (Buffer A first, then Buffer B). The absorbance within thewells was measured at 340 nm, using a kinetic protocol in which thewells are read every 1.5-2 min for 1 h. The reaction rate wasqualitatively assessed by subtracting the minimum absorbance value fromthe maximum value for each well, using either the SoftMax Pro platereader software or a spreadsheet program such as Excel. Using GraphPadPrism 8.0, the data was normalized, with 100% activity defined as theabsorbance change in the 1% DMSO vehicle wells and 0% assigned to nochange in absorbance over the course of the experiment. The normalizeddata were fit to a variable-slope four-parameter logistic model,constraining the bottom to be 0 or greater. Compounds of Table 1 to 4were tested and results of the assay appear in Table 5 herein. A=IC₅₀ isless than or equal to 10 μM; B=IC₅₀ is greater than 10 μM and less than100 μM; C=IC₅₀ is greater than 100 μM; D=IC₅₀ is greater than 60 μM.II.

Example 19. Cardiac Myofibril ATPase Assay

Following example 15, the counter screen was done using frozen myofibrilpellets obtained from cardiac tissue. The assay was done in the samemanner as above, with the following notable exceptions: the final wellconcentration of myofibrils was 1.0 mg/mL and KCl was omitted from therecipe.

Compounds of Table 1 to 4 were tested and results of the assay appear inTable 6 herein. A=IC₅₀ is less than or equal to 10 μM; B=IC₅₀ is greaterthan 10 μM and less than 100 μM; C=IC₅₀ is greater than 100 μM; andD=IC₅₀ is greater than 60 μM.

Example 20. Tibialis Anterior Muscle Assay

Skeletal muscles of patients with Duchenne muscular dystrophy (DMD) andmdx mice lack dystrophin and are more susceptible to contraction-inducedinjury than control muscles. Two stretches of maximally activatedtibialis anterior (TA) muscles in situ were used to evaluate thesusceptibility to injury of limb muscles in mdx mice following theadministration of a compound disclosed herein. stretches of 20% strainrelative to muscle fiber length were initiated from the plateau ofisometric contractions. The magnitude of damage was assessed one minutelater by the deficit in isometric force.

Animals

Mice aged 2-19 months were tested. Specific pathogen free (SPF) C57BLcontrol and mdx mice were either purchased or bred in-house with matingpairs purchased from the Jackson Laboratories. All control mice were ofC57BL/10J strain with the exception of the 19-month old mice that wereC57BL/6. The use of C57BL/6 mice for the oldest group was necessary,since unlike C57BL/10J mice, C57BL/6 mice may be purchased at advancedages from the colonies of aging rodents maintained by the NationalInstitute on Aging.

In Situ Preparation

Mice were anesthetized with an initial intraperitoneal injection ofAvertin (tribromoethanol; 13-17 ll/g). Anesthesia was supplemented untilno responses to tactile stimuli were detected. This level of anesthesiawas maintained throughout the experiment with additional doses ofAvertin. The tendon of the TA was exposed by an incision at the ankle.The tendon was cut several millimeters distal to the end of the muscle.The tendon was tied with 4.0 nylon suture as close to the muscleattachment as possible, and the tendon was folded back onto itself andtied again. The tendon and exposed muscle were kept moist by periodicapplications of isotonic saline. The mouse was placed on a heatedplatform maintained at 37° C. The foot of the mouse was secured to theplatform with cloth tape and the knee was immobilized in a clamp betweensharpened screws. The tendon of the muscle was tied securely to thelever arm of a servomotor. The servomotor controlled the position of themuscle and monitored the force developed by the muscle. All data weredisplayed on a digital oscilloscope and stored on a computer.

The TA muscle was stimulated with 0.2-ms pulses via two needleelectrodes that penetrated the skin on either side of the peroneal nervenear the knee. Stimulation voltage and subsequently muscle length (Lo)were adjusted for maximum isometric twitch force (Pt). While held at Lo,the muscle was stimulated at increasing frequencies, stepwise from 150Hz by 50 Hz, until a maximum force (Po) was reached, typically at 250Hz. A one- to two-minute rest period was allowed between each tetaniccontraction. Muscle length was measured with calipers, based onwell-defined anatomical landmarks near the knee and the ankle. Optimumfiber length was determined by multiplying Lo by the TA Lf/Lo ratio of0.6.

Lengthening Contraction Protocol

Each muscle was exposed to two stretches in situ, with the musclestimulated at 250 Hz, the frequency that most often resulted in Po. Aprotocol consisting of only two contractions was used to avoid fatigue.Stretches were initiated from the plateau of an isometric contraction atLo. At time 0, stimulation was initiated and the muscle was held with nomovement for 100 ms to allow maximum activation. From the plate au ofthe maximum isometric contraction, a length change of 20% Lf at avelocity of 1 Lf/s was imposed (LC1). Stimulation ceased at the end ofthe stretch ramp. The muscle was held at the stretched length for 100 msand then returned to Lo at the same velocity. A second lengtheningcontraction identical to the first was administered 10 min later (LC2).Maximum isometric force was measured after 1 min (b1 min) and then againeach 5 min for 15 min. Force deficits were calculated as the differencebetween the isometric force during LC1 and the maximum isometric forcemeasured at any given time and expressed as a percentage of theisometric force during LC1. The recovery during the 15 min following thetwo-lengthening-contraction protocol was quantified as the differencebetween the isometric force measured at 15 min and the isometric forceafter the second lengthening contraction and expressed as a percentageof initial Po.

The experimental protocol consisted of two muscle stretches duringmaximal activation, followed by maximal activation to measure thedecrease in maximum isometric force (Po). Panel A shows the lengthchange of the muscle of 20% strain relative to fiber length (Lf), where100% corresponds to optimum muscle length (Lo) for force development.The muscle was stretched at a velocity of 2 Lf/s. Panel B demonstratesthe decrease in Po after the two-stretch protocol in a representativemdx mouse. Each lengthening contraction was initiated from the plateauof a maximum isometric contraction. Ten minutes after the firstlengthening contraction (LC1), a second lengthening contraction occurred(LC2). Maximum force during an isometric contraction was measured 10 minafter LC2 (

1 min). The force deficit was calculated by dividing the differencebetween the Po during LC1 and the Po measured at any time after LC1 bythe Po during LC1 and multiplying by 100%. suture were trimmed from themuscle, and the muscle was weighed. After removal of TA muscles, deeplyanesthetized mice were euthanized by the induction of a pneumothorax.Total muscle fiber cross-sectional area (CSA) of TA muscles wascalculated by dividing muscle mass by the product of Lf and 1.06 mg/mm3,the density of mammalian skeletal muscle. Specific Po was calculated bydividing Po by CSA. The results of the assays are seen in FIGS. 3-6 .

FIG. 3 shows the force decrease pre injury at 100 Hz for compounds ofthe disclosure. Force was measured in the TA muscle of the mdx mouse insitu at 100 Hz before and after oral administration of the compound. A100 Hz stimulus was applied every 10 minutes and the change in force,before starting the eccentric injury protocol was recorded. This metricgives an indication of the relative ability of the compound to decreaseforce in a target tissue.

FIG. 4 shows the post injury force decrease at 175 Hz for compounds ofthe disclosure. Maximal force was measured at 175 Hz in the TA muscle insitu before and 10 minutes after two rounds of eccentric (lengthening)contraction. In mdx mice, lengthening contraction yields an exaggeratedforce drop. This measurement gives an indication of the ability of thecompound to reduce the relative drop in force after eccentriccontraction. FIG. 5 shows mid lengthening force drop for compounds ofthe disclosure. Injury to the TA muscle in situ was elicited via twomaximal eccentric contractions with 20% lengthening, 10 minutes apart.This metric measures the relative drop in pre-lengthening force betweenthe first and the second contraction.

FIG. 6 shows the TA mass increase after injury for compounds of thedisclosure. Lengthening injury of the TA muscle in mdx mice causes adelayed increase in muscle weight post-injury. This is presumably due tofluid accumulation in the form of edema. Muscles (both injured andcontralateral) were removed from the mouse 1 hour after injury andweighed. The relative increase in weight of injured to contralateral wasrecorded. Reduction in this relative change is indicative of reducededema post-injury.

In some embodiments, compounds of the disclosure are below in Table 1.

TABLE 1 Cmpd No. Structure Name NMR/MS 1

2-((5-chloropyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)- one ¹H NMR (300 MHz,DMSO-d₆) δ 9.18 (s, 2H), 8.61 (dd, J = 8.7, 1.5 Hz, 2H), 8.15 (d, J =9.9 Hz, 1H), 7.99 (s, 1H), 7.18 (d, J = 9.6 Hz, 1H), 5.39 (s, 2H), 5.12(q, J = 9.0 Hz, 2H) 2

2-((5-chloropyridin-3- yl)methyl)-6-(6- (difluoromethoxy)pyridin-3-yl)pyridazin-3(2H)- 1H NMR (DMSO-d6, 300 MHz): δ 8.78 (s, 1H),8.61-8.59 (s, 2H), 8.40 (dd, J₁ = 8.7 Hz, J₂ = 2.4 Hz, 1H), 8.15 (d,J_(\) = 9.9 Hz, 1H), 7.96-7.95 (m, 1H), 7.77 (t, J = 72.6 Hz, 1H),7.25-7.14 (m, 2H), 5.40 (s, 2H); LC/MS (ESI): 398 [M + H]⁺ 3

2-((6-chloropyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one LC/MS (ESI): 365[M + H]⁺ 4

2-(pyridin-3-ylmethyl)- 6-(2-(2,2,2- trifluoroethoxy)pyrimidin-5-yl)pyridazin-3(2H)-one 398.1 5

2-((6- (difluoromethoxy)pyridin- 3-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one m/z = 364.3 (M + H)6

2-((5-fluoropyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)- one 1H NMR (300 MHz,DMSO-d₆): δ 9.18 (s, 2H), 8.55-8.54 (m, 2H), 8.15 (d, J = 9.6 Hz, 1H),7.81- 7.77 (m, 1H), 7.19 (d, J = 9.9 Hz, 1H), 5.41 (s, 2H), 5.12 (q, J =9.0 Hz, 2H); m/z = 430.3 (M + H) 7

2-((6-methylpyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one LC/MS (ESI): 382[M + H]⁺ 8

6-(2-(2,2,2- trifluoroethoxy)pyrimidin- 5-yl)-2-((6-(trifluoromethyl)pyridin- 3-yl)methyl)pyridazin- 3(2H)-one [M + H]+378.2 9

6-(6- (difluoromethoxy)pyridin- 3-yl)-2-((5- fluoropyridin-3-yl)methyl)pyridazin- 3(2H)-one ¹H NMR (DMSO-d6, 300 MHz): δ 8.79 (d,J_(\) = 2.1 Hz, 1H), 8.54-8.53 (m, 2H), 8.40 (dd, J₁ = 8.7 Hz, J₂ = 2.4Hz, 1H), 8.14 (d, J_(\) = 9.9 Hz, 1H), 7.78 (t, J = 72.3 Hz, 1H),7.77-7.33 (m, 1H), 7.25-7.14 (m, 2H), 5.42 (s, 2H); m/z = 432.3 (M + H)10

6-(6- (difluoromethoxy)pyridin- 3-yl)-2-(pyridin-3- ylmethyl)pyridazin-3(2H)-one ¹HNMR (DMSO-d6, 300 MHz): δ8.78 (d, J_(\) = 2.1 Hz, 1H), 8.65(s, 1H), 8.52 (d, J = 3.9 Hz, 1H), 8.40 (dd, J₁ = 8.7 Hz, J₂ = 2.4 Hz,1H), 8.13 (d, J_(\) = 9.6 Hz, 1H), 7.83-7.80 (m, 1H), 7.77 (t, J = 72.3Hz, 1H), 7.41-7.371H), 7.24-7.17 (m, 2H), 5.38 (s, 2H); LC/MS (ESI): 349[M + H]⁺ 11

2-((5- chlorobenzo[d]oxazol- 2-yl)methyl)-6-(2- (2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one LC/MS (ESI): 331[M + H]⁺ 12

2-(benzo[d]oxazol-2- ylmethyl)-6-(2-(2,2,2- trifluoroethoxy)pyrimidin-5-yl)pyridazin-3(2H)-one m/z = 438.3 (M + H) 13

2-((3-methylisoxazol-5- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 404.1 14

6-(6- (difluoromethoxy)pyridin- 3-yl)-2-((3-methylisoxazol-5-yl)methyl)pyridazin-3(2H)-one 368.2 15

6-(6- (difluoromethoxy)pyridin- 3-yl)-2-(imidazo[1,2-a]pyridin-2-ylmethyl)pyridazin- 3(2H)-one 335.3 16

6-(6-(difluoromethoxy)pyridin- 3-yl)-2-((5-phenyloxazol-4-yl)methyl)pyridazin-3(2H)-one 370.2 17

6-(6- (difluoromethoxy)pyridin-3- yl)-2-((5-(4- fluorophenyl)-1,3,4-thiadiazol-2- yl)methyl)pyridazin- 3(2H)-one ¹H NMR (DMSO-d6, 300 MHz):δ 8.81 (d, J_(\) = 2.4 Hz, 1H), 8.42 (dd, J₁ = 8.7 Hz, J₂ = 2.7 Hz, 1H),8.20 (d, J_(\) = 9.9 Hz, 1H), 8.07-8.04 (m, 2H), 7.78 (t, J = 72.6 Hz,1H), 7.39-7.37 (m, 2H), 7.27- 7.23 (m, 2H), 5.82 (s, 2H); [M + H]+ 397.118

6-(6- (difluoromethoxy)pyridin- 3-yl)-2-((4-phenyl- 4H-1,2,4-triazol-3-yl)methyl)pyridazin-3(2H)-one LC/MS (ESI): 432 [M + H]⁺ 19

6-(6-(difluoromethoxy)pyridin- 3-yl)-2-((5-phenyl-1H-tetrazol-1-yl)methyl)pyridazin-3(2H)-one [M + H]+ 397.2 20

2-((5-methylisoxazol-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 398.2 22

6-(6- (difluoromethoxy)pyridin- 3-yl)-2-((5-phenyl-1,3,4-thiadiazol-2-yl)methyl)pyridazin- 3(2H)-one ¹H NMR (DMSO-d6, 400 MHz): δ8.81 (d, J_(\) = 2.4 Hz, 1H), 8.42 (dd, J₁ = 8.4 Hz, J₂ = 2.4 Hz, 1H),8.21 (d, J_(\) = 10.0 Hz, 1H), 7.99-7.97 (m, 2H), 7.79 (t, J = 73.2 Hz,1H), 7.59-7.53 (m, 3H), 7.27- 7.24 (m, 2H), 5.83 (s, 2H); LC/MS (ESI):414 [M + H]⁺ 23

6-(6-(difluoromethoxy)pyridin- 3-yl)-2-((5-phenyl-1H-pyrazol-4-yl)methyl)pyridazin-3(2H)-one [M + H]+ 396.2 24

6-(6-(difluoromethoxy)pyridin- 3-yl)-2-((4-phenyloxazol-5-yl)methyl)pyridazin-3(2H)-one [M + H]+ 397.2 25

6-(6- (difluoromethoxy)pyridin- 3-yl)-2-((4-phenyl-1H-pyrazol-5-yl)methyl) pyridazin-3(2H)-one [M + H]+ 396.1 26

2-((3- (difluoromethyl)isoxazol- 5-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 404.1 27

2-((3-phenylisoxazol-5- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 430.1 28

2-((5-fluoropyridin-3- yl)methyl)-6-(2-(2- methylpyrrolidin-l-yl)pyrimidin-5- yl)pyridazin-3(2H)-one [M + H]+ 367.1 30

2-((3-(pyridin-2- yl)isoxazol-5- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 431.2 31

2-((3- cyclopropylisoxazol-5- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5- yl)pyridazin-3(2H)-one [M + H]+ 394.1 32

5-((6-oxo-3-(2-(2,2,2- trifluoroethoxy)pyrimidin- 5-yl)pyridazin-1(6H)-yl)methyl)isoxazole-3- carboxamide [M + H]+ 397.1 33

2-((3-acetylisoxazol-5- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 396.1 34

2-((4-methylisoxazol-5- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 368.1 36

2-((3-ethylisoxazol-5- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 382.1 37

ethyl 5-((6-oxo-3-(2- (2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazin-1(6H)-yl)methyl) isoxazole-3-carboxylate [M + H]+ 426.238

2-((5-(pyridin-2-yl)- 1,3,4-thiadiazol-2- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin -5-yl)pyridazin-3(2H)-one [M + H]+ 448.5 39

2-((4-methyl-3- phenylisoxazol-5- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 444.2 40

2-((5-(pyridin-3-yl)- 1,3,4-thiadiazol-2- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 448.2 41

2-((6-methylpyridazin- 3-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 379.2 42

2-((2-hydroxypyridin-4- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 380.2 43

2-((3- (hydroxymethyl)isoxazol-5- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5- yl)pyridazin-3(2H)-one [M + H]+ 384.1 44

2-((5-(2-hydroxypyridin-4-yl)- 1,3,4-thiadiazol-2-yl)methyl)-6-(2-(2,2,2- trifluoroethoxy)pyrimidin-5-yl)pyridazin-3(2H)-one [M + H]+ 464.2 45

2-((5-(6- hydroxypyridin-3-yl)- 1,3,4-thiadiazol-2-yl)methyl)-6-(2-(2,2,2- trifluoroethoxy)pyrimidi-5- yl)pyridazin-3(2H)-one [M + H]+464.1 46

2-((6-hydroxypyridin-2- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 380.1 47

2-((2-hydroxypyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 380.2 48

2-((5-(pyridin-4-yl)- 1,3,4-thiadiazol-2- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 448.2 49

2-((3,4- dimethylisoxazol-5- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 382.1 50

2-((5-fluoropyridin-3- yl)methyl)-6-(2-(methyl(2,2,2-trifluoroethyl)amino)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 395.251

5-((6-oxo-3-(2-(2,2,2- trifluoroethoxy)pyrimidin- 5-yl)pyridazin-1(6H)-yl)methyl)nicotinonitrile [M + H]+ 389.1 52

2-((5-fluoro-6- methylpyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 396.1 53

2-(oxazol-5-ylmethyl)- 6-(2-(2,2,2,- trifluoroethoxy)pyrimidin-5-yl)pyridazin-3(2H)-one [M + H]+ 354.1 54

2-((5-fluoropyridin-3- yl)methyl)-6-(2-(2- (trifluoromethyl)pyrrolidin-l-yl)pyrimidin-5- yl)pyridazin-3(2H)-one [M + H]+ 421.2 55

2-((5- fluorobenzo[d]oxazol-2- yl)methyl)-6-(2-(2,2,2,-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 422.2 56

2-((3- (methoxymethyl)isoxazol- 5-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 398.2 57

5-((3-(6- (difluoromethoxy)pyridin- 3-yl)-6-oxopyridazin-1(6H)-yl)methyl)nicotinonitrile [M + H]+ 356.2 58

2-((1-methyl-1H- pyrazol-4-yl)methyl)-6- (2-(2,2,2-trifluoroethoxy)pyrimidin-5- yl)pyridazin-3(2H)-one [M + H]+ 367.1 59

2-(thiazol-5-ylmethyl)- 6-(2-(2,2,2- trifluoroethoxy)pyrimidin-5-yl)pyridazin-3(2H)-one [M + H]+ 370.1 60

2-((2-methyloxazol-5- yl)methyl)-6-(2-(2,2,2- trifluoroethoxy)pyrimidin-5-yl)pyridazin-3(2H)-one [M + H]+ 368.2 61

2-((2-methylthiazol-5- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 384.2 62

6-(6- (difluoromethoxy)pyridin- 3-yl)-2-((6- hydroxypyridin-3-yl)methyl)pyridazin-3(2H)-one [M + H]+ 380.1 63

2-((5-fluoropyridin-3- yl)methyl)-6-(2-(2- (trifluoromethoxy)ethoxy)pyrimidin-5- yl)pyridazin-3(2H)-one [M + H]+ 411.2 64

6-(2-(bicyclo[1.1.1]pentan-1- ylamino)pyrimidin-5-yl)-2-((5-fluoropyridin- 3-yl)methyl)pyridazin- 3(2H)-one ¹H NMR (300MHz, DMSO-d6) δ 8.81 (s, 2H), 8.54-8.52 (m, 2H), 8.30 (s, 1H),8.02 (d, J= 9.9 Hz, 1H), 7.77-7.72 (m, 1H), 7.08 (d, J = 9.9 Hz, 1H), 5.36 (s,2H), 2.46 (s, 1H), 2.09 (s, 6H); LC/MS Rt = 1.556 min; MS m/z: 365 [M +H]⁺ 65

2-((3-methylisoxazol-5- yl)methyl)-6-(2- (methylthio)pyrimidin-5-yl)pyridazin-3(2H)-one ¹H NMR (400 MHz, DMSO-d₆) δ 9.09 (s, 2H), 8.15(d, J = 9.6 Hz, 1H), 7.21-7.19 (m, 1H), 6.39 (s, 1H), 5.46 (s, 2H), 2.58(s, 3H), 2.21 (s, 3H); LC/MS Rt = 1.219 min; MS m/z: 316 [M + H]⁺ 66

6-(2-((3-fluorooxetan-3- yl)methoxy)pyrimidin- 5-yl)-2-((5-fluoropyridin-3- yl)methyl)pyridazin- 3(2H)-one ¹H NMR (DMSO-d₆, 400MHz) δ 9.13 (s, 2H), 8.54 (d, J = 2.8 Hz, 2H), 8.14 (d, J = 9.6 Hz, 1H),7.78 (dd, J = 9.6, 2.8 Hz, 1H), 7.17 (d, J = 9.6 Hz, 1H), 5.41 (s, 2H),4.87 (s, 1H), 4.81 (s, 1H), 4.77 (s, 2H)., 4.72 (s, 2H); LC/MS Rt =0.929 min, MS m/z: 388 [M + H]⁺ 67

2-((5-fluoropyridin-3- yl)methyl)-6-(2- propoxypyrimidin-5-yl)pyridazin-3(2H)-one ¹H NMR (400 MHz, DMSO-d₆) δ 9.09 (s, 2H),8.55-8.54 (m, 2H), 8.12 (d, J = 10 Hz, 1H), 7.79- 7.76 (m, 1H), 7.17 (d,J = 9.6 Hz, 1H), 5.40 (s, 2H), 4.33 (t, J = 6.4 Hz, 2H), 1.80-1.75 (m,2H), 0.99 (t, J = 7.2 Hz, 3H); MS m/z: 328 [M + H]⁺ 68

6-(2-ethoxypyrimidin-5- yl)-2-((5-fluoropyridin- 3-yl)methyl)pyridazin-3(2H)-one ¹H NMR (300 MHz, DMSO-d₆) δ 9.09 (s, 2H), 8.54 (d, J = 2.4 Hz,2H), 8.11 (d, J = 9.9 Hz, 1H), 7.80-7.75 (m, , 1H), 7.16 (d, J = 9.9 Hz,1H), 5.40 (s, 2H), 4.42 (q, J = 6.9, 7.2 Hz, 2H), 1.36 (t, J = 6.9 Hz,3H); LC/MS Rt = 0.850 min; MS m/z: 328 [M + H]⁺ 69

2-((5-fluoropyridin-3- yl)methyl)-6-(2- methoxypyrimidin-5-yl)pyridazin-3(2H)-one ¹H NMR (400 MHz, DMSO-d₆) δ 9.05 (s, 2H), 8.49(d, J = 2.8 Hz, 2H), 8.05 (d, J = 9.6 Hz, 1H), 7.75-7.71 (m, 1H), 7.12(d, J = 9.6 Hz, 1H), 5.39 (s, 2H), 3.97 (s, 3H); LC/MS Rt = 2.684 min;MS m/z: 314 [M + H]⁺ 70

2-((5-fluoropyridin-3- yl)methyl)-6-(2-(2- methoxyethoxy)pyrimidin-5-yl)pyridazin-3(2H)-one ¹H NMR (DMSO-d₆, 400 MHz) δ 9.10 (s, 2H), 8.54(d, J = 2.4 Hz, 2H), 8.12 (d, J = 10.0 Hz, 1H), 7.82- 7.74 (m, 1H), 7.16(d, J = 9.6 Hz, 1H), 5.40 (s, 2H), 4.52-4.45 (m, 2H), 3.73-3.66 (m, 2H),3.31 (s, 3H); LC/MS: Rt = 0.810 min, MS m/z: 358 [M + H]⁺ 71

6-(6- (bicyclo[1.1.1]pentan-1- ylamino)pyridin-3-yl)- 2-(pyridin-3-ylmethyl)pyridazin- 3(2H)-one ¹H NMR (300 MHz, Methanol-d₄) δ 8.68 (s,1H), 8.51-8.49 (m, 2H), 8.02-7.94 (m, 3H), 7.47- 7.43 (m, 1H), 7.07 (d,J = 9.9 Hz, 1H), 6.73 (d, J = 9.0 Hz, 1H), 5.46 (s, 2H), 2.50 (s, 1H),2.18 (s, 6H); LC/MS Rt = 0.732 min; MS m/z: 346 [M + H]⁺ 72

6-(6- (bicyclo[1.1.1]pentan-1- ylamino)pyridin-3-yl)-2-((5-fluoropyridin-3- yl)methyl)pyridazin- 3(2H)-one [M + H]+ 364.1 73

(R)-2-((5-fluoropyridin- 3-yl)methyl)-6-(2-(2-(trifluoromethyl)pyrrolidin- 1-yl)pyrimidin-5-yl)pyridazin- 3(2H)-one[M + H]+ 421.2 74

(S)-2-((5-fluoropyridin- 3-yl)methyl)-6-(2-(2-(trifluoromethyl)pyrrolidin-1- yl)pyrimidin-5-yl)pyridazin- 3(2H)-one[M + H]+ 421.1 75

6-(2- (bicyclo[1.1.1]pentan-1- ylamino)pyrimidin-5-yl)-2-((5-chloropyridin-3- yl)methyl)pyridazin-3(2H)-one [M + H]+ 381.276

6-(6- (difluoromethoxy)pyridin- 3-yl)-2-((5- (trifluoromethyl)pyridin-3-yl)methyl)pyridazin-3(2H)-one [M + H]+ 399.1 77

6-(2-(2,2,2- trifluoroethoxy) pyrimidin-5-yl)-2-((5-(trifluoromethyl)pyridin- 3-yl)methyl)pyridazin-3(2H)-one [M + H]+ 432.178

2-((4-hydroxypyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 380.2 79

2-((4-fluoropyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 382.1 80

3-((6-oxo-3-(2-(2,2,2- trifluoroethoxy)pyrimidin- 5-yl)pyridazin-1(6H)-yl)methyl)pyridine 1-oxide [M + H]+ 380.1 81

4-((6-oxo-3-(2-(2,2,2- trifluoroethoxy)pyrimidin- 5-yl)pyridazin-1(6H)-yl)methyl)pyridine 1-oxide [M + H]+ 380.1 82

3-fluoro-5-((6-oxo-3-(2-(2,2,2- trifluoroethoxy)pyrimidin-5-yl)pyridazin-1(6H)-yl)methyl) pyridine 1-oxide [M + H]+ 398.3 83

2-((2-methyloxazol-4- yl)methyl)-6-(2-(2,2,2- trifluoroethoxy)pyrimidin-5-yl)pyridazin-3(2H)-one [M + H]+ 368.1 84

2-((5-chloro-6- hydroxypyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 414.1 85

2-(isoxazol-4-ylmethyl)- 6-(2-(2,2,2- trifluoroethoxy)pyrimidin-5-yl)pyridazin-3(2H)-one [M + H]+ 354.1 86

2-((4-hydroxy-6- methylpyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 394.1 87

2-((5-chloro-6- methylpyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 412.1 88

2-((3-(4-fluorophenyl)- 1,2,4-oxadiazol-5- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one H NMR (300 MHz,DMSO-d6): δ 9.15 (s, 2H), 8.13 (d, J = 6.3 Hz, 1H), 8.11-8.05 (m, 2H),7.30-7.21 (m, 3H), 5.81 (s, 2H), 5.03 (q, J = 8.7 Hz, 2H), LC/MS (ESI):449 [M + H]+ 89

2-((3-phenyl-1,2,4- oxadiazol-5-yl)methyl)- 6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one 1H NMR (300 MHz,DMSO-d6): δ 9.16 (s, 2H), 8.15 (d, J = 9.9 Hz, 1H), 8.06-8.02 (m, 2H),7.59-7.48 (m, 3H), 7.23 (d, J = 9.9 Hz, 1H), 5.81 (s, 2H), 5.03 (q, J =8.4 Hz, 2H): LC/MS (ESI): 432 [M + H]+ 90

6-(2-((3-fluorooxetan-3- yl)methoxy)pyrimidin- 5-yl)-2-((3-(4-fluorophenyl)-1,2,4- oxadiazol-5- yl)methyl)pyridazin- 3(2H)-one 1H NMR(CD30D, 300 MHz): δ 9.13 (s, 2H), 8.17-8.05 (m, 3H), 7.30- 7.21 (m, 3H),5.80 (s, 2H), 5.03-4.75 (m, 6H); LC/MS (ESI): 456 [M + H]+ 91

6-(2-((3-fluorooxetan-3- yl)methoxy)pyrimidin- 5-yl)-2-((3-phenyl-1,2,4-oxadiazol-5- yl)methyl)pyridazin- 3(2H)-one 1H NMR (DMSO-d6, 300MHz): δ 9.13 (s, 2H), 8.24 (d, J = 9.6 Hz, 1H), 8.00-7.97 (m, 2H), 7.60-7.56 (m, 3H), 7.27 (d, J = 9.6 Hz, 1H), 5.80 (s, 2H), 4.88-4.71 (m, 6H);LC/MS (ESI): 437 [M + H]+ 92

6-(2-((3-fluorooxetan-3- yl)methoxy)pyrimidin- 5-yl)-2-((5-phenyl-1,3,4-thiadiazol-2- yl)methyl)pyridazin- 3(2H)-one 1H NMR (DMSO-d6, 300MHz): δ 9.14 (s, 2H), 8.20 (d, J\ = 9.6 Hz, 1H), 8.00-7.97 (m, 2H),7.59- 7.53 (m, 3H), 7.26 (d, J\ = 9.9 Hz, 1H), 5.83 (s, 2H), 4.88-4.71(m, 6H); LC/MS (ESI): 453 [M + H]+ 93

2-((6-hydroxypyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 380.2 94

2-((5-phenyl-1,3,4- thiadiazol-2-yl)methyl)- 6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 447.2 95

2-((5-(piperidin-1-yl)- 1,3,4-thiadiazol-2- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one [M + H]+ 454.2 96

2-((1H-indazol-5- yl)methyl)-6-(2-(2,2,2- trifluoroethoxy)pyrimidin-5-yl)pyridazin-3(2H)-one [M + H]+ 403.2 97

2-((5-fluoropyridin-3- yl)methyl)-6-(2-(2- (trifluoromethoxy)ethoxy)pyrimidin-5- yl)pyridazin-3(2H)-one 1H NMR (300 MHz, DMSO-d6) δ9.12 (s, 2H), 8.54 (d, J = 2.4 Hz, 2H), 8.13 (d, J = 9.9 Hz, 1H),7.83-7.73 (m, 1H), 7.17 (d, J = 9.9 Hz, 1H), 5.40 (s, 2H), 4.63 (t, J =3.9 Hz, 2H), 4.52-4.43 (m, 2H); LC/MS Rt = 1.677 min; MS m/z: 412 [M +H]+ 99

2-((2-ethylthiazol-5- yl)methyl)-6-(2-(2,2,2- trifluoroethoxy)pyrimidin-5-yl)pyridazin-3(2H)-one 1H NMR (400 MHz, DMSO-d₆): δ 9.16 (s, 2H), 8.12(d, J = 9.6 Hz, 1H), 7.75 (s, 1H), 7.17 (d, J = 9.6 Hz, 1H), 5.48 (s,2H), 5.12 (q, J = 8.8 Hz, 2H), 2.92 (q, J = 7.6 Hz, 2H), 1.24 (t, J =7.6 Hz, 3H); LC?MS Rt = 1.873 min; MS m/z: 398 [M + H]⁺ 100

2-((2- cyclopropylthiazol-5- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one ¹H NMR (DMSO-d₆, 300MHz) δ 9.17 (s, 2H), 8.13 (d, J = 9.9 Hz, 1H), 7.68 (s, 1H), 7.18 (d, J= 9.9 Hz, 1H), 5.45 (s, 2H), 5.13 (q, J = 9.0 Hz, 2H), 2.39- 2.30 (m,1H), 1.10-1.01 (m, 2H), 0.94-0.89 (m, 2H); LC/MS Rt = 1.370 min; MS m/z:410 [M + H]⁺ 101

2-((5-methylpyridin-3- yl)methyl)-6-(2-(2,2,2- trifluoroethoxy)pyrimidin-5-yl)pyridazin- 3(2H)-one ¹H NMR (DMSO-d₆, 300 MHz) δ 9.17 (s,2H), 8.46 (d, J = 3.0 Hz, 1H), 8.35 (d, J = 3.0 Hz, 1H), 8.14 (d, J =9.6 Hz, 1H), 7.63 (t, J = 2.4 Hz, 1H), 7.17 (d, J = 9.6 Hz, 1H), 5.33(s, 2H), 5.12 (m, 2H), 2.28 (s, 3H); LC/MS Rt = 0.734 min; MS m/z: 378[M + H]⁺ 102

2-((5-fluoropyridin-3- yl)methyl)-6-(2-(2- (methylthio)ethoxy)pyrimidin-5-yl)pyridazin-3(2H)-one 1H NMR (400 MHz, DMSO-d6) δ 9.11 (s, 2H), 8.54(d, J = 3.2 Hz, 2H), 8.12 (d, J = 10.0 Hz, 1H), 7.98-7.76 (m, 1H), 7.17(d, J = 9.6 Hz, 1H), 5.40 (s, 2H), 4.54 (t, J = 6.4 Hz, 2H), 2.90 (t, J= 6.8 Hz, 2H), 2.16 (s, 3H); LC/MS Rt = 1.424 min; MS m/z: 374 [M + H]+103

2-((5-fluoropyridin-3- yl)methyl)-6-(2-(oxetan- 3-ylmethoxy)pyrimidin-5-yl)pyridazin-3(2H)- one 1H NMR (300 MHz, DMSO-d6) δ 9.11 (s, 2H), 8.54(d, J = 3.0 Hz, 2H), 8.13 (d, J = 9.9 Hz, 1H), 7.78 (dt, J = 9.4, 2.3Hz, 1H), 7.17 (d, J = 9.9 Hz, 1H), 5.40 (s, 2H), 4.72 (dd, J = 7.8, 6.1Hz, 2H), 4.60 (d, J = 6.9 Hz, 2H), 4.45 (t, J = 6.0 Hz, 2H), 3.49-3.39(m, 1H); LC/MS Rt = 1.021 min; MS m/z: 370.3 [M + H]+ 104

2-((5-fluoropyridin-3- yl)methyl)-6-(2- (neopentyloxy)pyrimidin-5-yl)pyridazin-3(2H)-one 1H NMR (400 MHz, DMSO-d6) δ 9.08 (s, 2H),8.57-8.50 (m, 2H), 8.13 (d, J = 9.7 Hz, 1H), 7.79- 7.75 (m, 1H), 7.17(d, J = 9.6 Hz, 1H), 5.41 (s, 2H), 4.08 (s, 2H), 1.02 (s, 9H); LC/MS Rt= 1.721 min; MS m/z: 370 [M + H]+ 105

2-((2- (difluoromethyl)thiazol- 5-yl)methyl)-6-(2- (2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one ¹H NMR (DMSO-d₆, 400MHz) δ 9.18 (s, 2H), 8.16 (d, J = 9.6 Hz, 2H), 7.21 (d, J = 10.0 Hz,1H), 7.44, 7.30, 7.17 (t, J = 54 Hz, 1H), 5.62 (s, 2H), 5.13 (q, J = 8.8Hz, 2H); LC/MS Rt = 1.653 min; MS m/z: 420 [M + H]⁺ 106

6-(2-(2,2- difluoroethoxy)pyrimidin- 5-yl)-2-((5- fluoropyridin-3-yl)methyl)pyridazin-3(2H)-one 1H NMR (DMSO-d6, 400 MHz) δ 9.15 (s, 2H),8.54 (d, J = 2.4 Hz, 2H), 8.14 (d, J = 9.6 Hz, 1H), 7.83- 7.75 (m, 1H),7.18 (d, J = 9.6 Hz, 1H), 6.45 (t, J = 3.2 Hz, 0H), 5.41 (s, 2H), 4.70(td, J = 15.2, 3.6 Hz, 2H); LC/MS Rt = 1.228 min; MS m/z: 364 [M + H]+107

6-(2-((5-fluoropyridin- 3-yl)methoxy)pyrimidin-5-yl)-2-((5-fluoropyridin-3- yl)methyl)pyridazin-3(2H)-one 108

2-((5-fluoropyridin-3- yl)methyl)-6-(2- ((methylthio)methoxy)pyrimidin-5-yl)pyridazin- 3(2H)-one 1H NMR (300 MHz, DMSO-d6) δ 9.14 (s,2H), 8.54 (d, J = 2.7 Hz, 2H), 8.13 (d, J = 9.9 Hz, 1H), 7.79 (d, J =9.6 Hz, 1H), 7.17 (d, J = 9.6 Hz, 1H), 5.58 (s, 2H), 5.40 (s, 2H), 2.27(s, 3H); LC/MS Rt = 5.971 min; MS m/z: 360 [M + H]+ 109

2-((2- ((methylthio)methyl)thiazol- 5-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one ¹H NMR (DMSO-d₆, 300MHz) δ 9.17 (s, 2H), 8.14 (d, J = 9.6 Hz, 1H), 7.79 (s, 1H), 7.19 (d, J= 9.6 Hz, 1H), 5.51 (s, 2H), 5.13 (q, J = 9.0 Hz, 2H), 4.00 (s, 2H),2.08 (s, 3H); Rt = 1.458 min; MS m/z: 430 [M + H]⁺ 110

2-((5-fluoropyridin-3- yl)methyl)-6-(2- isobutoxypyrimidin-5-yl)pyridazin-3(2H)-one 1H NMR (300 MHz, DMSO-d6) δ 9.09 (s, 2H),8.55-8.53 (m, 2H), 8.12 (d, J = 9.9 Hz, 1H), 7.80- 7.76 (m, 1H), 7.17(d, J = 9.6 Hz, 1H), 5.40 (s, 2H), 4.16 (d, J = 6.9 Hz, 2H), 2.12-2.03(m, 1H), 0.99 (d, J = 6.6 Hz, 6H); LC/MS Rt = 1.317 min; MS m/z: 356[M + H]+ 111

2-((5- (methylthio)pyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one ¹H NMR (300 MHz,Methanol-d₄) δ 9.14 (s, 2H), 8.41 (dd, J = 12.9, 2.1 Hz, 2H), 8.06 (d, J= 9.6 Hz, 1H), 7.87 (t, J = 2.1 Hz, 1H), 7.16 (d, J = 9.9 Hz, 1H), 5.47(s, 2H), 5.04 (q, J = 8.7 Hz, 2H), 2.55 (s, 3H); LC/MS Rt = 2.406 min;MS m/z: 410 [M + H]⁺ 112

2-((2-ethylthiazol-5- yl)methyl)-6-(2- propoxypyrimidin-5-yl)pyridazin-3(2H)-one ¹H NMR (DMSO-d₆, 300 MHz) δ 9.08 (s, 2H), 8.10(d, J = 9.6 Hz, 1H), 7.75 (s, 1H), 7.16 (d,J = 9.6 Hz, 1H), 5.48 (s,2H), 4.33 (t, J = 6.9 Hz, 2H), 2.93 (q, J = 7.5 Hz, 2H), 1.812- 1.742(m, 2H), 1.25 (t, J = 7.5 Hz, 3H), 0.99 (t, J = 7.5 Hz, 3H); LC/MS Rt =1.349 min; MS m/z: 358 [M + H]⁺ 113

6-(2-(2,2- difluoropropoxy)pyrimidin- 5-yl)-2-((5- fluoropyridin-3-yl)methyl)pyridazin- 3(2H)-one 1H NMR (DMSO-d6, 300 MHz) δ 9.15 (s, 2H),8.54 (d, J = 2.4 Hz, 2H), 8.15 (d, J = 9.9 Hz, 1H), 7.84- 7.73 (m, 1H),7.18 (d, J = 9.9 Hz, 1H), 5.41 (s, 2H), 4.69 (t, J = 13.2 Hz, 2H),1.83-1.70 (t, J = 19.5 Hz, 3H); LC/MS Rt = 1.271 min; MS m/z: 378 [M +H]+ 114

2-((2-isopropylthiazol- 5-yl)methyl)-6-(2- (2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one ¹H NMR (DMSO-d₆, 300MHz) δ 9.17 (s, 2H), 8.13 (d, J = 9.9 Hz, 1H), 7.77 (s, 1H), 7.18 (d, J= 9.6 Hz, 1H), 5.49 (s, 2H), 5.13 (q, J = 9.0 Hz, 2H), 3.29- 3.15 (m,1H), 1.28 (d, J = 6.9 Hz, 6H); LC/MS Rt = 2.462 min; MS m/z 412 [M + H]⁺115

2-((5-fluoropyridin-3- yl)methyl)-6-(2- isopropoxypyrimidin-5-yl)pyridazin-3(2H)-one 1H NMR (DMSO-d6, 300 MHz) δ 9.08 (s, 2H), 8.54(d, J = 3.3 Hz, 2H), 8.11 (d, J = 9.9 Hz, 1H), 7.78 (m, 1H), 7.16 (d, J= 9.6 Hz, 1H), 5.40 (s, 2H), 5.27 (m, 1H), 1.36 (s, 3H), 1.34 (s, 3H);LC/MS Rt = 1.318 min; MS m/z: 342 [M + H]+ 116

2-((2-propylthiazol-5- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one ¹H NMR (DMSO-d₆, 300MHz) δ 9.17 (s, 2H), 8.13 (d, J = 9.6 Hz, 1H), 7.76 (s, 1H), 7.18 (d, J= 9.9 Hz, 1H), 5.49 (s, 2H), 5.13 (q, J = 9.0 Hz, 2H), 2.88 (t, J = 7.5Hz, 2H), 1.76- 1.63 (m, 2H), 0.92 (t, J = 7.2 Hz, 3H); LC/MS Rt = 1.432min; MS m/z: 412 [M + H]⁺ 117

2-((5-fluoropyridin-3- yl)methyl)-6-(2-(3,3,3-trifluoropropoxy)pyrimidin-5 -yl)pyridazin-3(2H)-one 1H NMR (300 MHz,DMSO-d6) δ 9.13 (s, 2H), 8.54 (d, J = 3.0 Hz, 2H), 8.13 (d, J = 9.6 Hz,1H), 7.81-7.76 (m, 1H), 7.17 (d, J = 9.9 Hz, 1H), 5.40 (s, 2H), 4.60 (t,J − 6.0 Hz, 2H), 2.95-2.73 (m, 2H); LC/MS Rt = 1.315 min; MS m/z: 396[M + H]+ 118

2-((6-fluoropyrazin- yl)methyl)-6-(2-(2,2,2- trifluoroethoxy)pyrimidin-5-yl)pyridazin-3(2H)-one 119

6-(2- (cyclopropylmethoxy) pyrimidin-5-yl)-2-((5- fluoropyridin-3-yl)methyl)pyridazin- 3(2H)-one 1H NMR (300 MHz, DMSO-d6) δ 9.09 (s, 2H),8.54 (d, J = 2.7 Hz, 2H), 8.12 (d, J − 9.6 Hz, 1H), 7.80-7.77 (m, 1H),7.17 (d, J = 9.9 Hz, 1H), 5.40 (s, 2H), 4.21 (d, J − 7.5 Hz, 2H),1.34-1.25 (m, 1H), 0.64-0.52 (m, 2H), 0.43-0.32 (m, 2H); LC/MS Rt =1.280 min; MS m/z: 354 [M + H]+ 120

(S)-6-(2-(sec- butoxy)pyrimidin-5-yl)- 2-((5-fluoropyridin-3-yl)methyl)pyridazin- 3(2H)-one 1H NMR (400 MHz, DMSO-d6) δ 9.07 (s, 2H),8.54 (d, J = 2.8 Hz, 2H), 8.11 (d, J = 10.0 Hz, 1H), 7.77 (d, J = 9.6Hz, 1H), 7.16 (d, J = 9.6 Hz, 1H), 5.39 (s, 2H), 5.15-5.07 (m, 1H),1.77-1.62 (m, 2H), 1.31 (d, J = 6.0 Hz, 3H), 0.92 (t, J = 7.2 Hz, 3H);LC/MS Rt = 1.674 min; MS m/z: 356 [M + H]+ 121

6-(2-(2-fluoro-2- methylpropoxy)pyrimidin- 5-yl)-2-((5-fluoropyridin-3-yl)methyl)pyridazin-3(2H)-one 1H NMR (300 MHz, DMSO-d6) δ 9.11 (s, 2H),8.54 (d, J = 3.0 Hz, 2H), 8.13 (d, J = 6.6 Hz, 1H), 7.80-7.76 (m, 1H),7.17 (d, J = 6.6 Hz, 1H), 5.41 (s, 2H), 4.47, 4.40 (d, J = 41.4 Hz, 2H),1.48 (s, 3H), 1.41 (s, 3H); LC/MS Rt = 0.985 min; MS m/z: 374 [M + H]+122

2-((2-cyclobutylthiazol- 5-yl)methyl)-6-(2- (2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one ¹H NMR (300 MHz,DMSO-d₆) δ 9.17 (s, 2H), 8.13 (d, J = 9.9 Hz, 1H), 7.78 (s, 1H), 7.18(d, J = 9.6 Hz, 1H), 5.49 (s, 2H), 5.13 (q, J = 9.0 Hz, 2H), 3.86-3.74(m, 1H), 2.40- 1.80 (m, 6H); LC/MS Rt = 1.581 min; MS m/z: 424 [M + H]⁺123

2-((5-fluoropyridin-3- yl)methyl)-6-(2-(2- (methylthio)propoxy)pyrimidin-5-yl)pyridazin- 3(2H)-one 1H NMR (300 MHz, DMSO-d₆) δ 9.08 (s,2H), 8.56 (s, 1H), 8.45 (d, J = 2.7 Hz, 1H), 8.05 (d, J = 9.9 Hz, 1H),7.80-7.75 (m, 1H), 7.15 (d, J = 9.6 Hz, 1H), 5.52 (s, 2H), 4.65 (dd, J₁= 10.8 Hz, J₂ = 5.4 Hz, 1H), 4.37 (dd, J₁ = 10.8 Hz, J₂ = 7.8 Hz, 1H),3.13 (m, 2H), 2.2 (s, 3H), 1.38 (d, J = 6.9 Hz, 3H); LC/MS Rt = 1.137min; MS m/z: 388 [M + H]⁺ 124

2-((2-ethylthiazol-5- yl)methyl)-6-(2- isobutoxypyrimidin-5-yl)pyridazin-3(2H)-one ¹H NMR (300 MHz, DMSO-d₆) δ 9.08 (s, 2H), 8.10(d, J = 9.9 Hz, 1H), 7.75 (s, 1H), 7.16 (d, J = 9.9 Hz, 1H), 5.48 (s,2H), 4.16 (d, J = 6.6 Hz, 2H), 2.93 (q, J = 7.5 Hz, 2H), 2.13-2.02 (m,1H), 1.25 (t, J = 7.5 Hz, 3H), 0.99 (d, J = 6.7 Hz, 6H); LC/MS Rt =1.462 min; MS m/z: 372 [M + H]⁺ 125

2-((5-fluoropyridin-3- yl)methyl)-6-(2-(2- methoxy-2-methylpropoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one ¹H NMR (400 MHz,DMSO-d₆) δ 9.09 (s, 2H), 8.55-8.53 (m, 2H), 8.14 (d, J = 10.0 Hz, 1H),7.78- 7.76 (m, 1H), 7.17 (d, J = 9.6 Hz, 1H), 5.40 (s, 2H), 4.28 (s,2H), 3.16 (s, 3H), 1.22 (s, 6H); LC/MS Rt = 1.151 min; MS m/z: 386 [M +H]⁺ 126

6-(2- (cyclobutylmethoxy) pyrimidin-5-yl)-2-((5- fluoropyridin-3-yl)methyl)pyridazin- 3(2H)-one 1H NMR (300 MHz, DMSO-d₆) δ 9.08 (s, 2H),8.54-8.53 (m, 2H), 8.15 (d, J = 9.9 Hz, 1H), 7.80- 7.76 (m, 1H), 7.16(d, J = 9.6 Hz, 1H), 5.40 (s, 2H), 4.35 (d, J = 6.9 Hz, 2H), 2.81-2.75(m, 1H), 2.09- 2.04 (m, 2H), 2.03-1.85 (m, 2H); LC/MS Rt = 1.484 min; MSm/z: 368 [M + H]⁺ 127

(R)-6-(2-(sec- butoxy)pyrimidin-5-yl)- 2-((5-fluoropyridin-3-yl)methyl)pyridazin-3(2H)-one ¹H NMR (300 MHz, DMSO-d₆) δ 9.07 (s, 2H),8.54 (t, J = 3.0 Hz, 2H), 8.11 (d, J = 9.9 Hz, 1H), 7.79-7.76 (m, 1H),7.16 (d, J = 9.9 Hz, 1H), 5.40 (s, 2H), 5.10-5.06 (m,1H), 1.78-1.58 (m,2H), 1.31 (d, J = 6.3 Hz, 3H), 0.93 (t, J = 7.5 Hz, 3H); LC/MS Rt =2.219 min; MS m/z: 356 [M + H]⁺ 128

2-((5-methoxypyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one ¹H NMR (300 MHz,DMSO-d₆) δ 9.17 (s, 2H), 8.25-8.23 (m, 2H), 8.15(d, J = 9.6 Hz, 1H),7.42-7.41 (m, 1H), 7.18 (d, J = 9.6 Hz, 1H), 5.36 (s, 2H), 5.12 (q, J =9.0 Hz, 2H), 3.82 (s, 3H); LC/MS Rt = 1.301 min; MS m/z: 394 [M + H]⁺129

6-(2-(2,2- difluoropropoxy)pyrimidin- 5-yl)-2-((2-ethylthiazol-5-yl)methyl)pyridazin-3(2H)-one ¹H NMR (300 MHz, DMSO-d₆) δ 9.14 (s, 2H),8.12 (d, J = 9.9 Hz, 1H), 7.76 (s, 1H), 7.17 (d, J = 9.9 Hz, 1H), 5.49(s, 2H), 4.70 (t, J = 13.2 Hz, 2H), 2.93 (q, J = 7.5 Hz, 2H), 1.77 (t, J= 19.5 Hz, 3H), 1.25 (t, J = 7.5 Hz, 3H); LC/MS Rt = 1.803 min; MS m/z:394 [M + H]⁺ 130

6-(2-isobutoxypyrimidin-5- yl)-2-((2-methylthiazol-5-yl)methyl)pyridazin- 3(2H)-one ¹H NMR (300 MHz, DMSO-d₆) δ 9.08 (s,2H), 8.10 (d, J = 9.9 Hz, 1H), 7.72 (s, 1H), 7.16 (d, J = 9.9 Hz, 1H),5.47 (s, 2H), 4.16 (d, J = 6.6 Hz, 2H), 2.60 (s, 3H), 2.27-2.04 (m, 1H),1.00 (d, J = 6.6 Hz, 6H); LC/MS Rt = 1.817 min; MS m/z: 358 [M + H]⁺ 131

2-((5-fluoropyridin-3- yl)methyl)-6-(2-(2- methylpropoxy-2-d)pyrimidin-5- yl)pyridazin-3(2H)-one ¹H NMR (400 MHz, DMSO-d₆) δ 9.09(s, 2H), 8.55-8.53 (m, 2H), 8.12 (d, J = 10.0 Hz, 1H), 7.77 (d, J = 9.6Hz, 1H),7.16 (d, J = 10.0 Hz, 1H), 5.40 (s, 2H), 4.15 (s, 2H), 0.98 (s,6H); LC/MS Rt = 1.676 min; MS m/z: 357 [M + H]⁺ 132

2-((6-methoxypyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one ¹H NMR (300 MHz,DMSO-d₆) δ 9.17 (d, J = 6.0 Hz, 2H), 8.28 (d, J = 1.8 Hz, 1H), 8.12 (d,J = 9.6 Hz, 1H), 7.82-7.78 (m, 1H), 7.15 (d, J = 9.9 Hz, 1H), 6.81 (d, J= 8.7 Hz, 1H), 5.27 (s, 2H), 5.12 (q, J = 9.0 Hz, 2H), 3.82 (s, 3H);LC/MS Rt = 1.460 min; MS m/z: 394 [M + H]⁺ 133

2-((5-fluoro-6- methoxypyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one ¹H NMR (400 MHz,DMSO-d₆) δ 9.18 (s, 2H), 8.16-8.08 (m, 2H), 7.78 (dd, J = 11.2, 2.0 Hz,1H), 7.16 (d, J = 9.6 Hz, 1H), 5.30 (s, 2H), 5.12 (q, J = 8.8 Hz, 2H),3.93 (s, 3H); LC/MS Rt = 1.298 min; MS m/z: 412 [M + H]⁺ 134

2-((6-methoxy-5- methylpyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one ¹H NMR (400 MHz,DMSO-d₆) δ 9.17 (s, 2H), 8.11 (d, J = 9.6 Hz, 2H), 7.64-7.59 (m, 1H),7.14 (d, J = 9.6 Hz, 1H), 5.24 (s, 2H), 5.12 (q, J = 8.8 Hz, 2H), 3.85(s, 3H), 2.12 (s, 3H); LC/MS Rt = 1.961 min; MS m/z: 408 [M + H]⁺ 135

2-((5-isopropylpyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5- yl)pyridazin-3(2H)-one ¹H NMR (300 MHz,DMSO-d6) δ 9.17 (s, 2H), 8.47-8.45 (m, 2H), 8.14 (d, J = 9.7 Hz, 1H),7.76 (d, J = 2.2 Hz, 1H), 7.18 (d, J = 9.7 Hz, 1H), 5.36 (s, 2H), 5.12(q, J = 8.9 Hz, 2H), 3.00-2.91 (m, 1H), 1.21 (d, J = 6.9 Hz, 6H); LC/MSRt = 2.011 min; MS m/z: 406 [M + H]⁺ 136

2-((5-fluoro-2- methylpyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin- 5-yl)pyridazin-3(2H)-one ¹H NMR (400 MHz,DMSO-d₆) δ 9.12 (s, 2H), 8.39 (d, J = 2.8 Hz, 1H), 8.17 (d, J = 9.6 Hz,1H), 7.51 (dd, J = 9.6, 2.9 Hz, 1H), 7.20 (d, J = 9.6 Hz, 1H), 5.38 (s,2H), 5.12 (q, J = 8.8 Hz, 2H), 2.57 (s, 3H); LC/MS Rt = 1.524 min; MSm/z: 396 [M + H]⁺ 137

2-((5-ethylpyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyridazinemidin- 5-yl)pyridazin-3(2H)-one ¹H NMR (300MHz, DMSO-d₆) δ 9.17-9.16 (m, 2H), 8.47 (d, J = 2.1 Hz, 1H), 8.39 (d, J= 2.1 Hz, 1H), 8.14 (d, J = 9.9 Hz, 1H), 7.69 (t, J = 2.1 Hz, 1H), 7.17(d, J = 9.9 Hz, 1H), 5.35 (s, 2H), 5.16-5.08 (m, 2H), 2.61 (q, J = 7.5Hz, 2H), 1.17 (td, J = 7.2 Hz, 3H); LC/MS Rt = 0.704 min; MS m/z: 392[M + H]⁺ 138

6-(2- (benzyloxy)pyrimidin- 5-yl)-2-((5- fluoropyridazine-yl)methyl)pyridazin- 3(2H)-one ¹H NMR (300 MHz, DMSO-d6) δ 9.13 (s, 2H),8.55-8.53 (m, 2H), 8.13 (d, J = 9.8 Hz, 1H), 7.86- 7.71 (m, 1H),7.52-7.45 (m, 2H), 7.44-7.31 (m, 3H), 7.17 (d, J = 9.8 Hz, 1H), 5.47 (s,2H), 5.40 (s, 2H); LC/MS Rt = 1.944 min; MS m/z: 390 [M + H]⁺ 139

2-((6-ethyl-5-fluoropyridin-3- yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyridazinemidin- 5-yl)pyridazin-3(2H)-one ¹H NMR (300MHz, DMSO-d6) δ 9.18 (s, 2H), 8.44 (s, 1H), 8.14 (d, J = 9.6 Hz, 1H),7.74-7.64 (m, 1H), 7.17 (d, J = 9.9 Hz, 1H), 5.36 (s, 2H), 5.12 (q, J =9.0 Hz, 2H), 2.82-2.74 (m, 2H), 1.20 (t, J = 7.5 Hz, 3H); LC/MS Rt =1.626 min; MS m/z: 410 [M + H]⁺ 140

2-((1-methyl-1H-1,2,3- triazol-4-yl)methyl)-6- (2-(2,2,2-trifluoroethoxy)pyridazinemidin- 5-yl)pyridazin-3(2H)-one ¹H NMR (300MHz, DMSO-d₆) δ 9.15 (s, 2H), 8.13-8.10 (m, 2H), 7.16 (d, J = 9.6 Hz,1H), 5.39 (s, 2H), 5.16-5.07 (m, 2H), 4.01 (s, 3H); LC/MS Rt = 0.904min; MS m/z: 368 [M + H]⁺

In some embodiments, compounds of the disclosure are below in Table 2.

TABLE 2 Cmpd No. Structure Name NMR/MS 201

6-(4- (difluoromethoxy)phenyl)- 2-((5-phenyl-1,3,4- thiadiazol-2-yl)methyl)pyridazin- 3(2H)-one 413.3 202

6-(4- (difluoromethoxy)phenyl)- 2-((3-phenyl-1,2,4- thiadiazol-5-yl)methyl)pyridazin- 3(2H)-one ¹H NMR (300 MHz, DMSO-d₆): δ 8.20 (d, J =9.6 Hz, 1H), 7.98 (d, J = 7.6 Hz, 4H), 7.60- 7.53 (m, 3H), 7.46-7.16 (m,4H), 5.79 (s, 3H); LC/MS (ESI): 397 [M + H]⁺ 203

2-(benzo[d]oxazol-2- ylmethyl)-6-(4- (difluoromethoxy)phenyl)-pyridazin-3(2H)-one ¹H NMR (300 MHz, DMSO-d₆): δ 8.17 (d, J = 9.9 Hz,1H), 7.97- 7.94 (m, 2H), 7.75-7.71 (m, 2H), 7.58-7.09 (m, 6H), 5.69 (s,2H); LC/MS (ESI): 370 [M + H]⁺ 204

6-(4- (difluoromethoxy)phenyl)- 2-((3-methylisoxazol-5-yl)methyl)pyridazin- 3(2H)-one ¹H NMR (400 MHz, DMSO-d₆): δ 8.11 (d, J= 10.0 Hz, 1H), 7.94 (d, J = 8.0 Hz, 2H), 7.52-7.12 (m, 4H), 6.34 (s,1H), 5.46 (s, 2H), 2.21 (s, 3H); LC/MS (ESI): 334 [M + H]⁺ 205

6-(4- (difluoromethoxy)phenyl)- 2-((4-methylthizol-2-yl)methyl)pyridazin- 3(2H)-one ¹H NMR (300 MHz, DMSO-d₆): δ 8.14-7.95(d, J = 9.9 Hz, 1H), 7.98-7.95 (m, 2H), 7.58-7.09 (m, 5H), 5.58 (s, 2H),2.34 (s, 3H); LC/MS (ESI): 350 [M + H]⁺ 206

2-((3- cyclopropylisoxazol-5- yl)methyl)-6-(4- (difluoromethoxy)phenyl)-pyridazin-3(2H)-one ¹H NMR (300 MHz, DMSO-d₆): δ 8.11 (d, J = 9.6 Hz,1H), 7.97- 7.92 (m, 2H), 7.58-7.09 (m, 4H), 6.24 (s, 1H), 5.42 (s, 2H),2.02-1.93 (m, 1H), 1.01-0.95 (m, 2H), 0.77-0.74 (m, 2H); LC/MS (ESI):360 [M + H]⁺ 208

2-((3-cyclopropyl-1,2,4- oxadiazol-5-yl)methyl)- 6-(4-(difluoromethoxy)phenyl)- pyridazin-3(2H)-one ¹H NMR (300 MHz, DMSO-d₆):δ 8.15 (d, J = 9.9 Hz, 1H), 7.96- 7.93 (m, 2H), 7.58-7.09 (m, 4H), 5.62(s, 2H), 2.16-2.07 (m, 1H), 1.09-1.00 (m, 2H), 0.88-0.86 (m. 2H); LC/MS(ESI): 361 [M + H]⁺ 209

6-(4- (difluoromethoxy)phenyl)- 2-((3-ethylisoxazol-5 -yl)methyl)pyridazin- 3(2H)-one ¹H NMR (DMSO-d6, 400 MHz): δ 8.16 (d,1H), 8.02-7.97 (m, 2H), 7.58-7.16 (m, 4H), 6.45 (s, 1H), 5.51 (s, 2H),2.65 (q, 2H), 1.22 (t, 3H); 348.2 210

2-((4- cyclopropylthiazol-2- yl)methyl)-6-(4- (difluoromethoxy)phenyl)-pyridazin-3(2H)-one ¹H NMR (300 MHz, DMSO-d₆): δ 8.13 (d, J = 9.9 Hz,1H), 7.96 (d, J = 8.7 Hz, 2H), 7.60- 7.05 (m, 5H), 5.55 (s, 2H),2.10-2.01 (m, 1H), 0.91-0.76 (m, 4H); LC/MS (ESI): 376 [M + H]⁺ 211

2-((5-chloropyridin-2- yl)methyl)-6-(4- (difluoromethoxy)phenyl)-pyridazin-3(2H)-one ¹H NMR (CDCl₃, 400 MHz): δ 8.56 (d, 1H), 8.12 (d,1H), 7.95- 7.91 (m, 3H), 7.52- 7.12 (m, 5H), 5.46 (s, 2H); 364.2 212

6-(4- (difluoromethoxy)phenyl)- 2-((5-phenyl-1,3,4- oxadiazol-2-yl)methyl)pyridazin- 3(2H)-one ¹H NMR (DMSO-d6, 400 MHz): δ 8.21 (d,1H), 8.05-7.98 (m, 4H), 7.71-7.62 (m, 3H), 7.58-7.19 (m, 4H), 5.77 (s,2H); 397.3 213

6-(4- (difluoromethoxy)phenyl)- 2-((3-ethyl-1,2,4- oxadiazol-5-yl)methyl)pyridazin- 3(2H)-one ¹H NMR (CDCl₃, 400 MHz): δ 7.79-7.70 (m,3H), 7.23-7.18 (m, 2H), 7.12-7.07 (m, 1H), 6.57 (t, 1H), 5.61 (s, 2H),2.76 (q, 2H), 1.31 (t, 3H); 349.3 214

2-((4- cyclopropyloxazol-2- yl)methyl)-6-(4- (difluoromethoxy)phenyl)-pyridazin-3(2H)-one ¹H NMR (DMSO-d6, 400 MHz): δ 7.77-7.74 (m, 2H), 7.68(d, 1H), 7.34 (s, 1H), 7.21- 7.18 (m, 2H), 7.07 (d, 1H), 6.56 (t, 1H),5.46 (s, 2H), 1.80-1.73 (m, 1H), 0.88-0.83 (m, 2H), 0.77-0.72 (m, 2H);360.3 215

6-(4- (difluoromethoxy)phenyl)- 2-((5- (trifluoromethyl)-1,3,4-oxadiazol-2- yl)methyl)pyridazin- 3(2H)-one ¹H NMR (CDCl₃, 400 MHz): δ7.78-7.71 (m, 3H), 7.24-7.19 (m, 2H), 7.11 (d, 1H), 6.57 (t, 1H), 5.71(s, 2H); 389.2 216

6-(4- (difluoromethoxy)phenyl)- 2-((3-methyl-1,2,4- oxadiazol-5-yl)methyl)pyridazin- 3(2H)-one [M + H]+ 335.1 217

2-((5-cyclopropyl-1,3,4- thiadiazol-2-yl)methyl)- 6-(4-(difluoromethoxy)phenyl)- pyridazin-3(2H)-one ¹H NMR (DMSO-d6, 400 MHz):δ 8.14 (d, 1H), 7.98-7.95 (m, 2H), 7.54-7.16 (m, 4H), 5.70-5.68 (m, 2H),2.50-2.47 (m, 1H), 1.22-1.17 (m, 2H), 1.03-0.99 (m, 2H); 377.2 218

6-(4- (difluoromethoxy)phenyl)- 2-((4-methyloxazol-2-yl)methyl)pyridazin- 3(2H)-one %). ¹H NMR (DMSO- d6,400 MHz): δ 8.17 (d,1H), 8.00-7.96 (m, 2H), 7.83 (s, 1H), 7.58- 7.16 (m, 4H), 5.47 (s, 2H),2.10 (s, 3H); 334.3 219

2-((5-cyclopropyl-1,3,4- oxadiazol-2-yl)methyl)- 6-(4-(difluoromethoxy)phenyl- pyridazin-3(2H)-one ¹H NMR (DMSO-d6, 400 MHz):δ 8.15 (d, 1H), 7.94-7.92 (m, 2H), 7.55-7.15 (m, 4H), 5.55 (s, 2H),2.28- 2.20 (m, 1H), 1.17- 1.11 (m, 2H), 1.00- 0.95 (m, 2H); 361.2 220

6-(4- (difluoromethoxy)phenyl)- 2-(pyrimidin-5- ylmethyl)pyridazin-3(2H)-one [M + H]+ 331.1 221

6-(4- (difluoromethoxy)phenyl)- 2-((1-methyl-1H- pyrazol-3-yl)methyl)pyridazin- 3(2H)-one [M + H]+ 331.1 222

6-(4- (difluoromethoxy)phenyl)- 2-((5-methyl-1,3,4- oxadiazol-2-yl)methyl)pyridazin- 3(2H)-one ¹H NMR (DMSO-d6, 400 MHz): δ 8.19 (d,1H), 8.00-7.95 (m, 2H), 7.58-7.19 (m, 4H), 5.63 (s, 2H), 2.54 (s, 3H);335.2 223

6-(4- (difluoromethoxy)phenyl)- 2-((5-methyl-1,3,4- thiadiazol-2-yl)methyl)pyridazin- 3(2H)-one ¹H NMR (DMSO-d6, 400 MHz): δ 8.14 (d,1H), 8.00-7.95 (m, 2H), 7.54-7.17 (m, 4H), 5.72 (s, 2H), 2.70 (s, 3H);351.2 224

6-(4- (difluoromethoxy)phenyl)- 2-((5-methyl-1H- imidazol-2-yl)methyl)pyridazin- 3(2H)-one m/z = 333.2 (M + H) 225

6-(4- (difluoromethoxy)phenyl)- 2-(pyrimidin-4- ylmethyl)pyridazin-3(2H)-one [M + H]+ 331.1 226

6-(4- (difluoromethoxy)phenyl)- 2-((1-(2,2,2- trifluoroethyl)-1H-imidazol-2- yl)methyl)pyridazin- 3(2H)-one [M + H]+ 401.1 227

6-(4- (difluoromethoxy)phenyl)- 2-((5-methyl-4H- 1,2,4-triazol-3-yl)methyl)pyridazin- 3(2H)-one [M + H]+ 334.1 228

2-((5-cyclopropyl-4H- 1,2,4-triazol-3- yl)methyl)-6-(4-(difluoromethoxy)phenyl)- pyridazin-3(2H)-one [M + H]+ 360.1 229

6-(4- (difluoromethoxy)phenyl)- 2-((5- (trifluoromethyl)-1,3,4-thiadiazol-2- yl)methyl)pyridazin- 3(2H)-one ¹H NMR (DMSO-d6, 400 MHz):δ 8.21 (d, 1H), 8.05-8.00 (m, 2H), 7.59-7.21 (m, 4H), 5.95 (s, 2H);405.1 230

2-((1H- benzo[d]imidazol-2- yl)methyl)-6-(4- (difluoromethoxy)phenyl)-pyridazin-3(2H)-one m/z = 369.2 (M + H) 231

6-(4- (difluoromethoxy)phenyl)- 2-((1-phenyl-1H- pyrazol-3-yl)methyl)pyridazin- 3(2H)-one [M + H]+ 395.2 232

6-(4- (difluoromethoxy)phenyl)- 2-(pyrimidin-2- ylmethyl)pyridazin-3(2H)-one [M + H]+ 331.1 233

6-(4- (difluoromethoxy)phenyl)- 2-((5-phenyl-4H- 1,2,4-triazol-3-yl)methyl)pyridazin- 3(2H)-one [M + H]+ 331.1 234

5-((3-(4- (difluoromethoxy)phenyl)- 6-oxopyridazin-1(6H)-yl)methyl)-1,3,4- oxadiazol-2(3H)-one m/z = 337.2 (M + H) 235

2-((5-amino-1,3,4- oxadiazol-2-yl)methyl)- 6-(4-(difluoromethoxy)phenyl)- pyridazin-3(2H)-one m/z = 336.1 (M + H) 236

6-(4- (difluoromethoxy)phenyl)- 2-((5- (trifluoromethyl)-4H-1,2,4-triazol-3- yl)methyl)pyridazin- 3(2H)-one [M + H]+ 388.1 237

6-(4- (difluoromethoxy)phenyl)- 2-((4-phenyloxazol-2-yl)methyl)pyridazin- 3(2H)-one m/z = 396.3 (M + H) 238

2-((5-fluoropyridin-3- yl)methyl)-6-(4-(2,2,2- trifluoroethoxy)phenyl)pyridazin-3(2H)-one [M + H]+ 380.1

In certain embodiments, compounds of the methods described herein may beselected from commercially available compounds including those describedin Table 3. Compounds of Table 3 and 4 were tested and IC₅₀ data appearsin Table 5 and 6 herein. A=IC₅₀ is less than or equal to 10 μM; B=IC₅₀is greater than 10 μM and less than 100 μM; C=IC₅₀ is greater than 100μM.

TABLE 3 Cmpd No. Structure Name 301

6-(3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-2-((3-methyl-1,2,4-oxadiazol-5- yl)methyl)pyridazin-3(2H)-one 302

methyl 5-((3-(4-(methylthio)phenyl)-6-oxopyridazin-1(6H)-yl)methyl)furan-2- carboxylate 303

6-(3,4-dihydro-2H-benzo[b][1,4]dioxepin-7- yl)-2-((3-methylisoxazol-5-yl)methyl)pyridazin-3(2H)-one 304

6-(4-ethoxyphenyl)-2-((3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)pyridazin- 3(2H)-one 305

6-(4-methoxyphenyl)-2-((3-(4- methoxyphenyl)-1,2,4-oxadiazol-5yl)methyl)pyridazin-3(2H)-one 306

6-(4-methoxyphenyl)-2-((3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)pyridazin- 3(2H)-one 307

2-((3-(4-methoxyphenyl)-6-oxopyridazin- 1(6H)-yl)methyl)-4H-pyrido[1.2-a]pyrimidin-4-one 308

6-(4-ethoxyphenyl)-2-((3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)methyl)pyridazin- 3(2H)-one 309

6-(4-methoxyphenyl)-2-((3-phenyl-1,2,4-oxadiazol-5-yl)methyl)pyridazin-3(2H)-one 310

6-(4-methoxyphenyl)-2-((3-(4- methoxyphenyl)-1,2,4-oxadiazol-5-yl)methyl)pyridazin-3(2H)-one 311

2-((6-oxo-3-(p-tolyl )pyridazin-1(6H)-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-one 312

6-(p-tolyl)-2-((3-(o-tolyl)-1,2,4-oxadiaxol-5-yl)methyl)pyridazin-3(2H)-one 313

6-(4-chlorophenyl)-2-((3-(p-tolyl)-1,2,4-oxadiazol-5-yl)methyl)pyridazin-3(2H)-one 314

2-((3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl)methyl)-6-(p-tolyl)pyridazin-3(2H)-one 315

6-(4-methoxyphenyl)-2-((3-(4- methoxyphenyl)-1,2,4-oxadiazol-5-yl)methyl)pyridazin-3(2H)-one

In certain embodiments, compounds for use in the methods describedherein include those in Table 4 or salts thereof.

TABLE 4 Compound No. Structure Name 350

6-(4-chlorophenyl)-2-((5-methyl-1,2,4-oxadiazol-3-yl)methyl)pyridazin-3(2H)-one 351

2-((5-fluoropyridin-3-yl)methyl)-6-(2-methylpyrimidin-5-yl)pyridazin-3(2H)-one 352

(Z)-2-((5-fluoropyridin-3-yl)methyl)-6-(2-(prop-1-en-1-yl)pyrimidin-5-yl)pyridazin- 3(2H)-one

Skeletal IC₅₀ values of compounds of the disclosure appear in Table 5.

TABLE 5 Cmpd No. IC₅₀  1 A  2 A  3 A  4 A  5 A  6 A  7 A  8 A  9 A  10 B 11 A  12 A  13 A  14 A  15 C  16 C  17 A  18 C  19 C  20 B  22 A  23 C 24 C  25 C  26 A  27 A  28 A  30 A  31 A  32 A  33 A  34 A  36 A  37 A 38 A  39 A  40 A  41 A  42 B  43 B  44 B  45 B  46 C  47 C  49 C  50 A 51 A  52 A  53 A  54 A  55 A  56 A  57 B  58 A  59 A  60 A  61 A  64 A 65 A  66 A  67 A  68 A  69 A  70 A  71 A  72 A  73 A  74 A  75 A  76 A 77 A  78 C  79 A  80 C  81 C  82 B  83 B  84 C  85 B  86 C  87 A  88 A 89 A  90 A  91 A  92 A  94 A  95 A  96 A  97 A  99 A 100 A 101 A 102 A103 A 104 A 105 A 106 A 107 C 108 A 109 A 110 A 111 A 112 A 113 A 114 A115 A 116 A 117 A 118 A 119 A 120 A 121 A 122 A 123 A 124 A 125 A 126 A127 A 128 A 129 A 130 A 131 A 132 A 137 A 138 A 201 A 202 A 203 A 204 A205 A 206 A 208 A 209 A 210 A 211 B 212 B 213 B 214 B 215 B 216 B 217 B218 B 219 B 220 B 221 B 222 B 223 B 224 C 225 C 226 C 227 C 228 C 229 C230 C 231 C 232 C 233 C 234 C 235 C 236 C 237 B 238 A 301 C 302 B 304 A305 A 306 B 307 B 308 A 309 A 310 A 311 B 312 A 313 B 314 C 315 A 350 C351 B 352 A A = IC₅₀ is less than or equal to 10 μM; B = IC₅₀ is greaterthan 10 μM and less than 100 μM; C = IC₅₀ is greater than 100 μM.

Certain compounds of the disclosure have cardiac IC₅₀ values as in Table6.

TABLE 6 Cmpd No. IC₅₀  1 B  2 C  3 C  4 C  5 C  6 C  7 B  8 C  9 C  10 C 11 C  12 B  13 C  14 C  15 C  16 C  17 C  18 C  19 C  20 C  22 C  23 C 24 C  25 C  26 B  27 A  28 B  30 B  31 C  32 C  33 C  34 C  36 C  37 C 38 A  39 C  40 C  41 C  42 C  43 C  44 C  45 C  46 C  47 C  48 C  49 C 50 B  51 C  52 B  53 C  54 C  55 B  56 C  57 C  58 C  59 C  60 C  61 C 65 C  66 C  67 B  68 B  69 B  70 C  71 C  72 C  73 C  74 C  75 C  76 C 77 B  78 C  79 C  80 C  81 C  82 C  83 C  84 C  86 C  87 B  88 C  89 C 90 C  91 C  92 C  94 A  95 B  96 C  99 C 100 C 101 C 102 C 103 C 104 C105 C 106 B 109 C 110 C 111 C 112 B 113 C 114 C 115 B 116 C 117 C 118 C119 B 120 B 121 C 122 C 123 C 124 C 125 C 126 C 127 C 128 C 129 C 130 C131 C 132 B 137 C 138 C 201 C 202 C 203 C 204 C 205 B 206 C 208 C 209 C210 B 211 C 212 C 213 C 214 C 215 C 216 C 217 C 218 C 219 C 220 C 221 C222 C 223 C 224 C 225 C 226 C 227 C 228 C 229 C 230 C 231 C 232 C 233 C234 C 235 C 236 C 237 C 238 C 301 C 302 C 304 D 305 D 306 D 307 D 308 C309 C 310 C 311 D 312 C 313 C 314 C 315 C 350 C 352 C A = IC₅₀ is lessthan or equal to 10 μM; B = IC₅₀ is greater than 10 μM and less than 100μM; C = IC₅₀ is greater than 100 μM; D is greater than 60 μM.

While preferred embodiments of the present invention have been shown anddescribed herein, it will be obvious to those skilled in the art thatsuch embodiments are provided by way of example only. Numerousvariations, changes, and substitutions will now occur to those skilledin the art without departing from the invention. It should be understoodthat various alternatives to the embodiments of the invention describedherein may be employed in practicing the invention. It is intended thatthe following claims define the scope of the invention and that methodsand structures within the scope of these claims and their equivalents becovered thereby.

What is claimed is:
 1. A method of treating activity-induced muscledamage, a neuromuscular condition, a metabolic myopathy, or a movementdisorder, wherein the neuromuscular condition is selected from DuchenneMuscular Dystrophy, Becker muscular dystrophy, myotonic dystrophy 1,myotonic dystrophy 2, facioscapulohumeral muscular dystrophy,oculopharyngeal muscular dystrophy, limb girdle muscular dystrophy,tendinitis, and carpal tunnel syndrome; wherein the movement disordercomprises muscle spasticity associated with multiple sclerosis;Parkinson's disease; Alzheimer's disease; cerebral palsy; injury; or atraumatic event, wherein the traumatic event is selected from stroke,traumatic brain injury, spinal cord injury, hypoxia, meningitis,encephalitis, phenylketonuria, and amyotrophic lateral sclerosis;wherein the metabolic myopathy is selected from McArdle's syndrome; themethod comprising administering to a subject in need thereof a compoundor salt of Formula (III′):

or a salt thereof, wherein: each Y is independently selected from C(R³),N, and N⁺(—O⁻); A is absent or selected from —O—, —NR⁴—, —CR⁵R⁶—,—C(O)—, —S—, —S(O)—, and —S(O)₂—; R¹ is selected from: C₁₋₆ alkyl, C₂₋₆alkenyl, and C₂₋₆ alkynyl, each of which is optionally substituted withone or more substituents independently selected from halogen, —OR¹⁰,—SR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰,—N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰,—OC(O)R¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), —CN, C₃₋₁₀carbocycle, and 3- to 10-membered heterocycle, wherein the C₃₋₁₀carbocycle and 3- to 10-membered heterocycle are each optionallysubstituted with one or more R⁹; and C₃₋₁₀ carbocycle and 3- to10-membered heterocycle, each of which is optionally substituted withone or more substituents independently selected from halogen, —OR¹⁰,—SR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰,—N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰,—OC(O)R¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), and —CN; or R¹together with R³ form a 5- to 10-membered heterocycle or C₅₋₁₀carbocycle, wherein the 5- to 10-membered heterocycle or C₅₋₁₀carbocycle is optionally substituted with one or more R⁹; or R¹ togetherwith R⁵ form a 3- to 10-membered heterocycle or saturated C₃₋₁₀carbocycle, wherein the 3- to 10-membered heterocycle or saturated C₃₋₁₀carbocycle is optionally substituted with one or more R⁹; or R¹ togetherwith R⁴ form a 3- to 10-membered heterocycle, wherein the 3- to10-membered heterocycle is optionally substituted with one or more R⁹;and when A is —NR⁴—, R¹ is additionally selected from hydrogen, and whenA is —C(O)—, R¹ is additionally selected from —N(R¹⁰)₂ and —OR¹⁰; when Ais absent, R¹ is further selected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂,—C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰, —N(R¹⁰)C(O)N(R¹⁰)₂,—OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰, —OC(O)R¹⁰, —S(O)R¹⁰,—S(O)₂R¹⁰, —NO₂, and —CN; R² is a heteroaryl optionally substituted withone or more substituents independently selected from: halogen, —OR¹⁰,—SR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰,—N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰,—OC(O)R¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), and —CN; and whenR² is pyridyl or pyrimidyl, a substituent on a nitrogen atom of thepyridyl or pyrimidyl is optionally further selected from —O—; C₁₋₆alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl, each of which is optionallysubstituted with one or more substituents independently selected fromhalogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰,—N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰,—OC(O)R¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), —CN, C₃₋₁₀carbocycle and 3- to 10-membered heterocycle, wherein the C₃₋₁₀carbocycle and 3- to 10-membered heterocycle are each optionallysubstituted with one or more R⁹; and C₃₋₁₀ carbocycle and 3- to10-membered heterocycle, each of which is optionally substituted withone or more R⁹; each R³, R⁵, and R⁶ are independently selected from:hydrogen, halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, —CN, and C₁₋₆ alkyloptionally substituted with one or more substituents independentlyselected from halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —NO₂, and —CN; or R³together with R¹ form a 5- to 10-membered heterocycle or C₅₋₁₀carbocycle, wherein the 5- to 10-membered heterocycle or C₅₋₁₀carbocycle is optionally substituted with one or more R⁹; or R⁵ togetherwith R¹ form a 3- to 10-membered heterocycle or C₃₋₁₀ carbocycle,wherein the 3- to 10-membered heterocycle or C₃₋₁₀ carbocycle isoptionally substituted with one or more R⁹; R⁴ is independently selectedfrom: hydrogen; and C₁₋₆ alkyl optionally substituted with one or moresubstituents independently selected from halogen, —OR¹⁰, —SR¹⁰,—N(R¹⁰)₂, —NO₂, and —CN; or R⁴ together with R¹ form a 3- to 10-memberedheterocycle, which is optionally substituted with one or more R⁹; eachR⁷ and R⁸ is independently selected from: halogen, —OR¹⁰, —SR¹⁰,—N(R¹⁰)₂, —NO₂, —CN, and C₁₋₆ alkyl optionally substituted with one ormore substituents independently selected from halogen, —OR¹⁰, —SR¹⁰,—N(R¹⁰)₂, —NO₂, and —CN; each R⁹ is independently selected from:halogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰,—N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰,—OC(O)R¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), and —CN; and C₁₋₃alkyl, C₂₋₃ alkenyl, and C₂₋₃ alkynyl, each of which is optionallysubstituted with one or more substituents independently selected fromhalogen, —OR¹⁰, —SR¹⁰, —N(R¹⁰)₂, —C(O)R¹⁰, —C(O)N(R¹⁰)₂, —N(R¹⁰)C(O)R¹⁰,—N(R¹⁰)C(O)N(R¹⁰)₂, —OC(O)N(R¹⁰)₂, —N(R¹⁰)C(O)OR¹⁰, —C(O)OR¹⁰,—OC(O)R¹⁰, —S(O)R¹⁰, —S(O)₂R¹⁰, —NO₂, ═O, ═S, ═N(R¹⁰), and —CN; each R¹⁰is independently selected from: hydrogen; and C₁₋₆ alkyl, C₂₋₆ alkenyl,and C₂₋₆ alkynyl, each of which is optionally substituted with one ormore substituents independently selected from halogen, —CN, —OH, —SH,—NO₂, —NH₂, ═O, ═S, —O—C₁₋₆ alkyl, —S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂,—NH(C₁₋₆ alkyl), C₃₋₁₀ carbocycle, and 3- to 10-membered heterocycle;and C₃₋₁₀ carbocycle, and 3- to 10-membered heterocycle, each of whichis optionally substituted with one or more substituents independentlyselected from halogen, —CN, —OH, —SH, —NO₂, —NH₂, ═O, ═S, —O—C₁₋₆ alkyl,—S—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —NH(C₁₋₆ alkyl), C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ carbocycle, 3- to 10-membered heterocycle,and haloalkyl; R³⁰ and R³¹ are independently selected from R¹⁰; or R³⁰and R³¹ come together to form a C₃₋₇ carbocycle or 3- to 7-memberedheterocycle, wherein C₃₋₇ carbocycle or 3- to 7-membered heterocycle isoptionally substituted with one or more R⁹; n is 0, 1, or 2; and p is 0,1, or
 2. 2. The method of claim 1, wherein each R³⁰ and R³¹ isindependently hydrogen.
 3. The method of claim 1, wherein A is absent.4. The method of claim 1, wherein each Y is independently selected fromC(R³) and N.
 5. The method of claim 1, wherein at least one Y is N orN⁺(—O⁻).
 6. The method of claim 1, wherein one Y is N, and one Y isC(R³).
 7. The method of claim 1, wherein one Y is N⁺(—O⁻), and one Y isC(R³).
 8. The method of claim 1, wherein one Y is N, and one Y isN⁺(—O⁻).
 9. The method of claim 1, wherein each Y is N.
 10. The methodof claim 1, wherein each Y is C(R³).
 11. The method of claim 1, whereinthe method is for treating a neuromuscular condition.
 12. The method ofclaim 11, wherein the neuromuscular condition is Duchenne musculardystrophy.
 13. The method of claim 11, wherein the neuromuscularcondition is Becker muscular dystrophy.
 14. The method of claim 1,wherein a movement disorder is treated, wherein the movement disordercomprises muscle spasticity.
 15. The method of claim 14, wherein themuscle spasticity is selected from spasticity associated with multiplesclerosis, Parkinson's disease, Alzheimer's disease, and cerebral palsy.16. The method of claim 1, wherein the compound or salt is administeredin an amount sufficient to reduce involuntary muscle contractions. 17.The method of claim 16, wherein the compound or salt is administered inan amount sufficient to reduce involuntary muscle contractions by atleast 10%.
 18. The method of claim 1, wherein the method furthercomprises administering to the subject an additional therapeutic agent.19. The method of claim 18, wherein the additional therapeutic agent iscorticosteroid.
 20. The method of claim 19, wherein the corticosteroidis deflazacort or prednisone.
 21. The method of claim 18, wherein theadditional therapeutic agent is vamorolone.
 22. The method of claim 18,wherein the additional therapeutic agent is a gene therapy.
 23. Themethod of claim 22, wherein the gene therapy comprises dystrophin geneor a variant or truncated version thereof.
 24. The method of claim 22,wherein the gene therapy comprises microdystrophin.
 25. The method ofclaim 18, wherein the additional therapeutic agent is an exon skippingagent.
 26. The method of claim 25, wherein the exon skipping agent iseteplirsen.
 27. The method of claim 25, wherein the exon skipping agentis ataluren.
 28. The method of claim 1, wherein the compound is selectedfrom

or a salt thereof.
 29. The method of claim 1, wherein the compound isselected from

or a salt thereof.
 30. The method of claim 1, wherein the compound isselected from

or a salt thereof.
 31. The method of claim 1, wherein the compound isselected from

a salt thereof.
 32. The method of claim 1, wherein the compound isselected from

or a salt thereof.
 33. The method of claim 1, wherein the compound isselected from

or a salt thereof.
 34. The method of claim 1, wherein the compound isselected from or

a salt thereof.
 35. The method of claim 1, wherein the compound isselected from

or a salt thereof.
 36. The method of claim 1, wherein the compound isselected from

or a salt thereof.
 37. The method of claim 31, wherein the compound isselected from

or a salt thereof.
 38. The method of claim 1, wherein the method is fortreating a metabolic myopathy, and the metabolic myopathy is selectedfrom McArdle's disease.
 39. The method of claim 1, wherein the compoundor salt is selected from

and

or a salt thereof.